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Abstract 
Streptococcus mutans, an oral pathogen, is considered as a principle etiological agent of 
dental caries. To colonize successfully in the oral cavity, this organism encounters fierce 
competition with other oral microbiota and this process is facilitated by ribosomally synthesized 
small cationic peptides called mutacins (bacteriocins) secreted by S. mutans. Although for long 
time mutacins are regarded as important virulence factors, it is not clear how these peptides 
work, what is the mechanism of self-immunity, and how they are regulated. In this study, we 
have characterized the activity, mechanism of self-immunity, and regulation of expression of a 
well-known bacteriocin, mutacin IV.  
To clarify the activity of mutacin IV, we studied the contribution of NlmA and NlmB 
peptides to mutacin IV activity. Using genetic and biochemical approaches, we showed that the 
presence of both genes is required for optimum mutacin IV activity. We also showed that 
mutacin IV is active against multiple Streptococcus species. Our studies revealed that mutacin IV 
has comparatively broader inhibitory spectrum than mutacin V; and both of them can work 
synergistically to inhibit various microorganisms. 
Next, we investigated the immunity activity of a putative immunity protein, SMU.152, 
which lies just downstream of the nlmAB operon. We observed that heterologous expression of 
SMU.152 in two sensitive strains converted the strains to become resistant to mutacin IV. We 
identified that C-terminal charged residues of SMU.152 is indispensible for conferring immunity 
to susceptible cells. In addition, our studies demonstrated that in absence of cognate immunity 
protein, S. mutans can employ other paralogous proteins to prevent the self-toxicity, which 
implies the presence of cross-immunity or immune redundancy in S. mutans UA159. 
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To get a clear understanding on regulation of mutacin IV production, we carried out 
pGh9:ISS1-mediated random transposon mutagenesis in a reporter strain containing the nlmAB 
promoter with a promoter less gusA (glucuronidase) gene. Mapping the position of transposon 
insertion sites revealed 22 unique genes of diverse cellular activities, which are involved in 
regulation of mutacins production. Highlight of our finding is that an extracellular ATP-
independent Lon-like protease functions specifically on maturation of peptide pheromone, CSP. 
Here, we show that functional form of CSP (18-amino acids) is generated by a specific post 
export cleavage with this Lon-like protease. Our study suggests that ComDE two-component 
system is primarily involved in regulation of mutacins production in S. mutans UA159. We also 
show that both the peptide pheromone (CSP) and mutacins use the same ABC transporter, 
NlmTE, for secretion. During the course of this study, we discovered two more novel regulators 
for gene expression in this bacterium. We show that a small hypothetical protein, SMU.2137, is 
required for normal cellular processes in S. mutans UA159 and a protein, SMU.832, required for 
glucose side chain formation, can also regulate mutacin production in this organism.  
Collectively, our data encourage us to propose a new model for regulation of mutacins 
production in S. mutans UA159. According to our model, peptide pheromone (BipC) is secreted 
as 21-amino acids and a specific Lon-like protease cleaves the C-terminal three amino acids to 
generate functional peptide pheromone (18-residue). BipC activates a two-component signal 
transduction system (BipDE), which in turn stimulates the expression of mutacins encoding 
genes (such as nlmAB and nlmC). A common ABC transporter, BipTE (NlmTE), is required for 
both mutacins and BipC secretion and proteolytic cleavage of leader peptide after GG-motif. In 
sum, our study has unraveled new pathways of gene regulation in S. mutans and strengthened our 
understanding on overall biology of mutacins production in S. mutans. 
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CHAPTER ONE 
 LITERATURE REVIEW 
All forms of life developed innate immune system to resist the challenge of other 
competing organisms. Ribosomally synthesized small antimicrobial peptides (AMPs) are one of 
the oldest and widely present antimicrobial strategies in living system, from bacteria to humans, 
plants to insects (54, 219). These peptides play vital roles in conferring immunity against 
microbial infection in plants and animals, such as α- defensins produced by neutrophils in the 
small intestine maintain the integrity of the barriers of mucosal surfaces (54). AMPs produced by 
bacteria are commonly referred as bacteriocins and are used for out-competing other bacteria 
present in the same micro-ecological niche. Both AMPs and bacteriocins are similar; they are 
cationic, hydrophobic or amphiphillic and membrane permeabilizing in nature (217). 
Bacteriocins might have either narrow spectrum (acting toward the same species) or broad 
spectrum of activity (acting across the genera) and are more potent than the eukaryotic AMPs; 
while AMPs  show activity at micro molar concentration, bacteriocins are active at nano molar 
concentration (219). Therefore, they pose the potential for developing species-specific 
therapeutics to fight against the ever increasing antibiotic resistant bacterial pathogens.  
Bacteriocin was first discovered in 1925 when inhibition between Escherichia coli strains 
first noticed (98). Originally it was named ‘colicin’ after the producer bacteria E. coli. Despite 
the commercial use of bacteriocins as food preservative was first proposed in 1951, it is likely 
that we human being  are using bacteriocins coincidentally since the first fermentation process  
was developed 8000 years ago (54). In fact, many studies have found that lactic acid bacteria 
(LAB) involved in cheese manufacturing also produce bacteriocins to maintain the composition 
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of complex microflora by inhibiting the unwanted bacteria (193, 260, 313). Nisin (group N 
inhibitory substances) was first reported in 1933 (313) and marketed in England in 1953 and to 
date, 48 countries have approved its use in  dairy industries (54) (Fig.1). Importantly, nisin was 
tested as safe for food use by the Joint Food and Agriculture Organization/ WHO Expert 
Committee on food additives in 1969. US Food and Drug Agency (FDA) approved its use in 
pasteurized, processed cheese industry in 1988 (54). 
The story of the successful commercialization of nisin from initial microbiological 
observation is a model that rebounded bacteriocins research in recent days in all over the world. 
However similar stories of other bacteriocins yet to be developed in the same scale (54). Despite 
this reality, we predict that bacteriocins can be exploited to use in various food industries to 
prevent the spoilage of foods, can be used in pharmaceutical industries to develop species-
specific therapeutic to target the specific pathogen without harming beneficial microorganisms or 
producer bacteria can be used as probiotic to inhibit the potential pathogens. To realize this 
potential, it is essential to study the biology of various bacteriocins; specifically their spectrum of 
activity, mode of action, immunity and regulation of biosynthesis. With this goal in mind, we 
have studied the bacteriocins from S. mutans UA159, an oral bacterium believed to be involved 
in tooth decay (176, 177). Human oral cavity harbors one of the most heterogeneous microbial 
population (>700 species) and this micro-ecological niche is an ideal model system to study the 
inter-species interaction (1, 275). Diversity of bacterial population and shortage of food supply 
trigger deadly competition among microbial species in this microenvironment. Interspecies 
competition between S. mutans and other bacteria in the oral cavity has been reported by various 
groups (22, 38). To inhibit the growth of competing bacteria and to establish a successful 
colonization in the plaque biofilm, S. mutans secretes a wide variety of bacteriocins, called  
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Fig. 1. Landmark of the bacteriocin development over the period of time [adapted from Cotter et 
al. (54)]. Bacteriocin was first identified in 1925 and marketed in 1953. US Food and Drug 
Agency (FDA) approved it in 1988. 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
1925 1928 19531933 1969 19881983
Colicin first reported Nisin discovered Nisin marketed in UK EU approval
Bacteriocins from 
LAB  identified
FAO/ WHO approval US FDA approval
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
‘mutacins’ that exhibit various inhibitory spectrum (8, 15). In this study, we have clarified the 
genetic organization and inhibitory spectrum of one of such bacteriocins called ‘Mutacin IV’ 
along with the mechanism of self-immunity and regulation of biosynthesis in S. mutans UA159. 
Antimicrobial peptides (AMPs) of eukaryotic origin 
AMPs maintain the first line of defense and also provide innate immunity in higher 
eukaryotes. Therefore, they help in the existence of producer organisms in a given ecological 
niche against the infections or competitor organisms (50, 217). Table-1 shows some examples of 
AMPs from eukaryotic origin with their activity spectrum. They might act against a particular 
group of organisms or have broad spectrum of activity (50). AMPs protect the producer 
organisms mostly by disrupting the target cell membrane causing irreversible leakage of cellular 
materials, although they have various other mode of actions (50).   
Antimicrobial peptides of bacteria (bacteriocins)  
Bacteriocins are defined as ribosomally produced, small peptides that are active against 
closely related bacteria. However, the producer bacteria is immune to its own bacteriocin due to 
the presence of specific immune mechanism (54). The first identified bacteriocins, colicins, 
comprise of a group of antibacterial proteins that kill other bacteria by diverse mechanisms such 
as blocking the cell wall synthesis, permeabilizing the cell membrane or by inhibition of RNase 
or DNase activity (50). Lactic acid bacteria have been extensively studied as an ample source of 
antimicrobial peptides for application in food industries (Table-2). Nisin is now effectively used 
as a preservative in cheese, skim milk, sausage, lean beef and Kimchi preparations to prevent 
spoilage caused by different bacteria (45, 57, 60, 83, 307).  
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Table-1: Antimicrobial peptides (AMPs) from eukaryotes [adapted from Cleveland et al.(50)] 
 
AMPs Source Mode of action Spectrum of activity References 
Pardexin Pardachiros 
maroratus 
Release neurotransmitter by 
forming pores 
Gram +; Gram - (228) 
Melittin Bee venom Membrane insertion Gram +; Gram - (228) 
Ceratotoxin Ceratitis capita Not known Gram +; Gram - (186) 
Histatins Human saliva Pore formation in membrane Bacteria; Fungi (117) 
Trichorzins Trichoderma spp. Voltage gated ion channel 
formation 
Staphylococcus 
aureus 
(97) 
Magainins Frogs & 
amphibian 
Create anion permeable 
channel in membrane 
Bacteria; Fungi (110) 
Defensins Mammalian 
neutrophils 
Voltage gated ion channel 
formation 
Bacteria; Fungi; 
Enveloped virus 
(121) 
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Table-2: Potential food applications of various bacteriocins  
Bacteriocin Producer Application and target bacteria Ref. 
Nisin L. lactis  To inhibit L. monocytogenes in cheese & B. cereus 
in skim milk 
(83, 307) 
Pediocin PA-
1/AcH 
Pediococcus 
acidilactici 
To inhibit L.monocytogenes & S. aureus in cheese; 
C. botulinum in chilled soup  
(73, 258) 
Divercin V41 Carnobacterium 
divergens  V41 
To inhibit L.monocytogenes in smoked salmon (74) 
Enterocin A Enterococcus faecium 
CTC492 
To inhibit L.monocytogenes in dry fermented 
sausage and soy milk 
(164-166) 
Enterocin 
CCM4231 
Enterococcus faecium 
CCM4231 
To inhibit S. aureus in soy milk (165) 
Leucocin A Leuconostoc 
carnosum UAL187 
To inhibit L.monocytogenes in ground beef (73) 
Plantaricin L. plantarum 423 To inhibit L.monocytogenes in ostrich meat salami (68) 
Sakacin  A  L. sakei 790 To inhibit L.monocytogenes in chicken cold cut (303) 
Sakacin  P  L. sakei 790 To inhibit L.monocytogenes in cold smoked salmon 
& LAB in brined shrimp 
(80, 143) 
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Bacteriocins and antibiotics are sometimes confusing but there are clear distinctions 
between them (73). Antibiotics are secondary metabolites and have broad target spectrum. 
Antibiotics are clinically used to kill pathogens; however, they have various side effects. They 
can target the cell wall, cell membrane or intracellularly but don’t provide any immunity to host 
cell. On the other hand, bacteriocins are ribosomally produced and mostly form pore in the 
membrane. They have narrow spectrum of activity without any side effects. Bacteriocins also 
provide the first line of defense to the host cells (73). 
Classification of bacteriocins  
Bacteriocins include heterogeneous group of small, extracellular antibacterial peptides 
produced  by bacteria (54). They have been classified into different groups based on their 
molecular structures and mode of actions (54, 118, 151, 209, 212). Cotter et al. (54) suggested 
two main classes of bacteriocins based on their structure such as lanthionine-containing 
bacteriocins in class I and non-lanthionine containing bacteriocins in class II. However, they 
expelled heat-labile peptides from the definition of bacteriocins. This attempt unjustifiably 
excluded the first described bacteriocin ‘colicin’. To redress this problem, Heng and Tegg (118) 
proposed a more inclusive approach of classification where they divided bacteriocins into four 
distinct classes. Due to the extensive diversity of bacteriocins, we propose this recent 
classification should be modified slightly; specifically for the classification of class II. Here, we 
offer a new classification scheme (Table-3) based on the classification systems proposed by 
Heng and Tegg (118) and Drider D. et al.(73). 
Class I bacteriocins (lantibiotics): The lantibiotics are lanthionine-containing small 
peptides (19-38 amino acids long) that are formed when an enzymatically dehydrated serine  
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Table-3: Classification of bacteriocins 
 Class I Class II Class III Class IV 
Type 
Lantibiotics (Post 
translationaly 
modified) 
Non-lanthionine, 
heat-stable 
peptides  
Large heat-labile 
proteins 
 
Cyclic peptides 
(N- and C- termini 
covalently linked)  
Molecular 
Weight 
<5kDa <10kDa >10kDa <10 kDa 
Subgroups 
Type Ia: Elongated 
peptides with a net 
positive charge 
Type Ib: Globular 
peptides with a net 
negative charge or 
no charge 
Type Ic: Multi-
component 
Type IIa: 
monopeptide and a 
YGNGVXC N-
terminal  motif 
Type IIb: Two-
peptide  and 
GXXXG motif 
Type IIc: 
Heterogeneous 
Type IIIa: 
Bacteriolytic  
 
 
Type IIIb: Non-
lytic  
None 
Examples 
 
Nisin, lacticin 481, 
lacticin 3147, 
mutacin I,II, III,  
Smb, BHT etc. 
Pediocin PA1, 
aureocin A53, 
plantaricin, 
mutacin IV& V  
Lysostaphin, 
helveticin J  
 
Enterocin AS-48  
 
 
 
 
 
 
 
10 
 
(dehydroalanine) forms a covalent bond (thioether) with the sulphydryl group of a neighboring 
cysteine. This forms an internal ring which is the distinctive feature of lantibiotics. This ring can 
also be formed between threonine and cysteine and is termed as β-methyllanthionine (54, 170). 
Moreover, lantibiotics might have some unusual residues such as substitution of D-alanine for L-
serine (132, 232, 319). Due to these unusual modifications, lantibiotics are highly resistant to 
extreme environmental conditions. For example, they are resistant to 121
0
C for 15 min and pH 
from 2-12 (64, 167). Lantibiotics are also divided into three subtypes based on their structure and 
function. Class Ia includes the elongated amphiphilic molecules of less than 4-kDa in mass and 
cationic in nature such as nisin (54, 73). They act by forming pores in the membrane (Fig. 2), 
which leads to disruption of membrane potential and the efflux of metabolites from the target 
cells (54). In contrast, class Ib (globular molecules with low molecular mass of 1.8 to 2.1 kDa 
such as mersacidin) inhibits the enzyme activity (141). However, it is now clear that nisin have 
both mode of actions (54). Two-peptide lantibiotic, such as lacticin 3147, shows the co-operative 
activity of individual peptides. This complex nature make them difficult to sub classify and 
recently it has been proposed that lantibiotics can be sub classified into 11 subgroups based on 
their primary amino acid sequences (53). Inhibitory concentration of lantibiotics resides in nano 
molar range toward the target species and their  activity is several order higher than the 
antimicrobial peptides of innate immune system (54).  
Despite the lack of accurate molecular mechanism of action for all lantibiotics, several 
studies have established that a docking molecule, such as lipid II, is necessary to exhibit their 
activities (35-37, 128, 314). The interaction of nisin with the lipid II blocks peptidoglycan 
synthesis by preventing the transport of peptidoglycan precursors from cytoplasm to cell wall.  
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Fig. 2. Mode of actions of bacteriocins. Based on the mode of action, bacteriocins from lactic 
acid bacteria can be classified into three categories (54). Class I (lantibiotics) has dual mode of 
actions. They can bind to the main transporter (lipid II) of peptidoglycan subunits which are 
involved in transport of peptidoglycan from cytoplasm to cell wall. Moreover, they can use lipid 
II as docking molecule to initiate membrane insertion and pore formation. Class II peptides, in 
general, have an amphiphilic helical structure which enables them to insert into the membrane of 
the target cells, leading to depolarization and death. Large bacteriocins (bacteriolysins) lyse the 
cell wall directly which leads to cell death. 
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Moreover, lipid II acts as docking molecules for membrane insertion and pore formation (35, 
314). Lacticin 3147, a two peptide lantibiotic, has these bi-functional activities imparted by 
individual peptides (188), whereas globular peptide, mersacidin, can bind to the lipid II only 
(54). It has been identified that membrane phospholipids, phosphatidylethanolamine, acts as the 
docking molecule for cinnamycin like lantibiotics (126, 181). Besides this, enterococcal two-
peptide lantibiotic (enterocin 1071) has broad spectrum of activity. They can target gram-
positive bacteria as well as eukaryotic cells such as human, bovine and horse erythrocytes; 
retinal cells; polymorphonuclear leukocytes; and intestinal epithelial cell (55).  
Class II bacteriocins (non-lanthionine containing bacteriocins): Class II bacteriocins 
are small (<10kDa), heat-stable peptides without any post-translational modification (54). Most 
of the class II bacteriocins cause disruption of proton-motive force by permeabilizing the cell 
membrane and act in nano molar range (Fig. 2). Class II can be further divided into several 
subclasses (54, 219). Class IIa consists of listeria-active pediocin like peptides, class IIb consists 
of two-peptide bacteriocins, and other multi-component peptides are included into class IIc 
(Table-3).  
Class IIa (mono-peptide bacteriocins): Class IIa bacteriocins consist of pediocin-like 
mono-peptides produced by various lactic acid bacteria and show narrow spectrum of activity 
but highly specific for Listeria monocytogenes (116, 202). They are also active against various 
Lactobacillus, Lactococcus, Leuconostoc, Clostridium perfringens, Bacillus cereus and 
Staphylococcus aureus (73, 79, 131). They are cationic, amphiphilic or hydrophobic and contain 
37- to 48-amino acid residues (54, 219). They have conserved N-terminal ‘pediocin box’ motif 
which harbors the consensus sequence YGNGVXCXXXXVXV (X denotes any amino acid) (54, 
73) and is believed to facilitate non-specific interaction with the target cell surface (44, 144). The 
14 
 
C-terminal domain, which is present after the hinge region, is less conserved and involved in 
membrane insertion due to their hydrophobic nature (86, 198). Generation of hybrid peptides 
suggested that C-terminal domain is involved in target cell specificity determination (84, 140)  
and interacts with the lipids or proteins in the hydrophobic parts of the cell membrane. It has 
been reported that membrane-associated mannose phosphotransferase system permease is 
involved in the sensitization of the target cells to pediocin-like bacteriocins (58, 115, 252, 253, 
321). Recently, a study suggested that MptC and/or MptD  subunit of mannose 
phosphotransferase permease binds with the pediocin-like bacteriocin (70). In addition, this 
study revealed that specific immunity protein binds strongly with the permease complex and 
subsequently protects from bacteriocin-mediated cell lysis. 
Class IIb (two-peptide bacteriocins): Two-peptide bacteriocins contain two different 
peptides and both peptides are required in equal amount for optimum bacteriocin activity (219). 
They exhibit very low activity when they were tested individually. More than 15 class two-
peptide bacteriocins have been isolated and characterized so far (219), such as thermophilin 13, 
lactococcin G, mutacin IV, plantaricin E/F, lacticin F etc. All of them alter the permeability of 
the membrane to small molecules that results in dissipation of proton-motive force and 
decreasing of intracellular ATP concentration which eventually leads to cell lysis (95). Based on 
the types of small molecules, these bacteriocins show some specificity and different bacteriocins 
differ in their specificities. For examples, lactococcin G permeabilizes the cell for monovalent 
cations but not for divalent cations, anions or H
+
 (199, 200). Plantaricin E/F or J/K permeabilizes 
membrane for monovalent cations and H
+
 but not for divalent cations or anions (201). 
Each of the peptides of two-peptides bacteriocins has distinct features and they are 
cationic, 30-50 amino acids long, hydrophobic and/or amphiphilic and all of them translated as 
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prepeptide with 15-30 amino acids N-terminal leader sequence ( Table-4). This leader sequence 
has double glycine motif, which is cleaved off at the C-terminal side of the double glycine motif 
by the peptidase activity of a dedicated ABC-transporter during export of the peptides from the 
cell (95, 217, 219, 225). Individual peptide of some two-peptide bacteriocins displays some  
antimicrobial activity, such as lacticin F (10) and plantaricin E/F and plantaricin J/K (11), 
although few others didn’t show any activity when tested individually. For example, lactococcin 
G, a two-peptide bacteriocins, didn’t show any activity when tested individually at concentration 
as high as 50 µM, but showed activity at 50 pM when both of the peptides were present (200, 
216). It has also been reported that a peptide from two-peptide bacteriocin only exhibit potent 
antimicrobial activity only if combined with the complementary peptide of the same two-peptide 
bacteriocin or in some cases combined with the peptide from a homologous two-peptide 
bacteriocin. For example, lactococcin G does not show any activity when combined with any of 
the peptide from plantaricin E/F or plantaricin J/K (11). However, they show activity when 
combined with the complementary peptide from lactococcin Q or enterocin 1071 (224, 225, 
327). This reality indicates that the two peptides of class IIb bacteriocins act together to display 
antimicrobial activity (219). This is in agreement with the facts that the genes encoding the two-
peptide bacteriocins are next to each other in a single operon along with a single immunity gene 
and both of them are expressed equally (18, 21, 89, 219, 247, 327). In addition, structural studies 
of the three two-peptide bacteriocins (lactococcin G, plantaricin E/F and plantaricin J/K) by 
circular dichrosim (CD) suggest that the complementary peptides interact in a structure-inducing 
manner upon arrival at the membrane (111, 112, 219). So, the synergistic activity of the two-
peptide bacteriocins is due to inter-peptide interactions, but not the activity of individual peptides 
at different sites of target cell (219). 
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Table-4: Amino acid sequences of two-peptide bacteriocins. The GXXXG-motifs are shaded 
yellow. Substitution of G with S has also been considered and shaded yellow along with 
GXXXG- motif. 
 
Name Chain Sequences Ref. 
Lactococcin G 
LcnGα GTWDDIGQGIGRVAYWVGKAMGNMSDVNQASRINRKKKH 
(216) 
LcnGβ KKWGWLAWVDPAYEFIKGFGKGAIKEGNKDKWKNI 
Enterocin 
1071 
Entα ESVFSKIGNAVGPAAYWILKGLGNMSDVNQADRINRKKH 
(89) 
Entβ GPGKWLPWLQPAYDFVTGLAKGIGKEGNKNKWKNV 
Plantaricin S 
Plsα RNKLAYNMGHYAGKATIFGLAAWALLA 
(280) 
Plsβ KKKKQSWYAAAGDAIVSFGEGFLNAW 
Lactocin 705 
705α GMSGYIQGIPDFLKGYLHGISAANKHKKGRLGY 
(297) 
705β GFWGGLGYIAGRVGAAYGHAQASANNHHSPING 
Plantaricin E/F 
PlnE FNRGGYNFGKSVRHVVDAIGSVAGIRGILKSIR 
(69) 
PlnF VFHAYSARGVRNNYKSAVGPADWVISAVRGFIHG 
Plantaricin J/K 
PlnJ GAWKNFWSSLRKGFYDGEAGRAIRR 
(69) 
PlnK RRSRKNGIGYAIGYAFGAVERAVLGGSRDYNK 
Salivaricin P 
Sln1 KRGPNCVGNFLGGLFAGAAAGVPLGPAGIVGGANLGMVGGALTCL 
(21) 
Sln2 KNGYGGSGNRWVHCGAGIVGGALIGAIGGPWSAVAGGISGGFASCH 
Mutacin IV 
NlmA KVSGGEAVAAIGICATASAAIGGLAGATLVTPYCVGTWGLIRSH 
(247) 
NlmB 
DKQAADTFLSAVGGAASGFTYCASNGVWHPYILAGCAGVGAVGSV
VFPH 
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Although the three dimensional structure of two-peptide bacteriocins is not well known 
as like class IIa peptides, CD and NMR studies of three peptides suggest that these peptides are 
unstructured in aqueous solution but gain helical structure when exposed to hydrophobic or 
membrane-like environment, such as trifluroethanol, micelles or liposome (87, 111, 112, 261). 
Almost all of the two-peptide bacteriocins carry GXXXG-motif (where X denotes any amino 
acid) which is believed to be involved in helix-helix interaction in membrane proteins (270). 
However, in some cases substitution of well-conserved G with S/A residue have been reported 
(81, 226). It has been proposed that α and β peptides of these two-peptide bacteriocins interact 
through GXXXG-motif (219). The proposed structural model suggests that α and β peptides in 
the helix-helix structure reside in a parallel orientation and staggered in a mode relative to each 
other (261), which in turn generate and/or stabilize helical structure in the GXXXG-motif and 
more unstructured region between the N- and C- terminal helical region in the α and β peptides. 
Proposed structural model also indicates that the immunity proteins of class IIb bacteriocin might 
interact with the N-terminal region of the α-peptide and C-terminal region of the β-peptide (219). 
Replacement of glycine residues in the GXXXG-motif is detrimental for antimicrobial activity of 
lactococcin G, suggesting that they are indeed involved in helix-helix interaction (226). 
Class III (bacteriolysins): Bacteriolysins are large heat-labile  proteins that cause 
hydrolysis of  cell wall peptidoglycan structure (54). They have different domains to exert their 
activities, in which every domain has its specific function, such as translocation, receptor binding 
and lethal activity. So far, genetic characterization has been done for four bacteriolysins from 
LAB strains (24, 135, 214, 273). These modular proteins have N-terminal catalytic domain 
which has homology to endopeptidase and a C-terminus probable target recognition site (140, 
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162). In contrary to other classes of bacteriocins, they do not always have specific immunity 
proteins, rather depends on producers’ cell wall modification to prevent the self-toxicity (54). 
Class IV (cyclic bacteriocins): This class of bacteriocins has covalently linked N- and 
C- terminal structure (219). They are cationic, hydrophobic and their size varies from 3.4 kDa to 
7.2 kDa. All of them permeabilize the target cell membrane to small molecules that cause the 
disruption of membrane potential, which ultimately results in cell lysis (219). Enterocin AS-48 is 
the best characterized cyclic bacteriocin which contains 70 residues and produced by several 
species of enterococcus (96, 189, 190). Cyclic structure might protect the bacteriocins from 
proteolysis (219) and are active against both gram-positive and gram-negative bacteria (184). 
Mutacins (bacteriocins of S. mutans): Mutacins, bacteriocins of S. mutans origin, were 
first studied by Kelstrup and Gibbons (145) and the word ‘mutacin’ was coined by Hamada and 
Ooshima in 1975 (106).  Interest was raised for their possible use as anti-caries agents, role in the 
colonization of the oral cavity and as epidemiological fingerprinting tools (100, 107). New 
interests are being developed for their potential use as food preservatives and as new 
antimicrobial therapeutics (205, 212). Several mutacins from both lantibiotics and non-
lantibiotics groups have been characterized to date (Table-5) (196). Mota-Meira et al. (205) and 
Morency et al. (203) showed that mutacin producing bacteria can inhibit food-borne pathogenic 
bacteria, such as L. monocytogenes, B. cereus, C. perfringens, S.  aureus and Campylobacter 
jejuni. Mutacins can also inhibit various streptococci and enterococci, including some multi-drug 
resistant strains (156, 206, 247, 248). Two prominent pathogens, Helicobacter pylori and 
Neisseria gonorrhoeae have also been shown to be sensitive to mutacins (206). 
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Table-5: Characteristics of known mutacins from Streptococcus mutans 
Class 
Name of 
Mutacins 
Producer 
strains 
Mature peptide Activity spectra 
 
 
 
 
I 
I 
UA140; 
CH43 
FSSLSLCSLGCTGVKNPSFNSYCC 
L. monocytogenes, C. 
perfringens, Bacillus, C.  
sporogenes, LAB, 
Campylobacter jejuni,& 
Staphylococcus aureus 
(17, 75, 196, 205, 247) 
II T8;UA96 NRWWQGVVPTVSYECRMNSWQHVFTCC 
III (1140) 
JH1140; 
UA787 
FKSWSLCTPGCARTGSFNSYCC 
B-NY266 NY266 FKSWSFCTPGCAKTGSFNSYCC 
SmbA GS5 STPACAIGVVGITVAVTGISTACTSRCINK L. monocytogenes, S. 
aureus and LAB (196, 
212, 239, 325) 
SmbB GS5 
GTTVVNSTFSIVLGNKGYICTVTVECMRN
CSK 
K8 K8 MGKGAVGTISHECRYNSWAFLATCCS 
Similar to mutacin I & C. 
botulinum (257, 298) 
 
 
 
II 
IV 
(NlmA) 
UA140; 
UA159 
KVSGGEAVAAIGICATASAAIGGLAGATL
VTPYCVGTWGLIRSH 
Listeria, Enterococcus, 
Lactobacillus, Bacillus , 
Streptococcus,  Clostridium 
& Leuconostoc (103, 212, 
247, 325) 
IV 
(NlmB) 
UA140; 
UA159 
DKQAADTFLSACGGAASGFTYCASNGVW
HPYIL AGCAGVGAVGSVVFPH 
V 
UA140; 
UA159 
GRGWNCAAGIALGAGQGYMATAGGTAF 
LGPYAIGTGAFGAIAGGIGGALNSCG 
L. lactis & Non-
streptococcal spp (104, 
299) 
VI UA159 
GMIRCALGTAGSAGLGFVGGMGAGTVT 
LPVVGTVSGAALGGWSGAAVGAATFC 
Enterococcus faecium 
(196, 320) 
N N 
SRQAADTFLSGAYGAAKGVTARASTGVY
VVPATL VALGVYGAGLNIAFP 
Similar to class I & oral 
streptococci (16, 102) 
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Mutacin B-Ny266 has inhibitory activity against many nisin-A resistant strains (L. 
monocytogenes Scott A, Pediococcus acidilactici), oxacillin-resistant strains (Enterococcus 
faecalis, S. aureus and S. epidermidis) and vancomycin-resistant strains (N. gonorrhoeae, E. 
faecalis) (205). Mutacins I and III have shown to have more potency than nisin to inhibit 
methicilin-resistant S. aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and S. 
epidermidis, displaying minimum inhibitory concentrations lower than 10 µg/ml (246, 249).  
Mutacins I, II, III and IV can inhibit the group A streptococci (GAS) and penicillin-resistant S. 
pneumoniae with MICs below 1µg/ml (249). 
Lantibiotic mutacins show  activity against the wide variety of gram-positive bacteria, 
whereas non-lantibiotic mutacins (Nlm) are mainly active against the closely related bacteria 
(196). So far, six lantibiotic mutacins have been characterized which  include mutacin I (248), 
mutacin II (220), mutacin III/ mutacin 1140 (122, 246), mutacin B-NY266 (206), mutacin K8 
(257) and mutacin Smb (325). All of the necessary genes (such as precursor, modification, 
transporter and immunity genes) required for lantibiotic mutacins production are organized in the 
same gene cluster (Fig.3) (196). On the other hand, the non-lantibiotic mutacins are widely 
present in every S. mutans strain analyzed so far (142, 196). In general, each of the strains 
encodes more than one non-lantibiotic mutacin genes. However, they have comparatively narrow 
spectrum of activity than the lantibiotic mutacins. For instance, mutacin IV is active against 
various non-mutans streptococcal species, staphylococci or enterococci (103, 247). So far, four 
different non-lantibiotic mutacins have been characterized, such as mutacins IV, V, VI and 
mutacin N (16, 103, 247, 320). In contrast to lantibiotic mutacins, genes necessary for non-
lantibiotic mutacins are not organized in the same gene cluster, despite the same ABC transporter 
is required for processing and transport of multiple non-lantibiotic mutacins (103).  
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Although the genome sequence of S. mutans UA159 (7) suggests the presence of several 
other non-lantibiotic mutacins encoding genes based on the presence of well-conserved GXXXG 
and GG motifs (Table-6) (212, 299), two of them are well recognized such as non-lantibiotic 
mutacin IV (NlmAB) and mutacin V (NlmC) (104). Mutacin IV is a two-peptide bacteriocin 
produced by S. mutans UA140 and UA159 which is active against the mitis group of streptococci 
(247). Both of the peptides are encoded by nlm operon, which contains two genes, nlmA and 
nlmB, organized in tandem (7). Both peptides contain signal sequences with well conserved GG 
motifs, the site where peptidase cleavage occurs during export. NlmTE, a transporter complex, 
cleaves the signal sequence and mediates the export of these peptides (103). Each peptide also 
contains a single GXXXG motif, which is essential for bacteriocin activity due to its 
involvement in the formation of the helix-helix interaction (219). Mutacin V (also called CipB), 
a single peptide bacteriocin, is encoded by nlmC. The NlmC peptide is 52 residues long, with a 
signal peptide and three GXXXG motifs (104). This mutacin is also secreted by the NlmTE 
export system (103) and appears to have broad antimicrobial activity, ranging from mitis 
streptococci to lactococci and micrococcus (104). However, unlike mutacin IV, which was 
purified from the culture supernatant (247), mutacin V activity has never been purified. 
Biosynthesis and export: At least four genetic components are required for production 
of class II bacteriocin (82, 219), such as (i) structural bacteriocin gene, encoding a 
prebacteriocin; (ii) a gene encoding an ABC transporter (ATP-binding cassette) for secretion; 
(iii) a gene encoding the immunity gene which provides protection to self-toxicity; and (iv) a 
peptide pheromone mediated two-component system to activate the bacteriocin gene expression. 
Bacteriocins are usually expressed as pre-peptide with an N-terminal leader sequence. This 
leader sequence is cleaved by site-specific protease while exporting through the ABC transporter  
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Table-6: Putative bacteriocins of S. mutans UA159 based on the presence of GG- and GXXXG-
motifs in the respective peptides. Substitution of G with S has also been considered and shaded 
yellow along with GXXXG- motif. 
 
Gene ID Size Mature peptide 
SMU.150 67 KVSGGEAVAAIGICATASAAIGGLAGATLVTPYCVGTWGLIRSH 
SMU.151 78 DKQAADTFLSAVGGAASGFTYCASNGVWHPYILAGCAGVGAVGSVVFPH 
SMU.281 92 VLGAGTGFTAGFKPAQFLWRVPVAGPYLALGTLDLTTVAGVYIGAREGWGDGGFW 
SMU.283 72 FDVKGVAASYLAMGTAALGGLACTTPVGAVLYLGAEVCAGAAVIYYGAN 
SMU.299 72 GLYDGANGYAYRDSQGHWAYKVTKTPAQALTDVVVNSWASGAASFAAYA 
SMU.423 76 GMIRCALGTAGSAGLGFVGGMGAGTVTLPVVGTVSGAALGGWSGAAVGAATFC 
SMU.1719 82 TFIARKQMEKYLEENPPLNEDVIRNMMSQMGQKPSEAKVQQVVRQMNKQQKAAKA
KAKKKK 
SMU.1882 117 YNSSIGYSAQGNRGFSNYPYDVSMDSDNSSSSSNTTGGYVNYNQSFNSGW 
SMU.1889 88 LAGAGTGAAVSAPAAEGGGLGPIAGAAIGWDLGAISGAGLGWANFCQ 
SMU.1892 61 SENIARFAAAFENEQVVSYARWFRRSWRGSGSSSRF 
SMU.1895 53 MTWAEIGAIVGATIGSFYIPNPVIVPFRVR 
SMU.1896 100 FGWDSIWRGFKCVAGTAGTIGTGALGGSATGGLTLPIIGHVSGGIIGGISGAGVGIASF
C 
SMU.1905 62 GRAPRCAALVGASIYDGLAVVGDPVGVAMAAGTIAAGSFC 
SMU.1906 70 GCSWKGADKAGFSGGVGGLIGAGGNPVGGVLGIAGGLDAYGELVGGN 
SMU.1914 76 GRGWNCAAGIALGAGQGYMATAGGTAFLGPYAIGTGAFGAIAGGIGGALNSCG 
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and the matured peptide is secreted (114, 302) or, sometimes, by general secretion pathway (Sec) 
of the cell (54). The C-terminal cytosolic domain of the transporter contains the ABC-binding 
cassette which propels the secretion of the peptides out of the cell with the hydrolysis of ATP 
and  the proteolytic N-terminal domain of cysteine protease family is involved in cleavage and 
maturation of the pre-peptide (13, 219). The pre-bacteriocins are cleaved off at the C-terminal 
site of the GG- motif (88) and transmembrane domains of the transporter as well as some 
accessory proteins are required for translocation of the mature bacteriocin through the membrane 
(82). For lantibiotics, the structural bacteriocin genes are normally organized with the genes 
needed for regulation, export, immunity and modifications (54). The leader sequence is believed 
to maintain the bacteriocins in inactive state in the cytosol to prevent self-toxicity. It might also 
act as specific signal sequence which is recognized by transporter system for export and required 
for post-translational modification by the modification apparatus in case of lantibiotics (43, 208, 
318). Supporting this hypothesis, it has  recently been shown that the secretion rate and the 
proteolytic efficiency are dependent on the amino acid sequences of the leader peptide (13).  
Regulation of biosynthesis: Bacteriocins production is regulated by various 
environmental and genetic factors. Temperature, pH, aeration, concentration of nitrogen and 
carbon sources, presence of essential elements, vitamins and cell density reportedly influence the 
bacteriocins production by altering the transcription of structural genes or operons (196, 212). 
However, it is still unknown how these environmental factors regulate the mutacins genes 
expression (196). Many studies have suggested that mutacins production in liquid medium is 
relatively low in compared to agar plate and yeast extract shown to be activator of mutacin 
production (211, 212, 233, 259). It has been shown that cell density has direct correlation with 
bacteriocin expression in S. mutans. Studies on the expression of lantibiotic mutacin I and non- 
24 
 
lantibiotic mutacin IV suggested relatively low level of expression in liquid media, which can be 
boosted to higher level if incubated at cell pellet (156, 158, 195) or allowed to form colonies 
onto agar plate (157).  
The genetic components required for mutacin biosynthesis are located in the chromosome 
and display little variation in their organization (Fig. 3). Many lantibiotics show auto-inducing 
ability and involve the activation of  two-component regulatory pathway which are organized in 
the same operon (152). In case of class II bacteriocins, inducing peptide is called peptide 
pheromone and is not present in the same operon (212). However, non-lantibiotic mutacins do 
not exhibit auto-inducing ability and they don’t have membrane-histidine kinase and cognate 
response regulator in their biosynthetic operon except for mutacin K8 (257). The presence of the 
homologous of Rgg-family (regulator gene of glycosyltransferase) transcriptional regulator has 
been reported in the biosynthetic operon of mutacin I, II and III and named MutR (42, 246). 
MutR is indispensable for mutacin genes expression in case of mutacin I and II and mutation of 
mutR gene cause drastic reduction of transcription of the downstream mutacin operon  and 
diminished mutacin activity in deferred antagonism assay (154, 246) (Fig. 4). Several other 
factors have been reported to be involved in mutacin production recently. CiaH, a two-
component sensor kinase, and an interspecies signaling system, LuxS, have been shown to 
regulate mutacin I expression (195, 250). However, role of CiaH in mutacin production among 
different strains vary considerably. While inactivation of ciaH in S. mutans T8 and UA140 does 
not have any role in expression of mutacin II and IV respectively (250), mutacin IV production 
in UA159 was reduced more than 100-fold (28). Merrit et al. (195) suggested that LuxS regulates 
mutacin I production and ComDE controls mutacin IV production in S. mutans. Deletion of 
another two-component sensor kinase, LiaS, and an AAA
+
 protease, ClpP, also reduced the  
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Fig. 3. Genetic organization of mutacins-encoding genes with their accessory factors in S. 
mutans [adapted from Merrit et al. (196)]. Green indicates the mutacin structural genes; red 
indicates the transcriptional regulator for mutacin production; purple color indicates the genes 
involved in post translational modification of lantibiotics; blue represents the genes necessary for 
transport and processing of pre-peptides; and immunity proteins are marked with orange color. 
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Fig. 4. Summary of the regulation of mutacins production. Various regulatory pathways involved 
in mutacin production are colored differently. Lightning bolt indicates direct transcriptional 
regulation and purple colored lines indicate conditional regulation. Dashed line indicates the 
indirect activation by unknown mechanism. Cell density is the most prominent extrinsic factor 
for mutacin genes expression which directly or indirectly activates ComCDE, HdrRM and 
BsrRM pathways. ComDE directly senses the external CSP and activates the expression of 
mutacin genes. HdrR and BrsR can activate the expression of mutacins only in the absence of 
their cognate repressors, HdrM and BrsM. All bacteriocins are exported outside the cell through 
a dedicated ABC transporter, NlmTE. 
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mutacin IV production in UA159 (41, 46). Random insertional mutagenesis revealed 25 
additional genes for the expression of mutacin I in the virulent strain UA140 (291). They include 
two-component signal transduction system (vicRK and hk03/rr03), a stress response regulator 
(hrcA), metabolic enzymes (pttB, adhE) and some genes involved in central cellular processes. In 
the same manner, Merrit et al.(197) identified a novel high-cell-density-responsive membrane 
bound protein, HdrM, which regulates mutacin production and competence development in S. 
mutans. Recently, another novel regulator for mutacin gene expression has been reported 
(BrsRM) and both of the new regulators bypass the classic ComCDE system for mutacin 
production (221, 222, 320). Both of these genes show similarity with LytTR family two-
component regulator of  various gram-positive bacteria (212). These newly identified regulatory 
systems (HdrRM and BrsRM) contain a membrane-bound inhibitor protein (M) and an 
associated LytTR family transcription factor, where inhibitor proteins (HdrM and BrsM) 
antagonize the activity of the transcriptional regulators (HdrR and BrsR)(196). For this reason, 
mutation of hdrM and brsM caused constitutive expression of hdrR and bsrR. As a result, 
mutacin genes were expressed greatly and increased mutacin production was observed during 
deferred antagonism bacteriocin assay (221, 320). Further studies suggested that BrsR can bind 
ComE-response-element (another LytTR family transcriptional activator) present in the promoter 
region of  bacteriocin genes (320). However, it is still unknown which cellular or environmental 
factors activate these genes.  
Expression of mutacins production in S. mutans UA159 is mostly driven by a two-
component signal transduction system through the quorum-sensing mechanism (Fig.5) (54, 196). 
In this organism, a two-component system (ComDE) is induced by a peptide pheromone called, 
CSP (competence stimulating peptide) in response to high cell density and some other 
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environmental stresses  (172, 237, 299). CSP-mediated response is also implicated in biofilm 
formation, competence development and acid-tolerance (6, 173). CSP is encoded by comC gene 
and translated as prepeptide with a leader sequence containing double-glycine (GG) motif which 
is cleaved off while exporting through the ABC transporter, CslAB (competence-related 
secretory locus) (103, 173, 212, 241). When a certain level of CSP reaches in the medium, it is 
recognized by membrane sensor kinase (ComD) and become autophosphorylated which in turn 
activates the response regulator (ComE) by transferring the phosphate group. The activated 
ComE then induces the expression of  mutacins and related genes by recognizing an conserved 
imperfect 11-bp direct repeats present in the promoter region of the bacteriocins encoded genes 
(1, 129, 153, 156, 158, 168, 237, 299). Due to this ability of binding to direct repeat motif, ComE 
is included to the group of AlgR/AgrA/LytR family transcription activators (213). The CSP-
stimulated signal transduction system also activates a competence-controlling alternative 
transcription factor, ComX (also known as SigX), by an unknown indirect mechanism (156), 
since ComE binding site is absent in the promoter region of comX gene. Instead, they contain a 
com-box (also termed cin-box) consensus sequence (TACGAATA) in the -10 promoter region of 
the responsive genes (173).  In streptococci, ComX regulates the expression of late competence 
genes comYA-G which encode proteins involved in DNA uptake and recombination process 
essential for competence development (187). Based on these outcomes, it was proposed that 
mutacin production and competence development in S. mutans is co-coordinately regulated by 
ComE and/or ComX (173). Recently, Mashburn-Warren et al. (191) showed that ComR/ComS is 
essentially required for competence development through the activation of SigX and ComE can’t 
activate the sigX expression in comR mutant, suggesting that ComE acts upstream of 
ComR/ComS regulon by an still unknown mechanism and can’t bypass it. Furthermore, comE  
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Fig. 5. Schematic diagram of the biosynthesis of class II bacteriocins by two-component signal 
transduction pathway. Mature inducer peptides (pheromone) pass through the ABC transporter 
and activate sensor histidine kinase (HK) which is autophosphorylated at the cytosolic side. 
Activated HK can now transfer the phosphate group to cytosolic response regulator (RR), which 
in turn activates the expression of bacteriocins related genes.  
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deletion neither blocked sigX expression, nor CSP could activate the transformation in comR 
mutation background. In addition, deletion of comC didn’t exhibit any significant effect on comX 
expression and transformation in S. mutans UA159 (6), which raised the question of the role of 
CSP in competence development.  
Bacteriocin immunity: Bacteria that produce bacteriocins always have immunity 
mechanism which protects them against the cognate bacteriocin. This system is highly specific 
and usually don’t provide protection against other bacteriocins (278, 297), even though, some 
exceptions have been reported (79, 90). For instance, lactococcin G immunity protein provides 
protection against lactococcin G, but not against enterocin 1071. However, lactococcin G 
immunity protein can protect enterococci against enterocin 1071 (212). In case of lantibiotics, 
the immunity system is conferred by three genes (lanFEG) which encodes the LanFEG ABC 
transporter which pumps out lantibiotics from the membrane to the external medium (212). 
These proteins might be associated with another gene (lanI) which encodes a lipoprotein that has 
membrane-bound specific lantibiotic-binding activity, thereby protecting the producer bacteria 
(286). These two immunity systems function either independently or cooperatively to provide the 
immunity activity against the cognate lantibiotic (12, 40, 279).   
For class II bacteriocins, immunity is generally conferred by one gene located just 
downstream of the bacteriocin structural gene(s) in a same operon (147, 212). For this conserved 
genetic organization, it is easy to identify the putative immunity genes for cognate bacteriocins 
and their functions have been tested by heterologous expression in sensitive cells. For instance, 
LagC immunity protein rendered the sensitive bacteria immune to cognate class II bacteriocin, 
lactococcin G  (223) and EntqC provides immunity activity to enterocin Q (56). Although 
immunity proteins for class II bacteriocins differ to a great extent in their size and sequences, 
34 
 
exact molecular mechanisms of immunity is still unclear for most of the bacteriocins. Recently, 
few studies have tried to understand the immunity mechanisms for some class II bacteriocins 
(70, 93, 149). To date, at least 20 tentative immunity proteins for class IIa bacteriocins have been 
identified based on their DNA sequences (73). They are highly charged (containing 25-35% 
charged residues) and mostly localized in the cytosol or loosely associated with the inside of the 
cell membrane (61, 251). Expression of these proteins can protect the sensitive cells to externally 
added cognate bacteriocins (85, 251). However, external addition of both the bacteriocins and 
immunity proteins can’t provide protection to sensitive cells, which indicates that immunity 
proteins to class IIa act from inside the cells. Similar results were also found for the immunity 
protein of non-class IIa bacteriocin, lactococcin A (215, 277, 301). 
Three-dimensional structure of at least two class IIa immunity proteins have been 
illustrated recently. Immunity proteins for carnobactericin B2 (ImB2) was studied by NMR (277) 
and immunity protein for enterocin A (EntA-im) was studied by X-ray crystallography (59, 138). 
Both of the studies revealed that they have the same 3D structure despite the presence of 
different amino acids and immunity activity toward two different class IIa bacteriocins. Both of 
them are globular in nature and cytosolic with four antiparallel left-turning alpha helices linked 
with short loops and the helices are oriented relative to each other forming a hydrophobic core in 
the center of the protein, whereas the hydrophilic and charged residues are present at the surface 
of the proteins (Fig. 6). ImB2 and EntA-im shows structural differences at the C-terminal parts 
the helix-4. Whereas ImB2 has distinct short alpha helix with a C-terminal extension, C-terminal 
ends of EntA-im is relatively flexible (138). Homology modeling revealed that the four-helix 
bundle is a conserved structural motif for class IIa immunity proteins and the length of the alpha 
helices are relatively constant with minor variation in the loops (73, 138). Presence of positively 
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charged residues on the surface of immunity proteins has been predicted to be involved in 
interaction with the negatively-charged phospholipids of the membrane (138, 277). However, 
structural analysis with circular dichroism of EntA-im while exposing to membrane-mimicking 
entities did not provide any further structuring, indicating that class IIa bacteriocins don’t interact 
with the cell membrane extensively (139). But the immunity protein to non-class II bacteriocin 
(lactococcin A) interacts with the membrane to display immunity activity (215, 301). Recently, 
Chang et al. (39) solved the crystal structure of the gene-product of locus Spy_2152 from S. 
pyogenes and found that it also contains an anti-parallel four-helix bundle that is structurally 
similar to other class IIa bacteriocin immunity proteins. This protein can be a possible immunity 
protein to class IIb bacteriocin based on the fact that  S. pyogenes does not contain any class IIa 
pediocin-like proteins but has class IIb bacteriocins encoding genes. It has been shown that the 
first methionine and C-terminal 23 residues are disordered and the four helices are organized 
tightly together around a well-defined hydrophobic core. However, its cognate bacteriocin has 
not been identified yet.  
The immunity proteins exhibit specificity to their cognate bacteriocins, even though their 
3D structures show high level of similarity (139, 251). Fimland et al. (85) demonstrated that 
immunity proteins to pediocin-like bacteriocins can protect against their cognate bacteriocins as 
well as to other class IIa bacteriocins, although the extent of immunity was lesser in case of non-
cognate bacteriocin. Cross-immunity was mainly directed toward closely related bacteriocins. 
For example, pediocin PA-1/AcH and sakacin P are very similar and immunity protein of 
pediocin or sakacin displayed immunity activity against both of them, even though they were 
only 28% similar (85). Cross-immunity is not limited to class IIa bacteriocins and it has been 
found that immunity protein for carnobacteriocin A can protect structurally related bacteriocin 
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Fig. 6. Crystal structure of a typical bacteriocin immunity protein (pyogenecin) isolated from 
Streptococcus pyogenes (39). The structure shows a four helix bundle in two-orthogonal view 
and the N- and C-termini are labeled blue and red color respectively. 
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enterocin B (90). Studies with hybrid immunity proteins, Johnsen et al. (139, 140) demonstrated 
that the C-terminal, disordered region of immunity proteins specifically interacts with the C-
terminal part of the cognate class IIa bacteriocin (140, 277). According to this model, there is no 
direct contact between bacteriocins and immunity proteins and both of them reside in opposite 
sides of the cell membrane (Fig. 7a). The mechanisms by which the C-terminal part of the 
immunity protein recognize the cognate bacteriocins and protect against it is still unknown (73). 
The length of the immunity proteins to Class IIa bacteriocins and lactococcin G varies in 
size from 88 to 118 amino acids and display very poor similarities in their sequences in 
compared to high sequence similarities among their target bacteriocins (79, 85). Immunity 
system to lactococcin G, a class II bacteriocin, is well studied and revealed the details 
mechanism of immunity functions in L. lactis. Cloning of lciA (lactococcin A immunity gene) to 
a sensitive strain has rendered it to be immune to lactococcin G (125). It has been proposed that 
mannose phosphotransferase system (man-PTS) is involved in target recognition for these 
bacteriocins to induce pore formation in the membrane (147), since resistant strains were found 
to lack in expression of  man-PTS (99, 253). In addition, introduction of Man-PTS from a 
sensitive cell converted the resistant lactococcal cells to become sensitive to various class IIa 
bacteriocins (70, 252). It has been reported that immunity proteins are always associated with the 
membrane fraction in producer bacteria although they are normally localized in the cytosol 
(301), suggesting two different conformations in producer cells. Recently, Diep et al. (70) 
showed that immunity protein, LciA, behaves differently whether bacteriocins are present or not. 
In the presence of bacteriocin, the immunity protein is strongly associated with the bacteriocin-
man-MPT complex, thereby providing immunity to the producer cells (Fig.7b). On the other 
hand, immunity proteins were found unassociated in the absence of bacteriocin. This study 
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indicated that similar bind-and-lock immunity mechanism is present to several other class IIa 
bacteriocins (70), suggesting the convergence of receptor targeting (man-PTS) in class II 
bacteriocins despite the lack of similarities in amino acid sequence of bacteriocins and their 
cognate immunity proteins (147).  
Transporter systems have also been shown to be involved in immunity activity against 
two bacteriocins (67, 93). Multidrug resistance (MDR) transporter system provides immunity to 
bacteriocins LsbA and LsbB in a natural isolate of Lactococcus lactis where the transporter 
LmrB is involved in secretion and immunity to this class II bacteriocin (93). In case of enterocin 
AS-48, immunity activity is conferred by specialized ABC transporters which are presumed to 
pump out the bacteriocins from the membrane (67).  
Immunity mechanisms to two-peptide bacteriocins are poorly understood. Recent studies 
suggest that a proteolytic mechanism might be involved in conferring immunity to class IIb 
bacteriocin (150). It has been reported that Abi family proteases determine the immunity activity 
in several class IIb bacteriocins encoding loci, such as pnc locus of S. pneumoniae (179), pln 
locus of Lactobacillus plantarum and the skk locus of Lactobacillus sakei (150). While immunity 
activity to class II bacteriocins show high level of specificity, Abi family immunity proteins 
display cross-immunity to different bacteriocins (150), which indicates that they provide 
immunity via a common proteolytic mechanism (147). Despite the fact that substrates of this 
proteases family are yet to be identified in bacteria; it has been shown that bacteriocin itself is 
not the proteolytic substrate of this proteases (150). 
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Fig. 7. Proposed model for immunity mechanism. (A) A model showing the presence of 
bacteriocins on the extracellular side of the cell membrane and cognate immunity protein on the 
cytosolic side. C-terminal part of the immunity protein recognizes the bacteriocins and protects 
against it; (B) this cartoon shows the mode of action (a) and immunity mechanism (b) for class 
IIa bacteriocin system. The N-terminal β-sheet of bacteriocin (red color) interacts with the 
extracellular loop of Man-PTS IIc protein (green bar) and thereafter C-terminal helical part 
inserts into the membrane by interacting with the transmembrane helices of the IIC and/or IID 
proteins (right panel) which leads to pore formation and cell death (a). During immunity, the 
specific immunity protein blocks the pore formation by binding tightly to the Man-PTS in 
response to bacteriocin-mediated conformational change (b). 
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In this study, I explored the role of NlmA and NlmB peptide in mutacin IV activity, 
mechanism of self-immunity and CSP-mediated regulation of nlmAB expression. By using 
genetic approaches and with semi-purified peptides, we showed that optimum activity is 
dependent on the presence of both peptides. We also showed that mutacin IV is active against 
multiple streptococci and lactococcal species. Our study suggests that a gene, SMU.152, located 
just downstream of nlmAB operon confers immunity activity to mutacin IV in S. mutans UA159. 
However, this immunity is not specific; several other putative immunity proteins could also 
provide cross-immunity to mutacin IV in producer strain in absence of cognate immunity 
protein, SMU.152. By using pGhost9::ISS1 mutagenesis, we have identified several new factors 
required for expression of mutacin IV. Further studies revealed that a well-conserved Lon 
protease-mediated cleavage of CSP is required for the activation of nlmAB genes expression. By 
site directed mutagenesis, we identified that S-235 and K-280 are essential for Lon protease 
activity of SMU.518. Our studies also demonstrated that a gene involved in glucose side chain 
formation, SMU.832, and a conserved hypothetical protein, SMU.2137, are also required for 
optimum mutacins production by S. mutans UA159. 
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CHAPTER TWO 
   METHODS AND MATERIALS 
Bacterial strains and growth conditions: Escherichia coli strain DH5α and T-10 were 
grown in Luria-Bertani medium supplemented, when necessary, with ampicillin (100 μg/ml), 
erythromycin (300 μg/ml), and kanamycin (100 μg/ml). Various streptococci strains were 
routinely grown in Todd-Hewitt medium (BBL; Becton Dickson) supplemented with 0.2% yeast 
extract (THY) at 37°C. Lactococcus lactis MG1363 was grown in M17 medium supplemented 
with 0.5% glucose or THY medium at 30°C. When necessary, erythromycin (5-10 μg/ml), 
kanamycin (300-500 μg/ml) or spectinomycin (300 μg/ml) was added to the sterile growth 
media. Bacterial growth was monitored with a Klett-Summerson colorimeter as described 
previously (30). 
Transformation assay: To carry out transformation assay, S. mutans strains were grown 
up to desired growth stage (A595 of 0.2 until or unless mentioned) and CSP (200nM) was added if 
needed followed by 10 min incubation at 37
0
C. 1.0 µg of linear or circular DNA was added to 
1.0 ml culture; followed by incubation at 37
0
C for 2-hr and plating onto THY-agar plate with or 
without antibiotics. Colonies were appeared after 2-3 days of incubation and a single colony was 
inoculated into THY-broth with respective antibiotics for further analysis. Transformation 
efficiency was measured as transformants/10
9
 cfu/µg of DNA if needed. Total counts were 
measured by plating onto THY agar plate without any antibiotic.  
Deletion of nlmAB operon: nlmAB operon was deleted using a Cre-loxP based method 
(20). First, nlmAB operon with approximately 700-bp flanking regions was amplified with primer 
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set SMU. NlmA Nested-F1and Xho-SMU-Nlm-R1 (for all the primers, see Table-9) using S. 
mutans UA159 chromosomal DNA as template and cloned into the pGEM-T Easy cloning vector 
(Promega) to create the plasmid, pIB-D10. A Km resistant cassette with flanking modified loxP 
sites, was amplified from pUC4 ΩKm (235) using the primers lox71-Km-F and lox66-Km-R and 
cloned into BbsI and BstEII digested, T4 DNA polymerase blunted pIB-D10, to generate pIB-
D16. Plasmid pIB-D16 was linearized with EcoRI and transformed into S. mutans UA159 as 
previously described (31). Transformants were selected on THY plates containing Km; one such 
transformant was named IBS-D1. To eliminate the loxP-Km
r
 cassette from the chromosome, 
IBS-D1 was transformed with pCrePA(20), which expresses the cre recombinase gene from a 
temperature-sensitive  replicon (pWV01).  Em
r 
and Km
s
 colonies were then selected which 
contain pCrePA and lost the Km
r 
resistance gene from the chromosome. To cure the plasmid, one 
selected colony was inoculated into THY broth without antibiotics and grown overnight at 37
0
 C 
and plated onto THY-agar plate. Em
s
 colonies were isolated by replica patching; one such clone 
was selected for further analysis and named IBS-D3. Deletion of nlmAB operon was verified by 
PCR analysis. 
Deletion of nlmA gene:  nlmA gene was deleted using a Cre-loxP- based method as 
previously described (20). First, approximately 1000-bp upstream and downstream regions were 
amplified with primer set SMU-NlmA-Nested-F1/EcoR-V SMU. NlmA-5’Fusion and EcoR-V 
SMU. NlmA-3’Fusion/SMU. Nlm Nested –R1 (for all the primers, see Table-9) using S. mutans 
UA159 chromosomal DNA as template. Two fragments were then digested with EcoRV 
followed by ligation and cloning into the pGEMT-Easy cloning vector (Promega) to create pIB-
D15. A Km resistant cassette with flanking modified loxP sites, was amplified from pUC4ΩKm 
using the primers lox71-Km-F and lox66-Km-R and cloned into the EcoRV digested site to 
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generate pIB-D17. Plasmid pIB-D17 was linearized with EcoRI and transformed into S. mutans 
UA159 as described above. Transformants were selected on THY plates containing Km; one 
such transformant was named IBS-D2. To eliminate the loxP-Km
r
 cassette from the 
chromosome, IBS-D2 was transformed with pCrePA, which expresses the cre recombinase gene 
from a temperature-sensitive replicon (pWV01). Subsequently, Em
r 
and Km
s
 colonies were 
selected; those colonies contain pCrePA and lost the Km resistance gene from the chromosome. 
To cure the plasmid, one selected colony was inoculated into THY broth without antibiotics and 
grown overnight at 37
0
 C and plated onto THY-agar. Em
s
 colonies were isolated by replica 
patching; one such clone was selected for further analysis and named IBS-D4. Deletion of nlmA   
gene was verified by PCR analysis (Fig. 8B) and sequencing. 
Deletion of nlmB gene:  nlmB gene was deleted by overlapping fusion PCR. First, 
approximately 1000-bp upstream and downstream regions were amplified with primer set SMU-
NlmA-Nested-F1/ nlmB 5' fusion-R and nlmB 3' fusion-F / XhoI SMU. Nlm-R using S. mutans 
UA159 chromosomal DNA as template. A Km resistant cassette was amplified from pIB-D7 ( 
created by cloning Km cassette into pGEMT-EZ vector)  using primers Kan D7 F and Kan D7 R 
which have the 20-bp overlapping region with the two fusion primers used for amplifying 
upstream and downstream sites of nlmB gene. Equal amount of PCR products from each of the 
three products were further used as template for overlapping PCR using the primer set SMU-
NlmA-Nested-F2/ SMU- Nlm-Nested-R1. Amplified product was PCR purified and transformed 
into UA159 as described above. Transformants were selected on THY plates containing Km and 
one such transformant was named IBS-D10. Deletion of nlmB gene was verified by PCR 
analysis (Fig. 8B) and sequencing. 
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Deletion of nlmAB and nlmC gene: To delete the nlmC gene, a fragment containing 
nlmC locus was amplified with ~1000-bp flanking regions from the genomic DNA of an nlmC 
deletion strain (containing Em
r
 cassette; kindly provided by C. Levesque, University of Toronto) 
with primers SMU NlmC F1 and SMU. 1913-R (237). Amplified product was PCR purified and 
transformed into IBS-D3 as described above. Transformants were selected on THY plates 
containing Em; one such transformant was named IBS-D13. Deletion of nlmC gene was verified 
by PCR analysis. 
Deletion of SMU.152: SMU.152 was deleted by fusion PCR as previously described 
(127).  Briefly, 1000-bp upstream and downstream regions were amplified with the primers sets 
SMU. NlmA Nested F/SMU.152 5' Fusion-R and SMU.152 3' Fusion-F/SMU.152 3' R using S. 
mutans UA159 chromosomal DNA as template. A Km resistant cassette was amplified from 
pIB-D38 with NcoI-Kan-F and PstI-Kan-R primers and overlapping fusion PCR was carried out 
using equal amount of each PCR products with the primers SMU. NlmA Nested F and SMU.152 
3' R. The amplified products were purified and transformed into S. mutans UA159 as described 
above. Deletion of the SMU.152 locus was verified by PCR analysis and named, IBS-16. To 
eliminate the loxP-Km
r
 cassette from the chromosome, IBS-D16 was transformed with pCrePA. 
This plasmid has cre recombinase gene, an Em
r
 gene for selection, and a temperature- sensitive 
replicon (pWV01). Transformants were grown at 30
0
C on THY-Em plates, and selected colonies 
were then grown into THY-Em broth and plated onto THY-Em plates. Colonies were patched 
onto THY plates containing Km. Selected Em
r
 and Km
s
 colonies were inoculated into THY broth 
and incubated overnight at 37
0
C to cure the pCrePA. After overnight growth, they were spread 
onto THY-agar without antibiotic. Colonies from THY-agar plate were then patched onto THY-
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agar and THY-Em plate. After two days of incubation, Em
s
 colony was selected for further 
analysis. One of such clone was verified by PCR analysis and named IBS-D56. 
Deletion of SMU.1909 to SMU.1913: The region spanning from SMU.1909 to 
SMU.1913 was deleted by fusion PCR as described above with the primer sets SMU.1908 F/ 
EcoRV SMU.1909 5’ Fusion  and EcoRV-SMU.1913-3’ Fusion/SMU.1915-R using S. mutans 
UA159 chromosomal DNA as template for generating upstream and downstream fragments. 
Two fragments were then digested with EcoRV, followed by ligation and cloning into the 
pGEM-T Easy cloning vector (Promega) to create pIB-D22. A Km-resistant cassette with 
flanking modified loxP sites was amplified from pUC4ΩKm using the primers lox71-Km-F and 
lox66-Km-R and cloned into the EcoRV-digested site to generate pIB-D23. Plasmid pIB-D23 
was linearized with EcoRI and transformed into UA159 and IBS-D3 to generate IBS-D6 and 
IBS-D8 respectively. Positive clones were verified by PCR analysis. 
Construction of multiple gene knockout mutant: Genomic DNA was isolated from 
ΔSMU.925-Em (237) and digested with EcoRV. Digested DNA products were then transformed 
into IBS-D8 and selected on THY medium plates containing Em; one such transformant was 
named IBS-D58.  
Deletion of PTS locus: PTS locus containing the genes SGO.1679 to SGO.1682 was 
deleted by fusion PCR as previously described (127). At first, approximately 1000-bp upstream 
and downstream regions were amplified with primer set SGO-PTS-F/SGO-PTS-5’Fusion-R and 
 SGO-PTS-3’-Fusion-F/ SGO-PTS-3’-R using S. gordonii DL-1 chromosomal DNA as template. 
A Km resistant cassette was amplified from pIB-D38 (Constructed by cloning the Km cassette 
into pGEMT-Easy) using the primers Nco-Kan-F and Pst- Kan-R, each of which has 20-bp 
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overlapping region with the upstream and downstream fragments respectively. Overlapping 
fusion PCR was carried out using the equal amount of each PCR products with the primers SGO-
PTS-F/ SGO-PTS-3’-R. The amplified products were purified and transformed into S. gordonii 
DL-1 as previously described (20). Deletion of the PTS locus was verified by PCR analysis. 
Insertional inactivation of SMU.518: The gene encoding the SMU.518 was 
insertionally inactivated using a Cre-loxP- based method as previously described (20). SMU.518 
operon was amplified from S. mutans UA159 chromosomal DNA using the primers, SMU.518 5’ 
F and SMU.518 3’ R and cloned into the pGEM-T Easy cloning vector (Promega) to create pIB-
D48. A Km resistant cassette with flanking modified loxP sites, was amplified from pUC4 Km 
(235) using the primers lox71-Km-F and lox66-Km-R and cloned into EcoRV-digested pIB-D48 
to generate the plasmid, pIB-D50. Plasmid pIB-D50 was linearized with EcoRI and transformed 
into S. mutans UA159 as previously described (31).The transformants were selected on THY-
Km plates containing Km and named IBS-D20. To eliminate the loxP-Km
r
 cassette from the 
chromosome, IBS-D20 was transformed with pCrePA. This plasmid has cre recombinase gene, 
an Em
r
 gene for selection, and a temperature- sensitive replicon (pWV01). Transformants were 
grown at 30
0
C on THY-Em plates, and selected colonies were then grown into THY-Em broth 
and plated onto THY-Em plates. Colonies were patched onto THY plates containing Km. 
Selected Em
r
 and Km
s
 colonies were inoculated into THY broth and incubated overnight at 37
0
C 
to cure the pCrePA. After overnight growth, they were spread onto THY-agar without antibiotic. 
Colonies from THY-agar plate were then patched onto THY-agar and THY-Em plate. After two 
days of incubation, Em
s
 colony was selected for further analysis. Deletion of SMU.518 was 
verified by PCR analysis and named IBS-D29. 
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Deletion of SMU.518: SMU.518 was deleted by advanced Cre-loxP based marker-less 
gene deletion system (20). Briefly, SMU.518 with the upstream and downstream regions was 
amplified with the primers set SMU.518 5’ F and SMU.518 3’R using S. mutans UA159 
chromosomal DNA as template and cloned into the pGEMT-Easy cloning vector (Promega) to 
create pIB-D48. A Km resistant cassette with flanking modified loxP sites, was amplified from 
pUC4 ΩKm (235) using the primers lox71-Km-F and lox66-Km-R and cloned into BbsI and 
EcoRV digested, T4 DNA polymerase blunted pIB-D48, to generate pIB-D54. Plasmid pIB-D54 
was then linearized with EcoRI and transformed into S. mutans UA159 as previously described 
(31). Transformants were selected on THY plates containing Km; one such transformant was 
named IBS-D30. To eliminate the loxP-Km
r
 cassette from the chromosome, IBS-D30 was 
transformed with pCrePA (20), which expresses the cre recombinase gene from a temperature-
sensitive  replicon (pWV01).  Em
r 
and Km
s
 colonies were then selected which contain pCrePA 
and lost the Km
r 
resistance gene from the chromosome. To cure the plasmid, one selected colony 
was inoculated into THY broth without antibiotics and grown overnight at 37
0
 C and plated onto 
THY-agar. Em
s
 colonies were isolated by replica patching; one such clone was selected for 
further analysis and named IBS-D31. Deletion of SMU.518 was verified by PCR analysis. 
Deletion of comC: SMU.1915 encoding the competence stimulating peptide (CSP) was 
deleted by overlapping fusion PCR. Briefly, 1000-bp upstream and downstream regions were 
amplified with the primers set XhoI SMU. 1913 R / SMU.1915 5' fusion-R and SMU.1915 3' 
fusion-F/ SMU.1915 3' R using S. mutans UA159 chromosomal DNA as template. A Km 
resistant cassette was amplified from pIB-D38 with the same primers as mentioned above and 
overlapping fusion PCR was carried out using the equal amount of each PCR products with the 
primers XhoI SMU.1913 R / SMU.1915 3' R  The amplified products were purified and 
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transformed into S. mutans UA159 as described above to get the clone, IBS-D36. To eliminate 
the loxP-Km
r
 cassette from the chromosome, IBS-D36 was transformed with pCrePA (20), 
which expresses the cre recombinase gene from a temperature-sensitive  replicon (pWV01).  Em
r 
and Km
s
 colonies were then selected which contain pCrePA and lost the Km
r 
resistance gene 
from the chromosome. To cure the plasmid, one selected colony was inoculated into THY broth 
without antibiotics and grown overnight at 37
0
 C and plated onto THY-agar. Em
s
 colonies were 
isolated by replica patching; one such clone was selected for further analysis and named IBS-
D39.  Deletion of the comC locus was verified by PCR analysis. 
Deletion of nlmTE: nlmTE, encoding the transporter of non-lantibiotic mutacins, was 
deleted by overlapping fusion PCR as described above. Briefly, 1000-bp upstream and 
downstream regions of nlmTE locus (SMU. 286 & SMU.287) were amplified with the primers 
set SMU. NlmT Nested F1/SMU. NlmT 5’ Fusion R and SMU. NlmTE 3’ Fusion F/ SacII 
NlmTE R1 using S. mutans UA159 chromosomal DNA as template. A Km resistant cassette was 
amplified from pIB-D38 with the same primers as mentioned above and overlapping fusion PCR 
was carried out using the equal amount of each PCR products with the primers SMU. NlmT 
Nested F and SacII NlmTE R1. The amplified products were purified and transformed into S. 
mutans UA159 as described above to get the clone, ΔnlmTE::loxP-km
r
. To eliminate the loxP-
km
r
 cassette from the chromosome, pCrePA (20) was introduced into the mutant bacteria, which 
expresses the cre recombinase gene from a temperature-sensitive  replicon (pWV01).  Em
r 
and 
Km
s
 colonies were then selected which contain pCrePA and lost the Km
r 
resistance gene from 
the chromosome. To cure the plasmid, one selected colony was inoculated into THY broth 
without antibiotics and grown overnight at 37
0
 C and plated onto THY-agar. Em
s
 colonies were 
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isolated by replica patching; one such clone was selected for further analysis and named IBS-
D32. Deletion of the nlmTE locus was verified by PCR analysis. 
Deletion of cslAB: The genetic locus spanning the cslAB gene was also deleted by 
overlapping fusion PCR as described above. Briefly, 1000-bp upstream and downstream regions 
of cslAB region (SMU. 1897 to SMU.1900) were amplified with the primers, SMU.1898 F/ 
SMU.1898 5' Fusion and SMU.1898 3' Fusion F/ SMU.1898 R using S. mutans UA159 
chromosomal DNA as template. A Km resistant cassette was amplified from pIB-D38 with the 
same primers as mentioned earlier and overlapping fusion PCR was carried out using equal 
amount of each PCR products with the primers SMU.1898 F and SMU.1898 R. The amplified 
products were purified and transformed into S. mutans UA159 as described above to get the 
clone IBS-H4. Deletion of the cslAB locus was verified by PCR analysis. 
Deletion of SMU.832: SMU.832 was deleted by Cre-loxP- based method as previously 
described (20). Briefly, SMU.832 operon was amplified from S. mutans UA159 chromosomal 
DNA using the primers set, SMU.832 5’ F and SMU.832 3’ R and cloned into the pGEM-T Easy 
cloning vector (Promega) to create pIB-D64. A Km resistant cassette with flanking modified 
loxP sites, was amplified from pUC4 Km (235) using the primers lox71-Km-F and lox66-Km-R 
and cloned into BbsI-digested, T4 DNA polymerase blunted pIB-D64 to generate the plasmid, 
pIB-D67. Plasmid pIB-D67 was linearized with EcoRI and transformed into S. mutans UA159 as 
previously described (31). The transformants were selected on THY-Km plates containing Km 
and named IBS-D48. To eliminate the loxP-Km
r
 cassette from the chromosome, IBS-D48 was 
transformed with pCrePA. This plasmid has cre recombinase gene, an Em
r
 gene for selection, 
and a temperature- sensitive replicon (pWV01). Transformants were grown at 30
0
C on THY-Em 
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plates, and selected colonies were then grown into THY-Em broth and plated onto THY-Em 
plates. Colonies were patched onto THY plates containing Km. Selected Em
r
 and Km
s
 colonies 
were inoculated into THY broth and incubated overnight at 37
0
C to cure the pCrePA. After 
overnight growth, they were spread onto THY-agar without antibiotic. Colonies from THY-agar 
plate were then patched onto THY-agar and THY-Em plate. After two days of incubation, Em
s
 
colony was selected for further analysis. One of such clone was named IBS-D51. Deletion of 
SMU.832 was verified by PCR and RT PCR analysis and named, IBS-D51. 
Deletion of SMU.2137: SMU.2137 was deleted by overlapping fusion PCR. Briefly, 
1000-bp upstream and downstream regions were amplified with the primers sets SMU.2137 5’F/ 
SMU.2137 5’Fusion R and SMU.2137 3’ Fusion F/ SMU.2137 3’ R using S. mutans UA159 
chromosomal DNA as template. A Km resistant cassette was amplified from pIB-D38 with the 
same primers as mentioned earlier and overlapping fusion PCR was carried out using equal 
amount of each PCR products with the primers SMU.2137 5’ F and SMU.2137 3’ R. Amplified 
products were purified and transformed into S. mutans UA159 as described above to get the 
clone IBS-D53. The fragment containing the ΔSMU.2137:: loxP-km was again amplified with 
the primers SMU.2137 5’ F and SMU.2137 3’ R and retransformed to get the clone, IBS-D55. 
Deletion of the SMU.2137 locus was verified by PCR and RT PCR analysis.  
Construction of plasmids for complementation: Plasmid pIB184-Km was used as the 
vector for cloning (127). To clone nlmA gene, a fragment containing nlmA gene with the native 
promoter was amplified from the genomic DNA of UA159 using the primers BamHI-NlmA-F 
and Xho-NlmA-R. The amplified fragment was digested with BamHI and XhoI, and cloned into 
BamHI - XhoI digested pIB184-Km to generate pIB-D28. Similarly, nlmB gene was amplified 
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from IBS-D4 where nlmA was absent using the primer set Bam-NlmA-F and Xho-SMU. Nlm-R. 
The amplified fragment was digested with BamHI and XhoI, and cloned into BamHI - XhoI 
digested pIB184-Km to generate pIB-D20. nlmC gene was also cloned using the similar 
approach with the primer set BamHI NlmC-F and XhoI NlmC-R. Complementing plasmids were 
verified with restriction digestion, RT PCR and sequencing. 
Cloning of SMU.152, SMU.925 and SMU.1909: To clone SMU.152, a fragment 
containing the SMU.152 gene and the promoter region was amplified from the genomic DNA of 
UA159 using the primers BamHI- SMU.152-F and XhoI-Nlm-R. The amplified fragment was 
digested with BamHI and XhoI, and cloned into BamHI - XhoI digested vector, pIB184Km to 
generate pIB-D8. SMU.925 and SMU.1909 were also cloned using the similar approach with the 
primer set BamHI SMU.925-F/XhoI SMU.925-R and BamHI-SMU.1909/ PstI SMU.1909 
respectively (for all the plasmids, see Table-7). Complementing plasmids were verified with 
restriction digestion. SKNK-residues were added to the 3’ end of SMU.1909 and SMU.925 by 
adding the coding sequences of SKNK from SMU.152 to the XhoI SMU.925+SKNK-R and 
XhoI SMU.1909 +SKNK R and cloned similarly as described above.  
Different versions of truncated SMU.152 were generated using the common forward 
primer BamHI SMU.152-F and respective reverse primers carrying desired truncation (for all the 
primers, see Table-9). The amplified fragments were digested with BamHI and XhoI, and cloned 
into BamHI - XhoI digested vector, pIB184Km to generate the respective plasmids (for all the 
plasmids, see Table-7). Insertion of the cloned fragments was verified by restriction digestion. 
Cloning of SMU.518: SMU.518 with ribosome binding site was amplified from the 
genomic DNA of UA159 with  high fidelity Accutaq DNA polymerase (Sigma) using the 
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primers, BamHI SMU.518 F and XhoI SMU.518 R. After digestion with BamHI and XhoI, 
fragment was cloned into the BamHI - XhoI digested vector, pIB184-Km. Positive clones were 
verified with restriction digestion and named pIB-D52. 
Cloning of SMU.1915: SMU.1915 with promoter region was amplified from the 
genomic DNA of UA159 with high fidelity Accutaq DNA polymerase (Sigma) using the 
primers, BamHI-SMU.1915 F and XhoI SMU.1915 R. After digestion with BamHI and XhoI, 
fragment was cloned into the BamHI - XhoI digested vector, pIB184-Km. Positive clones were 
verified with restriction digestion and named pIB-D58. Similarly, 18-amino acids version of 
comC was cloned by same approach except the reverse primers XhoI 18-aa comC R and named 
pIB-D57. 
Cloning of SMU.832: SMU.832 with promoter region was amplified from the genomic 
DNA of UA159 with high fidelity Accutaq DNA polymerase (Sigma) using the primers, BamHI 
SMU.832 F and XhoI SMU.832 R. After digestion with BamHI and XhoI, fragment was cloned 
into the BamHI - XhoI digested vector, pIB184-Km. Positive clones were verified with 
restriction digestion and named pIB-D71. 
Cloning of SMU.2137: SMU.2137 with promoter region was amplified from the 
genomic DNA of UA159 with  high fidelity Accutaq DNA polymerase (Sigma) using the 
primers, BamHI SMU.2137 F and XhoI SMU. 2137 R. after digestion with BamHI and XhoI, 
SMU.2137 was cloned into BamHI - XhoI digested pIB-D13. Positive clones were verified with 
restriction digestion and named pIB-D73.  
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Construction of pIB-D13: Plasmid pMM223 (305) which is 8.0 kb in size was used for 
construction of pIB-D13 to make more convenient cloning vector. pMM223 was digested with 
EcoRI, HindIII and AlwN1 to release 4.2kb fragments containing the MCS region, aad 
(encoding the spectinomycin gene) and trp-lacZ genes, followed by blunting and ligation to 
generate the vector pIB-D11. A MCS region containing the promoter region of P23 was amplified 
from pIB184Km and cloned into the PvuII digested pIB-D11 to generate the plasmid pIB-D13. 
Newly generated vector pIB-D13 now contains the broad host range lactococcal replicon pWV01 
with erythromycin resistant cassette Em
r
 and is 4.1kb in size. 
Site-directed mutagenesis of SMU.518: pIB-D48, generated from cloning of SMU.518 
into pGEM-T Easy vector, was used as a template to mutate the Lon active residues, S-235 and 
K-280. Site-directed mutagenesis was performed using the high fidelity Pfu polymerase (Quick 
change II XL site-directed kit; Agilent technologies, CA) with the mutagenic primers that encode 
the mutation S235A and K280A having additional recognition site of PvuII and PstI respectively. 
SMU.518 was then amplified from the intermediate mutated plasmids with BamHI SMU.518 F 
and XhoI SMU. 518 R and cloned into the BamHI - XhoI digested vector, pIB184km (127) to 
generate pIB-D86 and pIB-D87 respectively. The mutation was checked by restriction digestion 
and the expression was confirmed by western blotting. 
Construction of PnlmA-gus reporter strains: Plasmid pIB107 was used to construct 
different reporter strains (29). To construct the PnlmA-gus fusion, a fragment carrying the 
promoter region of nlmA gene was amplified from the genomic DNA of UA159 using the 
primers EcoRI SMU. NlmA F and XhoI NlmA IGS R. The amplified fragment was digested 
with EcoRI and XhoI, and cloned into EcoRI - XhoI digested pIB107 (a suicidal vector which 
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has sequences of SMU.1405) to generate the plasmid, pIB-D21. Plasmid pIB-D21 and pIB107 
were then digested with BglI and transformed into UA159 to get the strains, IBS-D5 and IBS-
D44 respectively. Construction was verified with PCR and sequencing. Similarly, BglI digested 
pIB-D21 was also transformed into ΔSMU.518, ΔcomC, ΔnlmTE, and ΔSMU.518 ΔcomC to 
generate respective reporter strains IBS-D37, IBS-D40, IBS-D41 and IBS-D46 (Table-8). 
Transposition assay, screening and identification of ISS1 integration sites: To 
identify the factors that regulate nlmA expression, we performed insertional mutagenesis with the 
plasmid pGh9:ISS1 according to the methods described by Maguin et al. (183) and later 
modified by Zhang et al.(328). IBS-D5 was transformed with pGh9:ISS1 and transformants were 
selected
 
on THY agar containing Em at 30°C. A single positive colony was grown in liquid 
culture for overnight and diluted 100-fold in the same medium, grown for 2-hr at 30°C,
 
and then 
transferred to water bath at 37°C for 4-h to select the
 
transposition events. This culture represents 
the starting transposon
 
library. This culture was then plated on THY-Em plates containing the X-
gluc and incubated at microaerophilic condition at 37°C. Transformants were selected based on 
the blue/white colony appearance. Selected white colonies were than tested for NlmAB 
production using Streptococcus gordonii DL-1 as indicator bacteria. After screening of ~12000 
CFU (colony forming units), we got 25 positive clones.  Chromosomal DNA from the selected 
colonies were then isolated and digested by HindIII, followed by heat inactivation
 
at 65°C.  2 µg 
of digested DNA was taken for self-ligation by T4 DNA ligase, and the ligated samples were 
subjected to
 
inverse PCR by using the primers ISS1R-out 2 and ISS1 For-4. The
 
PCR products 
were purified from agarose gel and sequenced with
 
the primer ISS1-Rout-2. The flanking 
sequences obtained from
 
sequencing analysis were mapped on the genome of S. mutans UA159
 
by a BLAST search. 
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Curing of integrated pGhost9:ISS1: To induce the excision of chromosomally 
integrated pGh9:ISS1, cells were subjected to several round of growth at permissive and non-
permissive temperature in THY-broth in the absence of antibiotic. During each cycle, overnight 
culture of IBS-D5 (grown at 37
0
C) carrying chromosomally inserted pGh9:ISS1 were diluted 
(1:1000) and inoculated into fresh THY-broth in the absence of
 
antibiotic, followed by 
incubation at 30°C for
 
16 h. After 16-hr, the cells were diluted and plated on THY agar.
 
Colonies 
were then replicated on THY agar with or without Em
 
to isolate the
 
pGh9:ISS1-cured strain. 
DNA extraction and PCR screening of various genes: Total DNA was extracted using 
a Master Pure DNA Purification kit (Epicentre Biotechnologies), according to the manufacturer’s 
instructions. The mutacin-producing strains were grown into THY-broth for overnight at 37
0
C 
under microaerophilic condition. 5-ml culture was centrifuged (5000 RPM for 5 min) and DNA 
was extracted from the pellet using the manufacturer protocol. The DNA purity was determined 
by calculating the A260/A280 ratio. The detection of various genes was performed by PCR using 
primers specific to each type of gene. Primers for the intended genes were designed based on 
sequences obtained from GenBank (http://www.ncbi.nlm.nih.gov) (7).  PCR amplification was 
performed using a PCR Master Cycler (Eppendorf). The PCR reaction was carried out using 2X 
Taq mix or high fidelity Accutaq DNA polymerase (Sigma, USA) when necessary using 50 ng 
templates DNA. In addition to the strains being tested, purified genomic DNA from S. mutans 
UA159 was used as a positive control and distilled water was used as a negative control in each 
PCR. The PCR products were analyzed by electrophoresis in 1.0% agarose gel.   
Isolation of RNA from bacterial cultures: Total RNA was isolated from bacterial 
cultures according to the protocol described earlier (27). Briefly, S. mutans cultures were grown 
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until the desired optical density was reached, and the bacterial cell pellet was resuspended into 5 
ml of RNA protect bacterial reagent (Qiagen). Total RNA was isolated using an RNeasy mini-kit 
(Qiagen) with a modified bacterial lysis step. The supernatant obtained after bacterial cell lysis 
was loaded onto an RNeasy mini column, and DNA contaminants were removed by on-column 
DNase I treatment following the manufacturer’s instructions. RNA was purified according to the 
supplier’s suggested protocol. The RNA concentrations were determined by UV 
spectrophotometer. 
Semi quantitative RT-PCR: 500 ng of RNA samples isolated from various S. mutans 
cultures were used for reverse transcription using the Titan one-tube reverse transcription-PCR 
(RT-PCR) system (Roche) as described previously (27). cDNA was purified using QIAGEN 
PCR purification kit and 10 ng of cDNA was used for PCR amplification of each gene. gyrA 
gene was used as an internal control to ensure that equal amount of RNA was being used in all 
RT-PCR mixtures. The PCR products were separated on 2.0 % agarose gel electrophoresis and 
quantified by Doc-It-LS (UVP) software. 
β-Glucuronidase assay (GusA assay): β-glucuronidase assays were performed as 
described previously by Biswas et al (29). Reporter strains were grown overnight at 37
0
C and 
dilute 1:20 in THY-broth followed by incubation at 37
0
C until the growth reached OD595 of 0.2. 
CSP (intact CSP or CSP’s processed with various strains) or the culture supernatants (40% 
ammonium sulfate precipitations from overnight cultures) of various strains were added and 
incubated until the OD595 reached 1.00. 10-ml of culture was precipitated at this point, washed in 
saline water and resuspended in Z-buffer. 500-ml of resuspended culture was then disrupted by 
bead beating (Fast Prep-24; M.P. Biomedical, California) to get the cell lysate. The protein 
59 
 
concentration of the lysate was measured by Bradford protein assay (Bio-Red) method 
standardized with BSA (34). The Gus activities of the culture lysates were standardized by 
comparison with known concentration of glucuronidase (Sigma-Aldrich). Equal amount of each 
lysates was mixed with p-nitro phenyl-β-D- glucoside (Sigma) to a final concentration of 0.8 
mg/ml and the reaction was initiated at 37
0
C. As soon as color developed in the reaction mixture, 
the reaction was stopped by the addition of Na2CO3 to a final concentration of 0.25M. The OD 
value at 420 nm and the time of sodium carbonate addition were noted. Gus activity was 
calculated as [1000×A420]/ [time (min) × cell A595] in Miller units (MU). 
For the isolation of culture supernatants, bacterial cultures were grown overnight and 
diluted 1:20 into THY broth and incubated at 37
0
C in shaker incubator for overnight. Culture 
supernatants were separated from the bacterial cells by passing through 0.45-µM membrane filter 
and precipitated with 40% ammonium sulfate. After resuspending into 50 mM Tris-Cl (pH-7.4), 
equal amount of each sample was added to the actively growing reporter strains (OD595 of 0.2), 
followed by incubation for another 4-hour. 
Purification of mutacin IV activity from the culture supernatant: For purification of 
active mutacin IV molecules, wild-type UA159 or complemented strains (IBS-D3 with PnlmA, 
PnlmB, and PnlmAB respectively) were inoculated into 10 ml Todd-Hewitt medium and 
incubated for overnight. 4-ml each overnight culture was then inoculated into 200 ml of fresh 
Todd-Hewitt medium and incubated for 24 h at 37°C in a shaker incubator at 150 rpm. An equal 
volume of chemically defined media (27) was then added and incubated for another 24-hr. 
Bacterial culture was then passed through a 0.45-µm membrane filter, followed by ammonium 
sulfate fractionation (40% saturation) as described by Yamamoto et al. (322). 
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  Cleavage of synthetic CSP (21-amino acid) by S. mutans: Competence stimulating 
peptide of S. mutans UA159 was synthesized commercially by Genscript (Genescript 
Corporation, USA) with a purity grade of >95%. The lyophilized peptides were resuspended into 
dimethyl formamide at 2.0 mg/ml concentration. Bacterial cultures were grown overnight or late 
logarithmic phase at 37
0
C. 1-ml of culture was precipitated and washed with PBS. Culture pellet 
was resuspended into 100 µl of PBS and CSP was added to a concentration of 120 µM and 
incubated at 37
0
C for an hour. Cells were pelleted again at 12000 RPM for 5-min and the 
supernatant containing the CSP was taken out. Processing of CSP was checked by spotting at 
different concentration onto X-gluc plate seeded with the reporter strain, ΔSMU.518::PnlmA-gus. 
Mass spectrometry of the processed CSP’s: ESI spectra were acquired on a SYNAPT 
G2 hybrid quadruple / ion mobility / Tof mass spectrometer (Waters Corp., Milford, MA) from 
the University of Kansas Mass Spectrometry/Analytical Proteomics Laboratory.  The instrument 
was operated in a sensitivity mode with all lenses optimized on the MH+ ion from the Leucine 
Enkephalin.  The sample cone voltage was 30eV.  Argon was admitted to the trap cell that was 
operated at 4eV for maximum transmission.  Spectra were acquired at 9091 Hz pusher frequency 
covering the mass range from 100 to 3000 u and accumulating data for 1.5 seconds per cycle.  
Time to mass calibration was made with NaI cluster ions acquired under the same conditions.  
Mass spectra of [Glu
1
]-Fibrinopeptide B were acquired in parallel scans and doubly charged ions 
at m/z 785.8426 were used as a lock mass reference. 
Samples were desalted on a reverse phase C4 column, 1cm, 1mm I.D.  (Vydac, 300 Å 
pore size, 5 µm particles packed by Micro-Tech Scientific) using a NanoAcquity 
chromatographic system (Waters Corp., Milford, MA).  The solvents were A (99.9% H2O, 0.1% 
formic acid) and B (99.9% acetonitrile, 0.1% formic acid).  A short gradient was developed from 
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1 to 70% B in 4 minutes with a flow rate of 20 µL/min. Mass Lynx 4.1 software was used to 
collect the data. MaxEnt 3 routine was used for processing data to convert peaks of multiple 
charged ions in continuum spectra into centroid singly charged spectra. 
Western blotting: Bacterial strains with the HA-tagged SMU.518 or indicated mutants 
(C-terminal HA tag) were grown up to 70 KU and harvested at 5000K for 5min. Cell pellets 
were resuspended in tissue and cell lysis solution (Epicenter) and homogenized with a Bead 
Beater. Protein lysates were separated by 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (161) and blotted onto membranes.  Western blotting was carried 
out using standard techniques with anti-HA monoclonal antibody (Sigma) as the primary 
antibody and horseradish peroxidase-conjugated anti-mouse secondary antibody (Sigma). The 
blots were developed with Pierce ECL plus reagent (Thermo Scientific) and the signals were 
detected by Typhoon FLA 9000 (GE Healthcare).  
Deferred antagonism bacteriocin assay: After overnight growth on THY agar plate, 
isolated colonies were stabbed into THY agar plate with a toothpick and grown overnight (~18-
hr) at 37°C under microaerophilic conditions. Indicator strains were grown to mid exponential 
growth phase in THY broth and 0.4-ml of the indicator culture was mixed with 10 ml of soft agar 
and overlaid on agar plates that were stabbed with the tester strains. Overlaid plates were then 
incubated overnight under same conditions and the diameter of the zones of inhibition around the 
mutacin-producing strains was measured.  Streptococcus gordonii (DL-1, ATCC 10558 and M5) 
and S. cristatus (BHT) were used as indicator strain for mutacin IV or NlmAB activity; while 
Lactococcus lactis MG1363 was used as indicator for mutacin V or NlmC activity (104). 
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Measurement of growth kinetics: Bacterial cultures were grown in THY-broth for 
overnight at 37
0
C. Equal amount of each inoculum (based on OD at 595) was added into the 
respective Klett Flasks as 1:20 dilution and incubated at 37
0
C in the water bath. Bacterial growth 
was monitored with a Klett-Summerson colorimeter (MP Biomedical) at different time intervals 
and recorded as Klett unit. 
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Table-7: List of plasmids constructed in this study 
Plasmid Marker Origin Construction Purpose 
pIB-D1 Ap pGEM-T Easy pGEM-T Easy::STP Clean deletion of STP 
pIB-D2 Ap pGEM-T Easy pGEM-T Easy::STK Clean deletion of STK 
pIB-D3 Ap pGEM-T Easy pGEM-T Easy::STP-STK Clean deletion of STP-STK 
pIB-D4 Km pGEM-T Easy pIB-D1::loxP-km Clean deletion of STP 
pIB-D5 Km pGEM-T Easy pIB-D2::loxP-km Clean deletion of STK 
pIB-D6 Km pGEM-T Easy pIB-D3::loxP-km Clean deletion of STP-STK 
pIB-D7 Km pGEM-T Easy pGEM-T Easy::loxP-Km For overlapping PCR 
pIB-D8 Km pIB184Km pIB184Km::SMU.152 Cloning of SMU.152 
pIB-D9 Em pORI23 pORI23::SMU.1909 Cloning of SMU.1909 
pIB-D10 Ap pGEM-T Easy pGEM-T Easy::nlmAB  Clean deletion of nlmAB 
pIB-D11 Em pMM223 ΔpMM223 Cloning vector 
pIB-D12 Em pMM223 pIB-D11::MCS of pIB184Km Cloning vector 
pIB-D13 Em pMM223 pIB-D11::MCS of pIB184Km Cloning vector 
pIB-D14 Em pIB-D11 pIB-D11:: nlmAB operon Complementation of nlmAB 
pIB-D15 Ap pGEM-T Easy pGEMT-Easy::5’-3’ fusion 
fragments of nlmAB operon 
For clean deletion of nlmA 
pIB-D16 Km pIB-D10 ΔpIB-D10::loxP-km  For clean deletion of nlmAB  
pIB-D17 Km pIB-D15 pIB-D15::loxP-km Clean deletion of nlmA 
pIB-D18 Km pIB104 ΔSMU.198::km
r
 For transformation assay 
pIB-D19 Km pIB184Km pIB184Km::nlmAB Complementation of nlmAB 
pIB-D20 Km pIB184Km pIB184Km::nlmB Complementation of nlmB 
pIB-D21 Km pIB107 pIB107::PnlmA-gus Cloning of nlmA IGS region 
pIB-D22 Ap pGEM-T Easy pEz:: 5’ & 3’ SMU.1909-1913 Clean deletion of full region 
pIB-D23 Km pGEM-T Easy pIB-D22::loxP-Km Clean deletion 
pIB-D24 Km pIB184Km pIB184Km::HA nlmA To study the mode of action 
pIB-D25 Km pIB184Km pIB184Km::irvR Complementation of irvAR  
pIB-D26 Km pIB-D19 GXXXG to AXXXA Structure-function relationship 
pIB-D27 Em pIB190 pIB190::N-His SMU.152 To study the immunity activity  
pIB-D28 Km pIB184Km pIB184Km::nlmA  To study the NlmA only 
pIB-D29 Km pIB184Km pIB184Km::nlmC Complementation of nlmC 
pIB-D30 Km pIB-D19 GXXXS to AXXXA of nlmB Structure-function relationship  
pIB-D31 Km pIB-D19 GXXXG to AXXXA Structure-function relationship  
pIB-D32 Km pIB184Km pIB184Km::nlmC Complementation of nlmC 
pIB-D33 Km pIB184Km pIB184Km::SMU.1909 To study the immunity activity 
pIB-D34 Km pIB184Km pIB184Km::SMU.925 To study the immunity activity 
pIB-D35 Km pIB184Km pIB184Km::SMU.152ΔC To study the immunity activity 
pIB-D36 Km pIB184Km SMU152ΔKRRSKNK To study the immunity activity 
pIB-D37 Km pIB184Km pIB184Km::SMU.152ΔSKNK To study the immunity activity 
pIB-D38 Km pGEM-T Easy pGEMT-Easy::loxP-km Cloning of loxP-Km 
pIB-D39 Km pIB184Km GXXXG to AXXXA of nlmB Not good 
pIB-D40 Km pIB184Km pIB184Km::SMU.152ΔKNK To study the immunity activity 
pIB-D41 Ap pGEM-T Easy pGEMT-Easy::SMU.152 To study the immunity activity 
pIB-D42 Ap pIB-D31 GGXXSG to AAXXAA Structure-function relationship 
pIB-D43 Km pIB184Km pIB184Km::nlmAB  Structure-function relationship 
pIB-D44 Ap pIB-D41 SMU.152::KRR to KAA To study the immunity activity 
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Plasmid Marker Origin Construction Purpose 
pIB-D45 Ap pIB-D44 SMU.152::KRR to AAA To study the immunity activity 
pIB-D46 Km pIB184Km SMU.152(KRR to KAA) To study the immunity activity 
pIB-D47 Km pIB184Km SMU.152(KAA to AAA) To study the immunity activity 
pIB-D48 Ap pGEM-T Easy pGEMT-Easy::SMU.518 Clean deletion of SMU.518 
pIB-D49 Km pIB-D48 pIB-D48::km
r
 Inactivation of SMU.518 
pIB-D50 Km pIB-D48 pIB-D48::loxP-km Inactivation of SMU.518 
pIB-D51 Sp pGEM-T Easy pGEMT-Easy::Sp Cloning of spectinomycin  
pIB-D52 Km pIB184Km pIB184Km::SMU.518 Complementation of SMU.518 
pIB-D53 Km pIB184Km pIB184Km::HA-SMU.518 Expression of SMU.518 
pIB-D54 Km pIB-D48 Δ518: loxP-km Clean deletion of SMU.518 
pIB-D55 AP pGEM-T Easy pGEMT-Easy::SMU.1915 Deletion of SMU.1915 
pIB-D56 Ap pIB-D48 pIB-D48ΔSMU.518  Deletion of SMU.518 
pIB-D57 Km pIB184Km pIB184Km::comC (18residue) Study the activity of 18-residue  
pIB-D58 Km pIB184Km pIB184Km::comC Complementation of comC 
pIB-D59 Km pIB184Km pIB184Km::HA-comC To study the secretion of CSP 
pIB-D60 Km pIB184Km pIB-D54ΔSMU.518 Inverse PCR to delete SMU.518  
pIB-D61 Ap pGEM-T Easy pGEMT-EZ::SMU.611 Deletion of SMU.611 
pIB-D62 Km pIB184Km pIB184Km::His-comC To study the transporter of CSP 
pIB-D63 Km pGEM-T Easy pIB-D61::loxP-km Deletion of SMU.611 
pIB-D64 Ap pGEM-T Ez pGEMT-EZ:: SMU.832 Deletion of SMU.832 
pIB-D65 Ap pGEM-T Ez pGEMT-EZ:: SMU.1509 Deletion of SMU.1509 
pIB-D66 Ap pGEM-T Ez pGEMT-EZ:: SMU.2137 Deletion of SMU.2137 
pIB-D67 Km pIB-D64 pIB-D64::loxP-km Deletion of SMU.832 
pIB-D68 Km pIB-D65 pIB-D65::loxP-km Deletion of SMU.1509 
pIB-D69 Km pIB-D66 pIB-D66::loxP-km Deletion of SMU.2137 
pIB-D70 Km pIB184Km pIB184Km::SMU.2137 Complementation of SMU.2137 
pIB-D71 Km pIB184Km pIB184Km::SMU.832 Complementation of SMU.832 
pIB-D72 Km pIB184Km pIB184Km::SMU.1909 SKNK Cloning of SMU.1909+SKNK 
pIB-D73 Em pIB-D13 pIB-D13:: SMU.2137 Complementation of SMU.2137 
pIB-D74 Em pIB-104 pIB-104::Em
r
  Transformation assay 
pIB-D75 Km pIB184Km pIB184Km::SMU.925+SKNK Cloning of SMU.925+SKNK 
pIB-D76 Ap pIB-D48 SMU.518::N296 to A Mutagenesis 
pIB-D77 Ap pIB-D48 SMU.518::R254 to A Mutagenesis 
pIB-D78 Km pIB184Km SMU.518:R254 to A Mutagenesis 
pIB-D79 Km pIB184Km SMU.518:N296 to A Mutagenesis 
pIB-D80 Ap pGEM-T Ez pEz::SMU.518 (GPS to AAA) Mutagenesis 
pIB-D81 Km pIB184Km SMU.518 (GPS to AAA) Mutagenesis 
pIB-D82 Ap pGEM-T Ez SMU.518 (S235A) Mutagenesis 
pIB-D83 Ap pGEM-T Ez SMU.518 (K280A) Mutagenesis 
pIB-D84 Ap pGEM-T Ez SMU.518 (S235A) Mutagenesis  
pIB-D85 Ap pGEM-T Ez SMU.518 (K280A) Mutagenesis  
pIB-D86 Km pIB184Km SMU.518 (S235A) Mutagenesis  
pIB-D87 Km pIB184Km SMU.518 (K280A) Mutagenesis  
pIB-D88 Km pIB184Km SMU.518 -HA(S235A) Expression of SMU.518 
pIB-D89 Km pIB184Km SMU.518-HA (K280A) Expression of SMU.518 
pIB-D90 Km pIB184Km SMU.518 (N296 A) Expression of SMU.518 
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Table-8: List of strains used in this study 
Name Construction/Description/Strain Comment 
Streptococcus mutans UA159  Wild type 
IBS-D1 ΔnlmAB::loxP-km This study 
IBS-D2 ΔnlmA::loxP-km This study 
IBS-D3 ΔnlmAB (clean deletion) This study 
IBS-D4 ΔnlmA (clean deletion) This study 
IBS-D5 ΔSMU.1405::PnlmA-gus This study 
IBS-D6 ΔSMU.1909-SMU.1913:: loxP-km This study 
IBS-D7 ΔSMU.1909-SMU.1913:: loxP-km in OMZ175 This study 
IBS-D8 ΔnlmAB::ΔSMU.1909-SMU.1913 This study 
IBS-D9 PnlmAB::lacZ This study 
IBS-D10 ΔnlmB::loxP-km This study 
IBS-D11 ΔSMU.61::Sp
r
 This study 
IBS-D12 ΔSMU.1882::Sp
r
 This study 
IBS-D13 ΔnlmAB;ΔnlmC This study 
IBS-D14 ΔSMU.381::Sp
r
 This study 
IBS-D15 ΔPTS::loxP-km in S. gordonii DL-1 This study 
IBS-D16 ΔSMU.152::loxP-km This study 
IBS-D17 IBS-D13::PnlmA-gus This study 
IBS-D18 IBS-D3::PnlmA-gus This study 
IBS-D19 ΔSMU.518:: loxP-km This study 
IBS-D20 ΔSMU.518:: loxP-km This study 
IBS-D21 ΔSMU.518::ISS1 This study 
IBS-D22 ΔSMU.518::ISS1 This study 
IBS-D23 IBS-D5::pGhost9-ISS1 This study 
IBS-D24 ΔSMU.287::ISS1 This study 
IBS-D25 ΔSMU.287::ISS1 This study 
IBS-D26 ΔSMU.121::ISS1 This study 
IBS-D27 ΔSMU.121::ISS1 This study 
IBS-D28 ΔSMU.286::ISS1 This study 
IBS-D29 ΔSMU.518 (clean deletion) This study 
IBS-D30 ΔSMU.518::loxP-km This study 
IBS-D31 ΔSMU.518 (clean deletion) This study 
IBS-D32 ΔnlmTE (clean deletion) This study 
IBS-D33 ΔSMU.1915::ISS1 This study 
IBS-D34 ΔSMU.121::loxP-km This study 
IBS-D35 ΔSMU.518::loxP-km This study 
IBS-D36 ΔSMU.1915::loxP-km This study 
IBS-D37 IBS-D29::PnlmA-gus This study 
IBS-D38 ΔSMU.518::loxP-km This study 
IBS-D39 ΔSMU.1915 (clean deletion) This study 
IBS-D40 ΔSMU.1915::PnlmA-gus This study 
IBS-D41 ΔnlmTE::PnlmA-gus This study 
IBS-D42 ΔSMU.518; ΔcomC::loxP-km This study 
IBS-D43 ΔSMU.518::loxP-km This study 
IBS-D44 ΔSMU.1405::gus (control) This study 
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Name Construction/Description/Strain Comment 
IBS-D45 ΔSMU.518; ΔcomC (clean deletion) This study 
IBS-D46 IBS-D45::PnlmA-gus This study 
IBS-D47 Δ SMU.611::loxP-km This study 
IBS-D48 ΔSMU.832::loxP-km This study 
IBS-D49 ΔSMU.1509::loxP-km This study 
IBS-D50 ΔSMU.2137::loxP-km This study 
IBS-D51 ΔSMU.832 (clean deletion) This study 
IBS-D52 ΔSMU.1509::loxP-km This study 
IBS-D53 ΔSMU.2137 loxP-km  This study 
IBS-D54 ΔSMU.832::PnlmA-gus This study 
IBS-D55 ΔSMU.2137 (retransformation) This study 
IBS-D56 ΔSMU.152 (clean deletion) This study 
IBS-D57 ΔSMU.832;ΔClpX:: loxP-km This study 
IBS-D58 ΔnlmAB;ΔSMU.1909-SMU.1913; ΔSMU.925 This study 
IBS-H4 ΔcslAB:: loxP-km This study 
S. mutans UA159 ΔSMU.1914::Em
r
 (ΔnlmC) (237) 
S. mutans UA159 Δ SMU.925::Em
r
 (237) 
Streptococcus gordonii  DL-1, ATCC 10558, M5 Wild type 
Lactococcus lactis  MG1363 Wild type 
S. agalactiae  NEM306 Wild type 
S. uberis  UT387 Wild type 
S. iniae  K388 Wild type 
S. pyogenes  K-56, AM3, JRS4 Wild type 
S. anginosus  CI Wild type 
S. constallatus  CI Wild type 
S.pneumoniae  ATCC 6303 Wild type 
S. cristatus  ATCC 51100 Wild type 
S. sanguis  SK36 Wild type 
S salivarious  ATCC 25975 Wild type 
S. bovis  TX20005 Wild type 
S. downeii  ATCC 33798 Wild type 
S. sobrinus  6715 Wild type 
S. criceti   AHT Wild type 
S. ratti  BHT Wild type 
S. mutans  UA130, GS-5, NG8,SM3208, OMZ175 Wild type 
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Table -9: List of oligonucleotides used in this study 
Name of the Primer Sequence Purpose 
SMU. Nlm Nested F1 
 
GGCGTGACCATTCATGAAGCGAATGCC Amplification of 
nlmAB operon  
SMU. Nlm Nested F2 GTGTTTCGTCTTTCATGGGATATTTAAAGGG Amplification of 
nlmAB operon  
SMU. Nlm Nested R1 GCCTACAGCTAAGGCGATTAATACACC Amplification of 
nlmAB operon  
SMU. Nlm Nested R2 GGCAGCAAAAAGTATCCAATAGACC Amplification of 
nlmAB operon  
Bam HI SMU. NlmA F GCGGGATCCGGCAATCGAAGTTTTGGTGTAGA
GGC 
Cloning of nlmAB 
operon  
Xho1-SMU.Nlm R GCGCTCGAGACAACTATTAGGCTTCGGCCTTA
GC 
Cloning of nlmAB 
operon 
EcoR-V SMU. NlmA-5’ 
Fusion 
GCGGATATCGTTTGGCTGTCCATTACATC Deletion of nlmA  
EcoR-V SMU. NlmA-3’ 
Fusion 
GCGGATATCGGGGACTCATTCGATCTCAT Deletion of nlmA  
XhoI-SMU. NlmA-R GCGCTCGAGCCATGGTATTAATTCTCCATTCC Cloning of nlmA  
XhoI NlmA R GCGCTCGAGTTTAATGAGATCGAATGAGTCCC
CAAGTGC 
Cloning of nlmA 
Kan D7 F 
 
CTCCCGGCCGCCATGGCGGCCGC Amplification of Km
r 
 
cassette 
Kan D7 R 
 
GGTCGACCTGCAGGCGGCCGCG Amplification of Km
r  
cassette 
NlmB 5' fusion-R 
 
GCCGCCATGGCGGCCGGGAGTTCTCCATTCCA
TTTAATTC 
Deletion of nlmB  by 
overlapping PCR 
NlmB 3' fusion-F CGCGGCCGCCTGCAGGTCGACCCCACACTAAA
TTGATATAATGG 
Deletion of nlmB  by 
overlapping PCR 
loxP-KanF CGATAACTTCGTATAATGTATGCTATACGAAGT
TATGAGGATGAAGAGGATGAGGAGGCAG 
For cre mediated 
clean deletion 
loxP-KanR CGATAACTTCGTATAGCATACATTATACGAAG
TTATGCTTTTTAGACATCTAAATCTAGG 
For cre mediated 
clean deletion 
BamHI NlmC-F GCGGGATCCCATTTTATATCTCCTTTTTTTG Cloning of nlmC 
XhoI NlmC-R GCGCTCGAGTTAAATTACTAACCACAGGAAT Cloning of nlmC 
NlmT-F TTAATCGTCATAGCCGTTAACATTC RT PCR  
NlmT-R CCTTACTCATCCTAGTCACCTTAAC RT PCR  
NlmB RT- F GGAATGGAGAATTAATACCATG RT PCR  
NlmB RT- R GTGTGGAAAAACTACAGATCCA RT PCR  
SMU. GyrA-F CTATGCTATGAGTGTTATTGTTGCTCGGGC RT PCR 
SMU. GyrA-R GGCCATTCCAACAGCAATACCTGTCGCTCC RT PCR 
SMU.1914c.F CGATGAATACACAAGCATTTGA RT PCR 
SMU.1914c.R CTAACCACAGGAATTAAGAGCT RT PCR 
SMU.1915-F CCGGATGAAAAAAACACTATCA RT PCR 
SMU.1915-R CCGGTTATTTTCCCAAAGCTTGT RT PCR 
NlmA-F ATGGATACACAGGCATTTG RT PCR 
NlmA-R ATGAGATCGAATGAGTCC RT PCR 
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Name of the Primer Sequence Purpose 
ComE-F GACGTCTTGAAACCACCATTG RT PCR 
ComE-R CTTCATTCATTTTGCTCTCCTT RT PCR 
KanR-For GAGGATGAAGAGGATGAGGAGGCAGATTGCC To amplify Km
r 
cassette 
KanR-Rev GCTTGTAGTTAAAGCTTTTTAGACATCTAAATC
TAGG 
To amplify Km
r 
cassette 
lox77-KanF CGTACCGTTCGTATAGCATACATTATACGAAGT
TATGAGGATGAAGAGGATGAGGAGGCAG 
Clean deletion 
lox66-KanR CGTACCGTTCGTATAATGTATGCTATACGAAGT
TATGCTTTTTAGACATCTAAATCTAGG 
Clean deletion  
SMU. NlmT-F GTCTTGGCTTTTGTTAGCCACGGGCCTTGC To amplify nlmTE  
SMU. NlmT-R CATTGAGAATGGTATTACGGGAAACTGC To amplify nlmTE 
SMU.NlmC.F-1 GCAACTCCTAATAATAAAATAGAGGAGGCC Sequencing of nlmC 
and comC 
SMU.NlmC-R-1 GTCCATCAATGTAAAATAAACAAAGG Sequencing of nlmC 
and comC 
SMU.1916-F GCAATCATATTCTTTATCTTGGATGGAAC To amplify comD  
SMU.1916-R GATATTATAACGGGTATCCTGCAATTG To amplify comD  
BamHI SMU.152 F GCGGGATCCGGATCTGTAGTTTTTCCACAC Cloning of SMU.152 
XhoI-SMU. Nlm R 
 
GCGCTCGAGGACAACTATTAGGCTTCGGCCTT
AGC 
Cloning of SMU.152 
XhoI Δ3’SMU.152 R GCGCTCGAGTTTAAAAGATGAGTAAGATGGCA
GC 
Generation of 
truncated SMU.152 
XhoI ΔRRSKNK 
SMU.152 R 
GCGCTCGAGTTTTATTTTAGCTCTTTATAGAGT
TCAACAGC 
Generation of 
truncated SMU.152 
XhoI ΔKNK SMU.152 
R 
GCGCTCGAGTTTAGCTTCTTCTTTTTAGCTCTTT
ATAG 
Generation of 
truncated SMU.152 
XhoI ΔKRRSKNK 
SMU.152 R 
GCGCTCGAGTTTTATAGCTCTTTATAGAGTTCA
ACAGC 
Generation of 
truncated SMU.152 
NcoI Kan  F CTCCCGGCCGCCATGGCGGCCGC To amplify Km
r
  gene 
PstI Kan  R GGTCGACCTGCAGGCGGCCGCG To amplifyKm
r 
 gene 
BamHI-SMU.925-F GCGGGATCCGACGCTGCCCTTGCAGCAGTG Cloning of SMU.925 
Xho1-SMU.925-R GCGCTCGAGGCTGCCATAACCACAAAAAGCC Cloning of SMU.925 
BamH1-SMU.1909  
 
GCGGGATCCGTCCTTGGTTCGTTAATAGATTGG
G 
Cloning of 
SMU.1909 
Pst1-SMU.1909 –R 
 
GCGCTGCAGGCCTGAAAGTAAAAACTGTTTAG
CGTC 
Cloning of 
SMU.1909 
XhoI SMU.1909+ 
SKNK R 
GCGCTCGAGTTTACTTATTCTTGCTGCGTCTCT
TATGCAGTTTAATGAG 
Cloning of 
SMU.1909+SKNK 
SGO PTS F CCGCCAGATAGATTGATAAAGTCC  Deletion of mpt locus 
SGO PTS 5’ fusion R 
 
GCCGCCATGGCGGCCGGGAGGTTTGACCAAAC
TTTAAGAAAAG 
Deletion of mpt locus 
SGO PTS 3’ fusion F 
 
CGCGGCCGCCTGCAGGTCGACCGGCAAATTTT
TTAAAAACCTATTTGC 
Deletion of mpt locus 
SGO PTS 3’ R GCTCATAGCTGTGAAGTAGATTGG Deletion of mpt locus 
SMU.518 F GAAAACAAACAAAAAATTTAAATG To amplify SMU.518 
SMU.518 R GTGTTTTCTTAGGTAATCAATAGC To amplify SMU.518 
SMU.152 3' R CTGCGTTACATATGAACATAGACC Deletion of SMU.152 
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Name of the Primer Sequence Purpose 
SMU.152 5' fusion-R GCCGCCATGGCGGCCGGGAGCCTCTCTTGAAA
TTCGACATTA 
Deletion of SMU.152 
SMU.152 3' fusion-F CGCGGCCGCCTGCAGGTCGACCGCTAAGGCCG
AAGCCTAATAGTTG 
Deletion of SMU.152 
XhoI SMU.925 +SKNK 
R 
GCGCTCGAGTTTACTTATTCTTGCTGCGTTTTCT
AAAAAAGCTGG 
Cloning of 
SMU.925+SKNK 
SMU. 1908-F GTACTTATCCTTATTTTGTTTTTATCTTGCTG Deleting SMU. 1909 
to SMU.1913 
EcoR-V SMU.1909 5’ 
Fusion 
GCGGATATCGAACTCATTAAACTGCATAAGAG
ACGC 
Deleting SMU.1909 
to SMU.1913 
EcoR-V SMU. 1913-3’ 
Fusion 
GCGGATATCGCTGCGCTGTTAAAAGTCTTAAT
AACC 
Deleting SMU.1909 
to SMU.1913 
SMU.1915-R CGGAAAAATGTTGATAGGCTTCCG Deleting SMU.1909 
to SMU.1913 
SMU. 518 5' F GCTGTTATTGAAGCTAATATCAGGATG Deletion of SMU.518 
SMU.518 3' R CTGCTGCCGCTACCTCTGGATTTTCC Deletion of SMU.518 
SMU.518 5' Fusion-R GCCGCCATGGCGGCCGGGAGGTTTGTTTTCAC
ATTTTTTCCCCA 
Deletion of SMU.518 
SMU.518 3' Fusion-F CGCGGCCGCCTGCAGGTCGACCTTACCTAAGA
AAACACTAATAAAGG 
Deletion of SMU.518 
BamHI SMU.518 F GCGGGATCCTTGGGGCAGACATCAGTCCTT Cloning of SMU.518 
XhoI SMU.518 R GCGCTCGAGTTAGTGTTTTCTTAGGTAATC Cloning of SMU.518 
XhoI-HA-SMU.518-R GCGCTCGAGTTATTCTAATTTAGCAGCATAATC
AGGAACATCATAAGGATAGTGTTTTCTTAGGT
AATCAATA 
To study the 
expression of 
SMU.518 
SMU.518 inverse F GTGCAGGAGGCTATTGATTACCTAAG Deleting SMU.518 
SMU.518 inverse R CTGATTAGCCACCATTTAAATTTTTTG Deleting SMU.518 
SMU.518 F2 GACTCTTAATACTGTTACTTAGAATG To amplify SMU.518 
SMU.518 R2 GGATTTGTGAAGGTCTGCCTTAGTAAG To amplify SMU.518 
SMU.1906F GAATACACACGTATTGGAAC RT PCR 
SMU.1906R CCTCCAACAAGTTCACCGTA RT PCR 
SMU.423 F GAATACACAAGCATTTGAAC RT PCR 
SMU.423R CAACAAAAAGTAGCAGCACC RT PCR 
ISS1-R-OUT 2 AATAGTTCATTGATATATCCTCGCTGTCA Mutagenesis 
ISS1-FOR4 GGTCTTAATGGGAATATTAGC Mutagenesis 
EcoRI SMU. NlmA F GCGGAATTCGGCAATCGAAGTTTTGGTGTAGA
GGC 
Cloning of nlmA  
promoter 
XhoI SMU. NlmA IGS 
R 
GCGCTCGAGTGTATCCATATGATAAACACCCC
TTTTTC 
Cloning of nlmA  
promoter 
SMU. NlmC F CCAGCCTTGTTTTATTCCAATG To amplify nlmC  
SMU. NlmC R GAACGCTACTGTGTCTTTTTTAC To amplify nlmC  
XhoI SMU.1913 R GATTTTTTTGAACGCTACTGTGTCTTTTTTAC Deletion of comC 
SMU.1915 5’ fusion GCCGCCATGGCGGCCGGGAGGTGTTTTTTTCAT
TTTATATCTCC 
Deletion of 
SMU.1915 
SMU.1915 3’fusion CGCGGCCGCCTGCAGGTCGACCGATAGGCTAA
CATTGGAATAAAAC 
Deletion of 
SMU.1915 
SMU.1915 R CTTTACAAGGATATTCGAAGTTTCC Deletion of comC 
SMU.2137 5’ F CCAGATCAACTTATTATTTTAGCTGC Deleting SMU.2137 
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Name of the Primer Sequence Purpose 
SMU.2137 3’ R GTGACCGTGATTTACAAATTGACGAG Deleting SMU.2137 
SMU.2137 5’ fusion R GCCGCCATGGCGGCCGGGAGCTGCAAATGCGT
CACTCATTGTTTC 
Deleting SMU.2137 
SMU.2137 3’fusion F CGCGGCCGCCTGCAGGTCGACCCTGAGAAAAC
ATTAATACGTTATTTTG 
Deleting SMU.2137 
SMU.832 5’ fusion R GCCGCCATGGCGGCCGGGAGCTCTCCTTCTAT
ATATTAGCATTG 
Deleting SMU.832 
SMU.832 3’fusion F CGCGGCCGCCTGCAGGTCGACCGATATCCCTT
ACTTAAAGAAAAGGTG 
Deleting SMU.832 
SMU.832 5’ F GAGTTGTTATTCACCCATCTTCGG Deleting SMU.832 
SMU.832 3’ R CACGTTCTCGATTCTCATAAGCTAC Deleting SMU.832 
SMU.832 RT F GATTGCTTATTGAATCAGTGACG RT PCR 
SMU.832 RT R GCAAAGCCGTATAAATAATCAAC RT PCR 
Xho1 ComC  6X His R GCGCTCGAGTTTAGTGATGGTGATGGTGATGTT
TTCCCAAAGCTTGTGTAAAAC 
To study the ComC 
transport 
XhoI HA-ComC-R GCGCTCGAGTTTAAGCGTAATCTGGAACATCG
TATGGGTATTTTCCCAAAGCTTGTGTAAAAC 
To study the ComC 
transport 
BamHI SMU.832 F GCGGGATCCGTTAATTCTAGTGATTTTACAGC Complementation 
XhoI SMU.832 R GCGCTCGAGCCTTGAAAATTAATAATTGGATT Complementation 
BamHI SMU.2137F GCGGGATCCGTAAAATTAATGTTCCAAAAAG Complementation 
XhoI SMU.2137 R GCGCTCGAGACTAATCAAAATAACGTATTAAT
G 
Complementation 
BamH1 ComC F GCGGGATCCGCTAATTTTACATTATGTGTCC Complementation 
XhoI 18aa ComC R GCGCTCGAG 
TTAAGCTTGTGTAAAACTTCTGTTA 
Complementation 
XhoI ComC 21-aa R GCGCTCGAGTTATTTTCCCAAAGCTTGTGTAAA
A 
Complementation 
SMU.1915 inverse F-out GCTAACATTGGAATAAAACAAGG Deletion of comC 
SMU.1915 R CTTTACAAGGATATTCGAAGTTTCC Deletion of comC 
SMU.925-F GAAAAGTCGGAAACTGAAGTTATTGAG To amplify SMU.925 
SMU.925-R CCATCAAAAGCAAAAACACGACAG To amplify SMU.925 
SMU.1898 F  GGTATATCAGGAGCTGGTGTAGG Deleting cslAB 
SMU.1898 R CATATAAAAAAAAGCGGAGCGTTC Deleting cslAB 
SMU.1898 5' Fusion 
 
GCCGCCATGGCGGCCGGGAGCAATCAGTGTCA
CCATTAAACTGG 
Deleting cslAB 
SMU.1898 3' Fusion F CGCGGCCGCCTGCAGGTCGACCCCTCTAAAGA
TGTCACCCGCCTC 
Deleting cslAB 
SMU.121 RT F GGAAATCTTGTGGGTACAAAAG RT PCR 
SMU.121 RT R GCCATTTTAAATGGAACAAGTCAG RT PCR 
SMU.121 F CTATAGCGATTAAAAGGAGCAG To amplifySMU.121 
SMU.121 R ATTTCTGTTATGCTTAACCTTG To amplifySMU.121 
SMU.121 5' fusion-R GCCGCCATGGCGGCCGGGAGCACTTCCCTTGG
TTAAGTCCGTC 
Deletion of SMU.121 
SMU.121 3' fusion-F CGCGGCCGCCTGCAGGTCGACCCTGATGCGCT
TAATCTATTTCAG 
Deletion of SMU.121 
SMU.121 5'F CTTTGAAATTGGATACGGGTTTAG Deletion of SMU.121 
SMU.121 3'R CGAACGGCTGAGCATAGGTTGGTC Deletion of SMU.121 
SMU.611 5’F GGTAACTTACAGTTCAAATACAGTG Deletion of SMU.611 
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Name of the Primer Sequence Purpose 
SMU.611 3’ R TGTATAAGCTCCCACAAATCCTTC Deletion of SMU.611 
SMU.611 5’ fusion R GCCGCCATGGCGGCCGGGAGGTGCGAAGCTAC
CTTATCAAACGTTAG 
Deletion of SMU.611 
SMU.611 3’ fusion F CGCGGCCGCCTGCAGGTCGACCGGTGACAGAT
AACCATTCAAATTC 
Deletion of SMU.611 
SMU.611 F GACATTCTTTCTGCTGTTGCAAAAG To amplify SMU.611 
SMU.611 R CTTTGCGATTTTTGTTAGAAGTCC To amplify SMU.611 
SMU.121 RT F GGAAATCTTGTGGGTACAAAAG RT PCR 
SMU.121 RT R GCCATTTTAAATGGAACAAGTCAG RT PCR 
NlmE F ATGGATCCTAAATTTTTACAAAG To amplify nlmE 
NlmE R GATATATAGAATATCTAATTATCC  To amplify nlmE 
N296A SMU.518 F ATCTTTTTTGTTCCCGCTAACCCGGTAAGTAAG
GCA 
Mutagenesis 
N296A SMU.518 R TGCCTTACTTACCGGGTTAGCGGGAACAAAAA
AGAT 
Mutagenesis 
SMU.518 S235A F CAAATGGTATTGGAGGGCCAGCTGCCGGTCTC
ATGTTTACC 
Mutagenesis 
SMU.518 S235A R GGTAAACATGAGACCGGCAGCTGGCCCTCCAA
TACCATTTG 
Mutagenesis 
SMU.518 K280A F GGCGGTGCCGATATGGCAGTGGCTGCAGCAGA
TAGGATTAATG 
Mutagenesis 
SMU.518 K281A R CATTAATCCTATCTGCTGCAGCCACTGCCATAT
CGGCACCGCC 
Mutagenesis 
SMU. NlmTE F GTCTTGGCTTTTGTTAGCCACGGGCCTTGC Deletion of nlmTE 
SMU. NlmTE R CATTGAGAATGGTATTACGGGAAACTGC Deletion of nlmTE 
SMU. NlmTE 5’ Fusion GCCGCCATGGCGGCCGGGAGCTCTAAGAGAAT
GTTAACGGCTATGAC 
Deletion of nlmTE 
SMU. NlmTE 3’Fusion CGCGGCCGCCTGCAGGTCGACCCTATATATCA
GCAGCAATCTTTGC 
Deletion of nlmTE 
 
 
 
 
 
 
 
72 
 
CHAPTER THREE 
CHARACTERIZATION OF MUTACIN ACTIVITY 
Abstract 
Streptococcus mutans UA159, whose genome is completely sequenced, produces two 
nonlantibiotic mutacins, mutacin IV (encoded by nlmAB) and mutacin V (encoded by nlmC). In 
this study, we investigated the contribution of nlmA and nlmB to mutacin IV activity and 
demonstrated by performing genetic studies as well as by using semipurified molecules that, in 
contrast to a previous report, both of these genes are required for optimum mutacin IV activity. 
We also showed that mutacin IV is active against multiple Streptococcus species. In contrast, 
mutacin V displayed a narrower inhibitory range than mutacin IV. Our results suggest that 
mutacin IV and mutacin V may act synergistically to inhibit various organisms. 
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Introduction 
Bacteriocins are ribosomally synthesized small antimicrobial peptides secreted by a wide 
variety of bacteria to inhibit the growth of other bacteria. The antimicrobial activity of the 
bacteriocins may or may not be against species that are closely related to the producer organism 
(133). In most cases, producer organisms secrete multiple bacteriocins, each displaying a distinct 
inhibitory spectrum, either narrow or broad, to provide a competitive advantage by eliminating 
organisms that share the same ecological niche with the producer organism. Bacteriocins 
produced by lactic acid bacteria (LAB) are active against clostridia, listeria, and other pathogens; 
therefore, these bacteriocins have the potential to be used as antimicrobial therapy. 
S. mutans, a lactic acid bacterium, is considered to be the primary causative agent of 
dental caries, commonly known as tooth decay (177). S. mutans resides in the dental plaque, a 
multispecies biofilm community that harbors over 600 different types of microorganisms (1). To 
inhibit the growth of competing bacteria and to establish a successful colonization in the plaque 
biofilm, S. mutans secretes a wide variety of mutacins that display a diverse inhibitory spectrum 
(8, 15). Based on the chemical structure, mutacins are generally classified into the following two 
groups: class I, the lantibiotics, and class II, the heat-stable nonlantibiotics (54, 151). Both 
lantibiotics and nonlantibiotics are synthesized ribosomally; however, lantibiotic peptides are 
post-translationally modified and contain either a lanthionine or methyllanthionine ring structure 
as well as dehydrated amino acids (315). On the other hand, nonlantibiotics are unmodified 
peptides and consist of either one or two separate molecules (219).The genome sequence of the 
reference strain S.mutans UA159 does not encode any genetic determinant for lantibiotic 
mutacins (7). However, this strain carries and produces at least two nonlantibiotics, mutacin IV 
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and mutacin V (104). The NlmA peptide consists of 44 residues with a molecular mass of 4169 
Da, while the NlmB peptide consists of 49 amino acid residues with the molecular mass of 4826 
Da. This strain also carries several other nonlantibiotics- like small peptides with unknown 
functions (299). 
Qi et al. (247) first purified mutacin IV activity from the culture supernatant of the 
UA140 strain and found that the active fractions contained both the NlmA and NlmB peptides. 
However, attempts to separate the complex of these two peptides into individual peptides by 
various high-pressure liquid chromatography (HPLC) protocols were unsuccessful (247). In 
contrast, when Hale et al. (104) deleted the nlmB gene, the mutant strain apparently retained its 
mutacin activity and thus raised doubt about the two-peptide action of the mutacin IV activity 
and suggested that NlmA was solely responsible for mutacin IV mediated inhibition of various 
bacteria.  
In this chapter, we focused strictly on the characterization of mutacins IV and V 
produced by the UA159 strain. We found that, contrary to the previous report, both the NlmA 
and NlmB peptides are required for optimum mutacin IV activity. Furthermore, we showed that 
mutacin IV activity has a broader inhibitory spectrum than previously described. 
Results 
Mutacin IV activity requires both the NlmA and NlmB peptides: To clarify the role 
of individual peptides in mutacin IV activity, we constructed individual single-deletion mutants 
and a double-deletion mutant. Since nlmA and nlmB are organized in an operon, insertion of any 
antibiotic resistance gene in nlmA would disrupt the normal expression of nlmB. To avoid this 
polar effect, we constructed a marker less nlmA mutant strain, IBS-D4, using the Cre-loxP 
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system (Fig. 8). We also deleted the nlmB gene and replaced it with a kanamycin resistance 
cassette that lacks a transcription terminator at its 3’ end and was inserted in the same orientation 
as the nlmB gene, therefore eliminating the concern of a polar effect on the nlmA gene (Fig. 8). 
Expression of nlmA in nlmB and nlmB in nlmA mutation background was verified by sqRT-PCR. 
The downstream SMU.152 gene contains its own promoter, and its expression was not affected 
by the replacement, as measured by semi quantitative reverse transcription- PCR (RT-PCR) 
assay (data not shown). We also constructed a marker less nlmAB double-deletion mutant, IBS-
D3, by using the Cre-loxP method (Fig. 8). These strains were evaluated for mutacin IV 
production against two indicator strains, S. gordonii and S. cristatus. These two indicator strains 
are sensitive to mutacin IV only when used against S. mutans strain UA159 (41). As shown in 
Fig. 9A, deletion of either nlmA or nlmB drastically reduced the zone of inhibition against both 
of the indicator strains, although there was some residual mutacin IV activity present in both of 
the mutants, with the ΔnlmA strain displaying slightly more activity than the ΔnlmB strain. As 
expected, deletion of the nlmAB genes completely abolished the mutacin IV production. To 
confirm that both the NlmA and NlmB peptides are necessary for the observed bacteriocin 
activity, we used a complementation assay. The IBS-D3 strain was complemented with plasmids 
carrying nlmA, nlmB, or nlmAB and tested against the same two indicator strains. We also used 
IBS-D3 carrying only the vector plasmid as a control. Expression of nlmA, nlmB, and nlmAB 
from the plasmids was confirmed by semi quantitative RT-PCR analysis (Fig. 8C and data not 
shown). To facilitate the selection of the complementing plasmids with antibiotics, the indicator 
strains were transformed with the same vector plasmid. As shown in Fig. 9B, expression of the 
nlmAB genes successfully restored mutacin activity, whereas expression of the nlmA gene alone  
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Fig. 8. Construction of nlmAB deletion mutants. (A) Schematic diagram of various deletions 
constructs. A Cre-loxP-based marker less gene deletion method was used for the construction of 
nlmA (IBS-D4) - and nlmAB (IBS-D3)-deletion strains. IBS-D3 was created by deleting the 
nlmAB operon by BbsI (Bs) and BstEII (EII) digestion and replacing it with a kanamycin 
resistance cassette (Km) that is flanked by loxP sites. The Km cassette was subsequently cured 
with Cre recombinase. An overlapping PCR method was used for the generation of IBS-D4. Two 
PCR fragments were generated by primers 1 and 2 and primers 3 and 6 and were fused with a 
loxP-flanked Km resistance cassette, which was later removed with Cre recombinase. Similarly, 
two PCR fragments were generated with primers 1 and 4 and primers 5 and 6 and fused with the 
loxP-flanked Km resistance cassette to create IBS-D10. The Km cassette was not cured in IBS-
D10. Symbols: block arrows, open reading frames; bent arrows, promoters; arrowheads, primers; 
arrowheads with tails, primers with regions overlapping; white box, loxP site. (B) PCR 
verification of the constructs using primers 1 and 6. (C) Verification of plasmid-driven 
expression of nlmA and nlmB by semi quantitative RT-PCR. Total RNA was harvested from the 
indicated strains and subjected to cDNA synthesis. Five nanograms of cDNA from each strain 
were used for semi quantitative RT-PCR. The gyrA gene was included to ensure that equal 
amounts of RNA were used for all reactions. The data are representative of RT-PCR analyses 
resulting from at least two different RNA isolations. 
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did not restore the mutacin activity compared with the wild type. Surprisingly, we found that 
expression of nlmB could restore the mutacin production to some extent; however, the activity 
was much less than that restored by the strain with nlmAB. Thus, taken together, our results 
suggest that optimum mutacin IV activity requires both the NlmA and NlmB peptides. 
To further confirm our observation, we purified the active molecules by ammonium 
sulfate precipitation from the culture supernatant. The purified molecules were tested for mutacin 
IV activity against the S. gordonii indicator strain. As a positive control, we also included the 
wild-type UA159 strain. As shown in Fig. 9C, deletion of the nlmAB genes completely abolished 
the mutacin activity. Although the overproduction of nlmB restored the mutacin activity, 
overproduction of both of the peptides significantly augmented the activity, confirming that 
optimum mutacin IV activity requires both the NlmA and NlmB peptides. 
Bacteriocins produced by S. mutans UA159 are active against Streptococcus 
pyogenes: S. pyogenes, a pathogenic streptococcus that also resides in the oral cavity, was shown 
by Hale et al. to be inhibited by mutacin IV (104). To refine and expand the observation, we 
tested our mutant strains against three S. pyogenes strains, JRS4, K56, and AM3, belonging to 
three different serotypes, M6, M12, and M3, respectively. As shown in Fig. 10A, deletion of 
nlmA, nlmB, or nlmAB caused a significant reduction in the zone of inhibition formation against 
the S. pyogenes strains. Although the reduction was not as drastic as that observed against the S. 
gordonii strain, nevertheless, the reduction was easily measurable. We then tested the effect of 
mutacin V against S. pyogenes strains. For this, we used either the nlmC mutant or the nlmAB 
nlmC triple mutant strains. As shown in Fig. 10B, deletion of nlmC also leads to a reduction of 
zone of inhibition compared with that of the wild type. However, the reduction was higher in   
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Fig. 9. Deferred antagonism assay for mutacin IV production by S. mutans strains. (A) Ability to 
produce mutacin IV by nlmA (IBS-D4)-, nlmB (IBS-D10)-, and nlmAB (IBS-D3)-deleted strains. 
(B) Complementation analysis of the ΔnlmAB strain (IBS-D3) with various levels of plasmid-
derived expression of nlmA, nlmB, or nlmAB. For the mutacin IV assay, S. mutans cultures were 
stabbed into THY agar and incubated overnight at 37°C under microaerophilic conditions. The 
plates were overlaid with soft agar containing S. gordonii DL-1 (SGO) or S. cristatus ATCC 
51100 (SCT) as indicator strains. The zones of inhibition of the indicator strains were evaluated 
after overnight incubation (*, strain also contains plasmid pIB184-Km). (C) Activity profile of 
semi purified mutacin IV from culture supernatant. Ammonium sulphate extractions from the 
clarified culture supernatant from the representative strains were tested for mutacin IV activity 
against the S. gordonii DL-1 indicator strain. A representative antagonism assay from at least 
three independent extractions is shown. WT, wild type.  
 
 
 
 
80 
 
 
 
 
ΔnlmA
ΔnlmB
ΔnlmAB
UA159
SGO SCT
A
 
 
 
 
 
 
81 
 
ΔnlmAB
::pnlmA
ΔnlmAB
::pnlmB
ΔnlmAB::
pnlmAB
ΔnlmAB
UA159
B
SGO SCT
 
C
PnlmAB
PnlmA
PnlmB
ΔnlmAB
 
 
82 
 
case of the nlmC mutant than that in the case of nlmAB mutant, suggesting that mutacin V is 
more active against S. pyogenes than mutacin IV (Fig. 10B, comparison of ii and iv). As 
expected, the zone of inhibition produced by the triple mutant was further reduced, although the 
mutant produced a very small but noticeable zone of inhibition. To confirm our results, we 
complemented the triple mutant strain (IBS-D13) with plasmid-based nlmAB or nlmC. As shown 
in Fig. 10C, expression of the nlmAB genes in IBS-D13 from a complementing plasmid 
completely restored the mutacin IV activity (comparison of i and ii). Similarly, expression of 
nlmC in IBS-D13 also restored mutacin V production; however, the efficiency of 
complementation was below the expected level (Fig. 10B, comparison ii and iii). Taken together, 
our results suggest that both mutacin IV and mutacin V inhibit S. pyogenes and that their effect is 
synergistic. 
Growth of the indicator strain dictates sensitivity to mutacin: It has been previously 
shown that L. lactis is not inhibited by mutacin IV (104). When we tested our mutant strains 
against L. lactis MG1363, we observed that depending on the growth stage of the culture, 
mutacin IV activity could inhibit L. lactis growth. When mid-exponential-growth-phase L. lactis 
culture was used for the overlay, we observed that the ΔnlmC strain produced a noticeable zone 
of inhibition that was absent when the indicator culture used was from the stationary growth 
phase (Fig.11A & B). As expected, the triple mutant strain IBS-D13 did not produce any zone of 
inhibition irrespective of the growth stage of the indicator strain. Thus, mutacin IV appears to 
inhibit L. lactis growth. It is known that mutacin IV inhibits S. gordonii growth, but very little is 
known about the inhibitory spectrum for mutacin V. Therefore, we tested the ΔnlmC and 
ΔnlmABC (IBS-D13) strains against S. gordonii culture that was grown to early stationary phase. 
As shown in Fig. 11C, the zone of inhibition produced by the ΔnlmC strain was drastically 
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Fig. 10. Bacteriocin activity of S. mutans UA159 against group A streptococcus. (A) Inhibitory 
effect of mutacin IV on S. pyogenes strain JRS4. i, ΔnlmA strain; ii, ΔnlmB strain; iii, ΔnlmAB 
strain; iv, strain UA159. (B) Activity of mutacin IV- or V-deficient mutant strains against S. 
pyogenes JRS4. i, ΔnlmABC strain; ii, ΔnlmAB strain; iii, UA159; iv, ΔnlmC strain. (C) 
Complementation analysis of the ΔnlmABC strain. i, UA159/pIB184-Km; ii, IBS-D13/pIB-D19 
(nlmAB); iii IBS-D13/pIB-D29 (nlmC); iv, IBS-D13/pIB184-Km. These plates are representative 
of at least three independent assays. 
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 reduced compared to that produced by the wild-type strain. On the other hand, the ΔnlmAB 
ΔnlmC mutant strain produced virtually no zone of inhibition against S. gordonii. These results 
indicate that mutacin V also can inhibit the growth of S. gordonii in addition to that of L. lactis. 
Interestingly, when we used the ΔnlmAB strain, we observed very little mutacin activity against 
the S. gordonii indicator strain, suggesting that mutacin V alone cannot work efficiently; the 
presence of mutacin IV augments the inhibitory activity of mutacin V. In this regard, these two 
mutacins seem to work synergistically. 
Inhibition of various streptococci by mutacin produced by S.mutans UA159: 
Because we found that both mutacin IV and mutacin V have wider ranges of inhibitory spectra 
than expected, we tested several other Streptococcus spp. belonging to all phylogenetic 
subgroups for sensitivity to both mutacins (Fig.12). For this, we used the same two mutant 
strains, IBS-D3 and IBS-D13, as well as the ΔnlmC strain, and tested them against 18 different 
Streptococcus spp. As shown in Table-10, mutacin IV inhibited growth of all the streptococcus 
subgroups, except the mutans group and S. pneumoniae, a mitis subgroup species. On the other 
hand, mutacin V inhibited growth of only five streptococci belonging to four subgroups 
(pyogenic, anginosus, mitis, and bovis). However, we found that not all species belonging to a 
particular subgroup were susceptible to mutacin V. For example, in the case of the pyogenic 
subgroup, only Streptococcus iniae and S. pyogenes were inhibited by mutacin V. Thus, we 
conclude that mutacin V has a narrower inhibitory spectrum than mutacin IV, which has a much 
broader inhibitory spectrum. Because we observed different inhibitory spectra for mutacin IV 
and mutacin V, it argues that the mechanisms of immunity against these two mutacins are 
different. 
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Fig. 11. Mutacin activity against other species. Derivatives of S. mutans UA159 were tested for 
inhibitory activity against L. lactis (LLC) (A and B) or S. gordonii (SGO) (C). For L. lactis, 
either freshly grown (A) or 1-day old (B) cultures were tested for growth inhibition. These plates 
are representative of three independent experiments. 
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Table-10: Inhibitory spectrum of S. mutans UA159 
Species (indicator strain[s]
b
  Group Zone of inhibition in diameter (mm)
a
 
Wild type 
Strain carrying: 
ΔnlmAB ΔnlmC ΔnlmABC 
S. uberis (UT387) pyogenic 22±2 - 22±2 - 
S. agalactiae (NEM306) pyogenic 16±1 - 13±1 - 
S. iniae (K388) pyogenic 14±1 13±1 9±1 5±0.5 
S. pyogenes (JRS4, K56, AM3) pyogenic 24±1 14±1 17±1 10±1 
S. anginosus (CI) anginosus 23±1 16±1 17±1 5±0.5 
S. constallatus (CI) anginosus 25±2 - 17±1 - 
S.pneumoniae (ATCC6303) mitis 10±1 10±1 10±1 10±1 
S. cristatus (ATCC51100) mitis 14±1  4±0.5 11±1 4±0.5 
S. gordonii (DL-1, M5, ATCC 10558) mitis 17±1 - 17±1 - 
S. sanguinis (SK36) mitis 10±1 - 9±1 - 
S salivarious (ATCC 25975) salivarious 8±1 - 8±1 - 
S. bovis (TX20005) bovis 9±1    4±0.5 - - 
S. downeii (ATCC 337908) mutans - - - - 
S. sobrinus (6715) mutans - - - - 
S. criceti (AHT) mutans - - - - 
S. mutans (UA159, UA130, GS-5) mutans - - - - 
S. ratti BHT mutans - - - - 
↵a: −, none or a < 4-mm zone of inhibition. Values are means ± standard deviations resulting 
from at least three independent experiments performed in duplicates. 
↵b: three different strains for three streptococci were tested, as indicated. CI, clinical isolates. 
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Fig.12. Mutacin activity against various streptococci. Phylogenetic classification of various 
streptococci based on 16S rRNA sequence analysis. The species tested for sensitivity against 
mutacin IV (circle) or mutacin V (square) produced by S. mutans UA159 are shown.  
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Discussion 
Streptococcus mutans, a lactic acid bacterium, is one of the primary causative agents of 
dental caries (108, 177). Occasionally, S. mutans can enter the blood stream and cause transient 
bacteremia and infective endocarditis (177). The organism possesses several properties which 
allow it to successfully colonize and survive in the human host. In the oral cavity, the bacterium 
can form dental plaque, a type of biofilm, on the tooth surfaces (19). Dental plaque is home to 
one of the most complex bacterial floras associated with human body. So far, more than 700 
different bacterial species have been identified from human oral cavity, and the majority of them 
are associated with dental plaque (2, 65). However, S. mutans has ability to outcompete other 
bacteria by producing various bacteriocins known as mutacins (8, 15). In this study, we have 
characterized the role of a well recognized bacteriocin called Mutacin IV. Mutacin IV is a two-
peptide bacteriocin produced by S. mutans UA140 and UA159 and is active against the mitis 
group of streptococci (247). By definition, both of the peptides should be present at eqiomolar 
concentration to exert their activities (219). Qi et al. (247) first purified mutacin IV activity from 
the culture supernatant of the UA140 strain and found that the active fractions contained both the 
NlmA and NlmB peptides. However, Hale et al. (104) showed that deletion of the nlmB gene 
produced the same phenotype as compared to wild type, suggesting the sole role of NlmA in 
mutacin IV activity.  
To clarify the role of individual peptide in mutacin IV activity, we constructed a panel of 
clean mutants of each peptide and tested their activity against the susceptible bacteria. Our 
deletion and complementation studies clearly established that both of the peptides are required 
for optimum mutacin IV activity, despite the fact that NlmB displayed killing activity against S. 
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gordonii to a certain extent in nlmA background but not against S. cristatus, where both of the 
mutants lost activity completely. Further study with semi-purified molecules clearly showed that 
both of the peptides should be present in equal amount to display optimum inhibition of the 
susceptible cells (Fig. 9). Although it is not entirely clear why Hale et al. (104) failed to observe 
any function for the NlmB peptide, it is possible that the inhibition assay and the growth media 
used by those authors were different from the ones used here. In our case, a direct overlay of the 
indicator strain was used to avoid the chloroform vapor. Our data also suggest that 
overproduction of the NlmB peptide is able to inhibit the growth of the indicator strains. We 
speculate that NlmB itself can form a homodimeric transmembrane helical structure needed for 
the activity since it also contains the GXXXG motif. In this regard, mutacin IV is similar to 
lactacin F, which is also a dipeptide bacteriocin, composed of LafA and LafX. The individual 
peptides display inhibiting activity, although the efficiency is lower than when both the peptides 
are used together (10). Alternatively, in the absence of NlmA, NlmB can form the heterodimeric 
helix-helix structure with other bacteriocin-like peptides such as SMU.283, which shows high 
homology to NlmA. Further in vitro studies with purified or synthetic peptides may tell us 
whether NlmB can form such structures in vivo. Our study showed that mutacins produced by S. 
mutans UA159 have much broader inhibitory spectra than expected. We also found that 
maximum mutacin IV activity requires both the NlmA and NlmB peptides. In this regard, 
mutacin IV truly belongs to class IIb bacteriocins, which require complementary interaction of 
two separate peptides.  
In this study, we also analyzed and characterized the NlmC activity and found that NlmC 
can work with NlmAB to produce optimum mutacin IV phenotype. Interestingly, we found that 
NlmAB also imparts in mutacin V activity depending on the status of indicator bacteria. An early 
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or mid exponential culture of L. lactis is prominently susceptible to mutacin IV activity; whereas 
stationary phase culture was exclusively inhibited by stationary phase culture. These findings 
suggest the expression of different membrane receptors at different growth stages. Our studies 
revealed that mutacin IV activity can inhibit more bacterial species than reported before. We 
found that streptococci from almost all groups, except mutans group, can be inhibited by mutacin 
IV activity and this spectrum of activity is often associated with mutacin V activity.  
Interestingly, while some streptococci are susceptible to both of the mutacins, most of the 
strains are not, suggesting that immunity against these two mutacins is different. Mechanisms of 
immunity against a given bacteriocin can vary widely. The immunity factors can interact directly 
with the bacteriocin itself, thereby blocking interaction with the membrane receptors, or facilitate 
expulsion of intracellularly accumulated bacteriocins (40, 192). Another novel mechanism by 
which immunity protein blocks the interaction of bacteriocin with its cognate membrane receptor 
is mannose phosphotransferase (man-PTS) (70). Since very little is known about the mode of 
action for these two mutacins, further studies are required to understand the molecular 
mechanism of target specificity as well as immunity against the activity of these mutacins.  
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CHAPTER FOUR 
MECHANISM OF SELF-IMMUNITY 
Abstract 
Streptococcus mutans, principal causative agent of dental caries, secretes antimicrobial 
peptides known as mutacins to suppress the growth of competing species to establish a 
successful colonization. S. mutans UA159, a sequenced strain, produces at least two major 
mutacins, mutacin IV and V. Mutacin IV is a two-peptide bacteriocin encoded by nlmAB genes, 
which are mapped just upstream of a putative immunity-encoding gene, SMU.152. Here we 
explored the function of SMU.152 as an immunity protein. We observed that over expression of 
SMU.152 in two sensitive host strains converted the strains to become immune to mutacin IV. 
To identify the residues that are important for immunity function; we sequentially deleted 
residues from the C-terminal region of SMU.152. We observed that deletion of as few as seven 
amino acids, all of which are highly charged (KRRSKNK), drastically reduced the immunity 
function of the protein. Furthermore, we identified two other putative immunity proteins, 
SMU.1909 and SMU.925, which lack the last four charged residues (SKNK) that are present in 
SMU.152 but contains the KRR residues. Synthetic addition of SKNK residues to either 
SMU.1909 or SMU.925 to reconstitute the KRRSKNK motif and expressing these constructs in 
sensitive cells rendered the cells resistant to mutacin IV. We also demonstrated that deletion of 
Man-PTS system from a sensitive strain made the cells partially resistant to mutacin IV, 
indicating the Man-PTS system plays a role in mutacin IV recognition. 
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Introduction 
Bacteriocinogenic bacteria also contain the specific immunity mechanism to its own 
bacteriocin (54). This system determines the distinction between ‘self’ vs. ‘non-self’ and 
provides protection to the producer strains. Two different classes of immunity mechanisms are 
prevalent among the producer bacteria (93) and these immunity mechanisms are highly specific 
and don’t confer protection against other bacteriocin (54, 278). Immunity can be achieved by 
specific immunity protein or a specialized ABC-transporter which pumps the bacteriocin from 
the producers membrane (101, 229, 238, 256). In case of lantibiotics, one or both of these 
systems are involved for providing immunity (278), whereas specific immunity protein is present 
for class II bacteriocins and cyclic peptides are dependent on ABC-transporters (67). In most 
cases, immunity proteins either sequester the bacteriocin peptides or compete for the receptor 
binding to confer protection (124, 302). Immunity to bacteriolysins are mediated by alteration of 
the peptidoglycan structure of the producer strain (25).  For some pediocin-like (class IIa) and 
some class IIc bacteriocins, the proteins that confer immunity have been shown to directly bind 
to the bacteriocin receptor and therefore block the pore formation by the bacteriocin (70). 
Recently, it has been shown that Abi family proteins consist of membrane bound putative 
metalloproteases could confer protection against two-peptide bacteriocins such as plantaricins 
(PlnEF and PlnJK) produced by Lactobacillus plantarum (150). Furthermore, Abi family 
proteins display extensive cross-immunity against non-cognate two-peptide bacteriocins. 
Because Abi encodes putative metalloproteases, it has been proposed that Abi-mediated 
immunity could involve direct proteolytic degradation of the bacteriocins (150). 
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Immunity activity to mutacins has been studied on lantibiotics (mutacin I, II, III) where 
immunity function is conferred by mutFEG genes that are closely related to the LanFEG 
immunity system (194, 246, 248). For dipeptide lantibiotic (Smb), immunity system is dependent 
on two proteins, SmbF and SmbG respectively (212, 325). However, no cognate immunity 
proteins have been identified so far for non-lantibiotic dipeptide mutacin IV. After the first 
isolation of a two-peptide bacteriocin, lactococcin G (216), several two-peptide bacteriocins have 
been isolated and characterized (218). The genes encoding the two-peptide bacteriocins are 
always found next to each other, along with a gene that encodes a membrane associated 
immunity protein that seems to protect the bacteriocin producer strain from being killed by its 
own bacteriocin. 
Immediately downstream of the nlmAB operon lies another gene, SMU.152, which is 
annotated in the GenBank database as an immunity protein. In this study, we have characterized 
this gene and showed that SMU.152 can confer protection against mutacin IV in S. gordonii, an 
indicator strain traditionally used for mutacin IV activity. Furthermore, we show that the last 
seven charged amino acid residues at the C-terminal domain of the protein are essential for 
optimum immunity. 
Results 
  SMU.152 can confer immunity against mutacin IV: SMU.152 encodes a hypothetical 
protein that is topologically linked to nlmAB operon, which encodes the structural genes for 
mutacin IV. An intergenic sequence (IGS) of 193-bp is present in between the stop codon of 
nlmB gene and the initiation codon of SMU.152. A schematic diagram of the SMU.152 locus and 
the upstream nlmAB genes are shown in Fig.13A.  Sequence analysis, confirmed using BPROM 
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online software (prediction of bacterial promoters, Softberry, http://linux1.softberry.com), 
indicates the presence of putative -35 (TTAGAA) and -10 (TATACT) box motifs 78- and 55-bp, 
respectively, upstream of the putative start codon with a  putative ribosomal binding site 
(AGAGG) 11-bp upstream of the start codon. A putative rho-independent terminator sequence 
(AATTATGGAGGAGGA) was also identified at position 66-bp downstream of SMU.152 by 
TransTermHP (http:// transterm. cbcb.umd.edu) program (146). Thus, it appears that the 
SMU.152 is a single gene stand-alone operon.   
We analyzed the primary amino acid sequences of SMU.152 by several topology 
predicting algorithms {(TopPred (304), HMMTOP (293)} and found that SMU.152 contains at 
least  four transmembrane helices (Fig 13B). SMU.152 primary sequence was also subjected to a 
protein threading algorithm {MUlti-Sources ThreadER (317)} to predict the 3-dimensional 
structure of SMU.152, the predicted structure is shown in Fig. 13C. From the structure, it appears 
that the last few residues are not part of any transmembrane helix and are disorganized. 
 To evaluate the function of SMU.152 as an immunity protein, we cloned the entire 
coding region and the promoter region of SMU.152 into a shuttle plasmid and introduced the 
plasmid into S. gordonii, which was used as the indicator strain. As shown in Fig.14A, 
heterologous expression of SMU.152 in S. godonii confers protection against mutacins secreted 
by S. mutans UA159.  This result suggests that SMU.152 alone can give protection against 
mutacin IV and therefore acts as an immunity protein. We also over expressed SMU.152 in S. 
constellatus, a strain that is susceptible to mutacin IV (127). We found that as in S. gordonii, the 
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Fig. 13. Mutacin IV and its immunity protein. (A) Genetic organization of nlmAB and SMU.152. 
The intergenic sequence along with the putative promoter region is shown. Co-expression of 
SMU.152 with nlmAB genes is verified by linkage PCR. (B) Predicted secondary structure of 
SMU.152 determined by HMMTOP transmembrane topology prediction software 
(http://www.enzim.hu/hmmtop). Symbols are: i, inside the cell; H, helical (within membrane); o, 
outside of the membrane. (C). Predicted three dimensional structure of SMU.152 as determined 
by MUlti-Sources ThreadER (317). 
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S. constellatus strain containing SMU.152 is also refractory to lysis by mutacin (Fig. 14A-B).  
To explore further, we attempted to delete the SMU.152 locus from UA159 leaving the nlmAB 
loci intact. To our surprise, we were able to construct SMU.152 deleted strain (IBS-D16) and 
found no significant difference in growth in liquid medium between IBS-D16 and UA159 (data 
not shown). We then tested whether IBS-D16 strain produces mutacins and as shown in Fig. 
14C, IBS-D16 produces mutacin and there was no difference in the level of production between 
UA159 and IBS-D16. We also used IBS-D16 as an indicator strain in a deferred antagonism 
assay against UA159 and found that IBS-D16 is not susceptible to mutacins  produced by 
UA159 (data not shown). Therefore, our data suggest that UA159 probably encodes other 
immunity proteins that confer protection. 
S. mutans UA159 immunity proteins show cross-reactivity: According to KEGG 
database, three other SMU.152 paralogous genes are encoded by S. mutans UA159. One of them, 
SMU.925, which is also known as CipI, is previously shown to function as an immunity protein 
against mutacin V (encoded by nlmC) (237). Two other putative immunity proteins, SMU.1909 
and SMU.1913, are located near putative bacteriocin-like proteins (Blp) such as SMU.1906 and 
SMU.1914. Since SMU.152 shows sequence homology with SMU.925 as well as with 
SMU.1909 and SMU.1913, we wanted to test the possible role of these proteins for immunity to 
mutacin IV. We constructed various deletion derivatives of these putative immunity genes and 
used the strains as indicator against UA159. When we used as indicator, a strain in which 
SMU.925 was deleted (ΔSMU.925) or a strain in which both SMU.1909 and SMU.1913 were 
deleted (ΔSMU.1909 – SMU.1913), we did not observe any  significant changes in the 
sensitivity to mutacin IV or V (data not shown). We then constructed a multiple deletion strain in  
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Fig. 14. Immunity activity of SMU.152 in S. gordonii. S. mutans UA159 and an nlmAB strain 
(IBS-D3) were stabbed into THY agar and incubated overnight at 37°C under microaerophilic 
conditions. The plates were overlaid with soft agar containing the indicator strains. The zone of 
inhibition of the indicator strains was evaluated after overnight incubation. The indicators strains 
are S. gordonii DL-1 (A) and S. constellatus (SCO) (B) containing the vector (pIB184Km) or the 
vector with SMU.152 (pSMU.152). (C). Mutacin activity of ΔSMU.152 (IBS-D16) strain. These 
plates are representative of three independent assays. 
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the ΔnlmAB background, where we knocked out SMU.152, SMU.925, as well as SMU.1909 to 
SMU.1913. When we tested this IBS-D58 strain as indicator, to our surprise we found that the 
strain became sensitive to its own mutacins (Fig. 15). However, the zone of lysis was not as large 
as the zones produced against S. gordonii or other indicator bacteria. Taken together, our results 
suggest that SMU.152 may interact with other immunity proteins to confer complete protection 
against its own mutacins. 
  C-terminal charged residues of SMU.152 are required for optimum activity: Since 
SMU.152 confers immunity against mutacins, and because the predicted three dimensional 
structures indicate a disordered coil at the C-terminus, we wanted to evaluate the role of C-
terminus in mutacin immunity. We made sequential deletions of 19, 7, 6, and 3 residues from the 
C-terminal region and tested for immunity activity. As shown in Fig.16, deletion of as few as six 
residues from the C-terminal region caused drastic reduction in the immunity activity. Therefore, 
it appears that charged residues KRRSKNK at the C-terminal regions are required for optimum 
immunity activity against mutacins. 
SMU.1909 with SKNK residues can confer immunity against mutacin IV: As 
mentioned above, SMU1909 shows significant homology to SMU.152 and is annotated as a 
paralogous gene for SMU.152. When we performed a sequence alignment (Fig.17A), we found 
that SMU.1909 protein shares 49% similarity (including 30% identity) with SMU.152. Most 
importantly, we found that SMU.1909 lacks the last four residues of the KRRSKNK sequence. 
To verify whether SMU.1909 can confer immunity against mutacin IV, we over expressed 
SMU.1909 and SMU.1909 carrying SKNK residues in S. gordonii. As shown in Fig. 17B, 
expression of SMU.1909 does not provide protection (compare the zone of lysis for the top two 
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Fig: 15. Immunity activity of different mutants. UA159, ΔnlmAB, ΔnlmC, and ΔnlmABC were 
stabbed into THY agar and mutacin activity was measured against IBS-D16 (ΔSMU.152) and 
IBS-D58 (Δ nlmAB, ΔSMU.152, Δ SMU.1909 -SMU.1913, Δ SMU.925). These plates are 
representative of three independent assays. 
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Fig.16. Immunity activity of truncated SMU.152. Various C-terminal deletions of SMU.152 
were created and tested for immunity activity in S. gordonii as described in Figure 2. The data 
shown (in millimeter) are means ± standard deviations (error bars) of at least three independent 
experiments. Student's t-test was used to calculate the significance of the difference between the 
mean diameters of the zone of lysis. Asterisks indicate the P values that are <0.001. 
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Fig. 17. Immunity activity of SMU.1909 (A) Sequence alignment between SMU.152 and 
SMU.1909. An asterisk (*) indicates positions which have a single, fully conserved residue; a 
colon (:) indicates conservation between groups of strongly similar properties; and a period (.) 
indicates conservation between groups of weakly similar properties (B) S. gordonii strains 
containing SMU.1909 alone or SMU.1909 with four additional residues (SKNK) were tested for 
sensitivity against mutacin IV produced by UA159. Assays were repeated at least three times and 
a representative plate is shown. Student's t-test was used to calculate the significance of the 
difference between the mean diameters of the zone of lysis (P<0.001). 
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panels). However, when we added SKNK sequence to SMU.1909, the zone of lysis was reduced 
to approximately half as compared to the vector control. Thus, it appears that while SMU.1909 
alone does not confer immunity against mutacin IV, when we restored the complete KRRSKNK 
sequence that is present in SMU.152, we observed significant amount of protection against 
mutacin IV activity conferred by the modified SMU.1909. 
SMU.925 with SKNK also can confer immunity to mutacin IV: As mentioned above, 
SMU.925 also shows significant similarity with SMU.152. Since, SMU.925 also shares sequence 
homology with SMU.152 (Fig. 18A), we wanted to test whether over expression of SMU.925 in 
S. gordonii can confer protection against mutacin IV. As shown in Fig. 18B, over expression of 
SMU.925 did not produce noticeable difference in the zone of lysis (compare the top panel with 
the middle panel). Like SMU.1909, SMU.925 also lacks the last four charged amino acids that 
are present in SMU.152. We added these residues (SKNK) to SMU.925 and tested sensitivity 
against mutacin IV. We observed a slight but reproducible decrease in the zone of lysis produced 
by wild-type UA159 (Fig. 18B, bottom panel). To further  confirm that SMU.925+SKNK can 
confer immunity against mutacin IV, we tested against an nlmC deletion strain that 
predominantly produces mutacin IV (127). As observed before, the zone of lysis produced by the 
ΔnlmC strain in S. gordonii is smaller than the zone produced by the wild type strain (127). 
However, when we over expressed SMU.925+SKNK in S. gordonii, the zone of lysis were 
significantly smaller (~25% reduction) compared to the vector control strain. Thus, it appears 
that addition of SKNK to SMU.925 can confer some level of immunity against mutacin IV. 
Man-PTS system is required for optimum mutacin IV activity: The Man-PTS, which 
is a major sugar uptake system in Firmicutes, was recently shown to act as a receptor for class- 
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Fig: 18. Immunity activity of SMU.925. (A) Sequence alignment between SMU.152 and 
SMU.925. Symbols are described in Fig. 17A (B). Deferred antagonism assay was carried out 
with S. gordonii DL-1 strain as described in Fig. 17B, except that the indicator strain also 
contains the vector plasmid to facilitate selection during antagonism assay. Assays were repeated 
at least three times and a representative plate is shown. Student's t-test was used to calculate the 
significance of the difference between the mean diameters of the zone of lysis and the P values 
are shown. 
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Fig. 19. Mannose-PTS is required for optimum sensitivity. Assays were done as described in Fig. 
14. UA159 was stabbed in THY agar plate. The indicator strains were wild type S. gordonii DL-
1 (SGO) and a mutant DL-1 without a functional Man-PTS system (ΔPTS, IBS-D15). Assays 
were repeated at least three times and a representative plate is shown. Student's t-test was used to 
calculate the significance of the difference between the mean diameters of the zone of lysis 
(P<0.001). 
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IIa bacteriocins and for lactocococci A, a class-IIc bacteriocin (70, 148, 149). However, these 
two classes differ from class-IIb bacteriocins since they are single peptide bacteriocins. To verify 
whether Man-PTS system plays a role as a receptor for mutacin IV, we deleted the entire Man-
PTS system from S. godonii and subjected the deletion strain in a deferred antagonism assay for 
mutacin IV sensitivity. As shown in Fig. 19, the zone of lysis was approximately 30% smaller in 
the Man-PTS deleted strain as compared to the wild type of S. gordonii strain. Thus, Man-PTS 
system appears to play a role in mutacin IV sensitivity. Since we observed some degree of lysis 
in the Man-PTS deleted strain, it suggests that the Man-PTS is not the only complex that acts as 
receptor for mutacin IV in S. godonii. 
Discussion 
Bacteriocins that belong to class II generally kill target cells either by pore formation or 
by interfering with the integrity of the cell membrane; however, the exact molecular pathways by 
which the bacteriocins exert their effect on membrane are unknown (73). Since each bacteriocin 
display a specific inhibitory spectrum, it indicates that individual bacteriocin might recognize a 
particular receptor on the target cells. Some immunity proteins, specifically those that are related 
to class-IIa and -IIc bacteriocin have been shown to bind directly to these cell surface receptors 
and block pore formation  (70). However, no immunity mechanism is known for any class-IIb 
two peptide bacteriocins, except for the Abi-family proteins that presumably degrade the 
bacteriocins. In this study, we have characterized a self-immunity protein for mutacin IV, a two-
peptide bacteriocin. 
 The genes that encode self-immunity proteins for class-IIb are often located just 
downstream of the structural genes for bacteriocin. Because of this genetic organization, putative 
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immunity proteins for most of the bacteriocins can be readily identified. However, their function 
as an immunity protein has been demonstrated for only few of them (223). SMU.152 is also 
located downstream of nlmAB operon and therefore, it was an appropriate candidate to test for 
immunity activity. Indeed our results indicate that SMU.152 when expressed in heterologous 
sensitive hosts can confer complete protection against mutacin IV, suggesting that SMU.152 
alone is sufficient to counteract mutacin IV activity. However, surprisingly we found that when 
SMU.152 was deleted from S. mutans, the deletion strain was still refractory to mutacin IV 
activity. Several possibilities can explain why SMU.152 deficient strain is resistant to mutacin 
killing. For example, there may be other immunity proteins in S. mutans to offer cross protection 
when the cognate immunity protein for a specific mutacin is absent. However, when we tested 
two putative immunity proteins (SMU.1909 and SMU.925) in S. gordonii, including the one 
(SMU.925) that confers protection against mutacin V (237), we did not observe any protection. 
Although this does not rule out that these two proteins cannot function as an immunity protein in 
the native host and may require a cellular component as suggested for LcnG, the lactococcal G 
immunity protein (223). Moreover, genome analysis indicates that S. mutans encodes several 
other proteins with similar structural features and sizes, and some of these proteins could 
function as immunity protein. Furthermore, this possibility has been corroborated by the findings 
that S. mutans OMZ175, which does not carry the nlmAB operon, is insensitive to mutacin IV 
(data not shown). Moreover, deletion of SMU.1909 in a nlmAB deficient strain (127), and 
OMZ175 (which lacks nlmAB locus) do not show sensitivity against mutacin IV (data not 
shown). Our data also suggest that SMU.152 may interact with other putative immunity proteins 
to confer full protection in the native host since deletion of multiple putative immunity proteins 
leads to sensitivity. 
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Our data strongly indicate that SMU.152 is sufficient to provide immunity to sensitive 
strains. We also showed that the C-terminal seven charged residues are important for the 
immunity activity. Theoretical structure prediction suggested that SMU.152 contains four helical 
domains and the last ten residues are highly disorganized. Deletion of last seven amino acids 
completely abolished the immunity function of this protein. Thus, these charged amino acids are 
important for the activity. We speculate that this region of the protein directly interacts with the 
mutacin peptides and therefore provides specificity. A recent study on lactococcal G suggests 
that the N-terminal 13 residues of one peptide (Lcnα) and 11 residues at the C terminal half of 
the other peptide (Lcnβ) are involved in the recognition by the immunity protein (223). Since 
mutacin IV is highly homologous to lactococcin G, we speculate a similar situation where the N-
terminal portion of NlmA and the C-terminal portion of NlmB will interact with SMU.152. It is 
possible that this two-peptide mutacin IV might interact with a membrane integrated protein that 
functions as the receptor and induce membrane leakage. Binding of SMU.152 to the mutacin IV-
receptor complex blocks the membrane leakage. This mechanism is similar to what has been 
demonstrated for class IIa pediocin-like bacteriocin involving Man-PTS system as the receptor 
(70). It is important to point out that we also identified Man-PTS as one of the putative receptors 
for mutacin IV activity since deletion of the Man-PTS rendered the S. gordonii strain less 
sensitive to mutacin IV. Since we did not observe complete protection against mutacin IV when 
Man-PTS was deleted, it indicates that there may be other cell surface proteins in S. gordonii that 
function as mutacin IV receptor. 
Spontaneous resistance can occur for some class-II bacteriocins when the sensitive cells 
are continuously exposed to bacteriocins. The frequency of such occurrence depends on the type 
of bacteriocins as well as the type of the sensitive cell. Listeria monocytogenes can achieve 
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resistance frequency as high as 10
- 4
 when exposed to class-IIa type bacteriocins including 
leucocin A and pediocins (99). The mechanisms of resistant generation can vary depending on 
the nature of the bacteriocin and it has been extensively studied for class-IIa type bacteriocins. In 
most cases expression of Man-PTS is down regulated in the resistant mutants (99, 148, 227, 
287). However, Man-PTS independent generation of resistance cells has also been reported in L. 
monocytogenes where changes in the cell envelop have been found to be associated with the 
resistant mutants (295, 296). So far no spontaneous resistance mutant has been isolated for 
mutacin IV and we speculate that frequency of resistant occurrence would be very low. 
  Mutacin IV produced by S. mutans can inhibit growth of all groups of streptococci except 
the mutans group of streptococci that include S. criceti, S. downei, S. ratti, and S. sobrinus (127). 
The exact mechanisms by which these mutans streptococci are immune to mutacin IV are not 
known. It is possible that the entire mutans streptococci group lacks a functional receptor for 
mutacin IV and possibly for other mutacins as well. Alternatively these mutans streptococci 
encode the immunity genes without the corresponding mutacin genes, a phenomenon known as  
immune mimicking mechanism and demonstrated to be present for sakacin and pediocin 
immunity (85, 204). Mutans streptococci may also encode transporters to pump peptides out 
from the cell envelope; thereby, conferring resistance against mutacins, as has been shown for 
some lantibiotics (9, 25).  Further investigation such as comparative genome analysis of the 
sensitive and resistant streptococci may reveal additional mechanisms of immunity against 
mutacins secreted by S. mutans. 
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CHAPTER FIVE 
REGULATION OF MUTACIN PRODUCTION 
PART-A 
Abstract 
S. mutans, a gram-positive pathogen, is primarily responsible for dental caries. Its 
outstanding ability to produce a variety of bacteriocins confers it selective advantage for 
successful colonization and thus considered as an important virulence factor. Although several 
studies have shed light on regulation of mutacin production in S. mutans, a comprehensive 
picture is necessary to unravel the entire molecular mechanisms of mutacin production. To 
search for new regulatory factors associated with mutacin IV production, we employed a random 
insertional mutagenesis by pGh9::ISS1 on the reporter strain, PnlmA-gus. We screened ~12,000 
clones for defective mutacin phenotypes (pale blue or white colonies) on media containing 
chromogenic substrate (X-gluc) and identified 22 unique genes including six previously reported 
regulators by mapping the insertion of transposon. One of these genes is SMU.518 that encodes a 
PDZ domain containing hypothetical protein with a Lon-like proteolytic motif. Gene inactivation 
coupled with complementation studies confirmed SMU.518’s role as one of the key regulators of 
mutacin production. Further studies revealed that SMU.518 works in the ComDE pathway. Our 
genetic, biochemical and mass spectrometric analyses suggested that SMU.518 is required for 
post-transport cleavage of CSP and the processed CSP is the active component to induce the 
mutacin genes expression. Moreover, by site-directed mutagenesis, we found that S-235 and K-
280 residues are essential for proteolytic function of SMU.518. We have also characterized the 
role of two more novel regulators, SMU.832 and SMU.2137, in mutacins production. We found 
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that SMU.832 (encodes a protein required for glucose side chain formation on ramnose-glucose 
polysaccharide) controls mutacins production by regulating the expression of comC, a gene 
encoding the competence stimulating peptide. We demonstrated that a conserved short 
hypothetical protein, SMU.2137, is also involved in regulation of mutacins production by 
severely down regulating the regulatory genes necessary for expression of mutacins in this 
organism. Taken together, our results suggest that the mutacin IV production is controlled at 
multiple levels by several regulatory factors of diverse cellular activities and this process is 
intricate with normal cellular homeostasis. 
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Introduction 
Streptococcus mutans, an oral pathogen, leads a biofilm lifestyle in the oral cavity and 
considered as the primary etiological agent of dental carries (177, 320). In the oral habitat which 
harbors more than 700 different species, this organism undergoes fierce competition with other 
bacteria for successful colonization to initiate biofilm formation (210, 320). This process is aided 
by the ribosomally produced small cationic peptides called mutacins (107). Ability to produce 
mutacins, biofilm formation, competence developments, to produce acid from the carbohydrate 
and to survive at low pH is considered as important virulence factors to cause tooth decay (19, 
160, 233). Most of the mutacins identified so far from S. mutans are lantibiotics and the 
production of two well characterized mutacins (mutacin I and mutacin 1140) is dependent on the 
presence of agar or agarose in culture medium (122, 247, 299). Nonlantibiotic class II 
bacteriocin, mutacin IV, was first purified from S. mutans UA140 (247), which also produces 
lantibiotic mutacin I. The genome sequence of the reference strain S.mutans UA159 does not 
encode any genetic determinant for lantibiotic mutacins (7); however, this strain carries and 
produces  nonlantibiotics, mutacin IV and mutacin V(104).  
Various studies suggest that mutacins production and competence development in S. 
mutans UA159 are coordinately regulated (153, 156, 173, 237, 299, 325). An inducer peptide 
together with  a two-component signal transduction system is required for mutacins expression 
along with the stimulation of competence development in S. mutans UA159 (103, 156, 158, 168, 
237, 299). During growth, this bacterium produces the peptide pheromone, CSP (competence 
stimulating peptide), encoded by comC and secretes through the dedicated ABC transporter 
CslAB (also called ComAB) as matured peptide (21-amino acids) while N-terminal leader 
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peptide is cleaved off by the proteolytic activity of the transporter (103, 173, 241). When the 
CSP concentration reaches a certain threshold, it is sensed by membrane sensor kinase ComD 
and gets activated by autophosphorylation and transfer the phosphate group to response 
regulator, ComE (158, 320). The activated ComE then stimulates the expression of mutacins and 
mutacins-associated genes by recognizing a set of conserved direct repeat present in the 
promoter region along with indirect activation of ~20 early competence genes (153, 168, 237, 
299). In addition to this classic view of regulation, CiaH, LiaS, ClpP, HdrRM, BrsRM and 
VicKR also influence the bacteriocin expression at different levels (28, 41, 46, 221, 269, 320). 
  However, this classical notion bears some scientific limitations which need to be 
clarified. Specifically, the origin of this notion is S. pneumoniae which does not show any 
coordinated regulation of bacteriocin production and competence development. Instead they 
contain two distinct regulon of bacteriocin production and competence development (168, 187). 
BlpABCRH regulon activates the bacteriocin production and comprises of several bacteriocin-
like peptides (Blp) with double glycine motif, a peptide pheromone named BIP (Blp inducing 
peptide and encoded by blpC), a ComAB paralogue transporter system BlpAB, a sensor histidine 
kinase BlpH and response regulator BlpR (63, 254). On the other hand, ComABCDE regulon in 
S. pneumoniae exclusively controls competence development which contain a peptide 
pheromone, CSP (an unmodified 17-residue mature peptide) (113). CSP is secreted and 
processed by an ABC transporter (ComAB), which processes the 45-residue pre-CSP right after 
GG-motif and generate mature peptide (114). ComDE is the two-component system where 
ComD senses the extracellular CSP and activates response regulator ComE by phosphotranfer. 
ComE is included to AgrA/AlgR/LytR family response regulators (213) and activated ComE 
stimulates the com genes expression for competence development (310). 
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Based on the genetic organization and sequence similarities, it has been shown that 
ComABCDE regulon of S. mutans is more similar to BlpABCRH system of S. pneumoniae (179, 
187). Interestingly, S. mutans UA159 contains two ortholog loci for BlpAB or ComAB of S. 
pneumoniae and Martin et al.(187) confirmed that S. mutans’ comAB-cslAB genes arrangement is 
highly similar to BlpAB of S. pneumoniae. Several experimental evidences also indicate that 
ComABCDE system of S. pneumoniae and S. mutans differ in several aspects. It has been shown 
that S. mutans CSP needs post-export cleavage at the C-terminal end by an unknown factor for 
efficient activation of ComDE regulon (239) and the synthetic CSP of S. mutans  works at 
comparatively much higher concentration than any other characterized CSPs to exhibit the  
maximum response (242). For instance, maximum response in S. pneumoniae and S. intermedius 
is achieved at 20 nM concentration (113, 240), whereas S. mutans requires 0.5 µM to 1.0 µM 
concentration of CSP to get optimum response (156, 242, 299, 326). In addition, it takes ~2-hr to 
get maximum transformation efficiencies in S. mutans (156), indicating that expression of comX 
is not directly regulated by ComE. In consistent with this idea, there are no ComE-binding sites 
in front of comX gene. In contrast, the expression of nlmAB (mutacin IV) is induced rapidly upon 
addition of CSP (156) and comCDE mutants cannot express mutacin genes in S. mutans UA159 
(153, 299) suggesting an exclusive requirement for ComCDE in nlmAB expression which relies 
on the presence of conserved direct repeat in the upstream of nlmAB and other mutacin related 
genes (299). In S. pneumoniae, comE mutation caused abolition of transformation phenotypes, 
which hinted that ComE is essential for ComX activation (168). Surprisingly, comC mutation  
didn’t change the transformation phenotype in S. mutans UA159 (6) and comDE mutations only 
affect the CSP mediated transformation keeping the basal level of transformation intact which 
suggest that ComCDE system up regulates transformation phenotype by indirect activation of 
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ComX (6, 172, 191). Recently, Mashburn-Warren et al. (191) showed that a novel regulatory 
system, ComR/ComS (encodes XIP/Shp61peptide pheromone), is exclusively required for comX 
gene expression and competence development. A mutation in comR/comS abolished the 
transformation phenotype and ComCDE system can’t activate comX gene in comR/comS 
background suggesting the auxiliary role of ComCDE system upstream of ComRS regulon.  
Another marked point of difference exists in regard to nature of CSPs from S. mutans and 
S. pneumoniae (9). To date, six distinct pherotypes of CSP have been identified from S. 
pneumoniae and most of the strains demonstrate competence only in the presence of their 
cognate CSP (245, 312). Variability among competence pherotypes in S. pneumoniae is based on 
the variation of hydrophobic patch in the CSP and on the sensor domain of ComD (130, 137). S. 
mutans CSP does not exhibit any variation in its hydrophobic patch and it has been shown that 
two distinct functional domains control binding to and activation of ComDE system to trigger the 
responsive genes expression (9, 284). Although comC gene locus shows little allelic variability, 
there was no correlation between the CSP genotype and transformability of these strains (9, 239). 
Moreover, various strains of S. mutans can sense and trigger the transformability upon addition 
of synthetic CSP from other strains (9). In addition, response to CSP in S. pneumoniae is a global 
phenomenon where ~100%  of the cells develop competence in the laboratory condition (48). 
Whereas only a subpopulation of S. mutans develop competence temporarily, expression of 
nlmAB genes is global (~100%) in response to CSP addition (168). Based on all of these facts, it 
was assumed that ComC is essentially involved in induction of bacteriocins production and CSP 
has the dual function as bacteriocin inducing peptide (BIP) and competence stimulating peptide 
(CSP) and clarification of the entire regulatory process was warranted (187). To clarify these 
contrasts and confusions and to get a comprehensive view of regulation of mutacins production 
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in S. mutans UA159, we carried out a transposon mediated insertional mutagenesis. In this study, 
we have found that mutacin IV production is regulated by numerous regulatory factors at 
different levels and characterized the role of a membrane-associated extracellular Lon protease in 
regulation of mutacin production in S. mutans UA159. 
Results 
Identification of the genes involved in activation of mutacin IV: To identify the genes 
that are involved in regulation of mutacins production, we carried out ISS1-mediated 
transposition mutagenesis which integrates into the chromosome of streptococci randomly (30, 
289, 328) and rarely inserts more than one place into the genome of the same cell (30, 32). 
Plasmid pGhost9:ISS1 (182, 183) was used to deliver the insertion element into the strain IBS-
D5 (PnlmA-gus), which has the blue phenotype on THY-X-gluc plate. The insertion frequency 
was less than 0.5% which is in consistent with several previous reports (30, 32, 289). We 
performed three independent screening of the master transposon library and tested ~12,000 CFU 
for white/pale blue colonies onto THY-X-gluc plate. We excluded most of the whitish colonies 
which displayed severe growth defect or small colony phenotype. We obtained ~200 tentative 
positive clones after first round of blue/white screening. These colonies were rescreened for 
mutacin production against S. gordonii DL-1, which is the indicator for mutacin IV (104, 247). 
We obtained 32 mutants after second round of screening which displayed either no or 
significantly reduced (<10 mm in diameter) level of mutacin production in compared to IBS-D5 
(16-mm in diameter). 
Mapping the position of ISS1 in the genome of IBS-D5: To map the position of 
transposon insertions, we did inverse PCR as described in methods and materials. Chromosomal 
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DNA from the selected colonies was isolated and digestion by HindIII, followed by heat 
inactivation
 
and self-ligation by T4 DNA ligase. The ligated DNA was subjected to
 
inverse PCR 
by using the primers ISS1R-out 2 and ISS1 For-4. The
 
PCR products were sequenced with
 
the 
primer ISS1-Rout-2. The flanking sequences (after the GAACC) obtained from
 
sequencing 
analysis were mapped on the genome of S. mutans UA159
 
by a BLAST search. We were able to 
determine the location of insertion explicitly for all 32 mutants, which contain 22 unique genes 
(Table-11). Among them, we found double insertion for only three mutants. The position of 
insertion was further confirmed by PCR using the gene-specific primers. We observed consistent 
results upon deferred antagonism bacteriocin assay for most of the cured mutants, except 
SMU.121, which displayed variable phenotypes. Some of the mutants were already known for 
their role in regulation of mutacin IV (comC, comD, comE, nlmT, nlmE, ciaH) along with other 
unknown factors. We have classified all of them based on the mutacin production against the 
indicator bacteria. Class I includes the mutants that displayed white colony morphology and no 
mutacin production. Among them five were already documented for their proven role in mutacin 
production. A two-component signal transduction system (ComC, ComD and ComE) and a 
dedicated ABC transporter (NlmTE) were in class I along with a Lon-like domain containing 
conserved hypothetical protein, SMU. 518.  Class II produced very little mutacin (< 6-mm zone 
of lysis) and includes one sensor kinase (ciaH), one gene involved in glucose side chain 
formation on ramnose-glucose backbone (SMU.832), two conserved hypothetical proteins 
(SMU.2137 and SMU.1634), and five other genes involved in energy metabolism and central 
cellular processes. Class III produced intermediate level of mutacin and includes six genes of 
diverse functions. Only one gene (SMU.121) has been categorized as class IV, which displayed 
variable properties in initial mutacin assay. This gene got seven insertions at the same place in all 
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three independent screening and designated as MATE efflux family/damage inducible protein/ 
cation efflux pump (DinF). To further understand the role of some unknown factors, we made 
deletion construct of SMU.121, SMU.611, SMU.518, SMU.832 and SMU.2137. Two of the 
deletion constructs (ΔSMU.611 and ΔSMU.121) did not produce any phenotype, whereas other 
three mutations affected mutacin production significantly and were used for further 
investigations. Among them, SMU.518 encodes a conserved hypothetical protein with lon-like 
proteolytic domain, SMU.832 encodes a membrane protein involved in glucose side-chain 
formation on S. mutans rhamnose-glucose polysaccharide (RGP) (231) and SMU.2137 encodes 
small cytoplasmic protein of unknown function. 
Characterization of SMU.518 locus: SMU.518 encodes a 346-residue long polypeptide 
which is highly conserved among gram-positive bacteria and mycobacterium (Fig. 20B). It 
contains an N-terminal uncleavable signal sequence for secretion with a transmembrane domain 
(from residue 10-26) (http://www.oralgen.lanl.gov/oralgen/bacteria/smut), a eukaryotic type 
PDZ domain (from residue 131-195) and a C-terminal Lon-like protease (S16) domain (from 
residue 233-314) (http://www.kegg.jp/ssdb-bin/ssdb_motif?kid=smu:SMU_518).  C-termini also 
contain a domain of Birnavirus VP4 protein (residue 221-287), which overlaps with the Lon-like 
domain. However, this protein does not contain any canonical ATP binding motifs (walker A or 
B). SMU.518 appears to be organized in a single operon with SMU.516 and a gene encoding 
phosphopantetheine adenylyltransferase (kdtB) and involved in biosynthesis of 
lipopolysaccharide) with a common promoter (Fig. 20A). 3’ region of kdtB gene has 23-base pair 
overlapping with the 5’region of SMU.518. The ISS1insertions occurred in SMU.518 gene at 
position 116 and 229-amino acid. There is no promoter region just before SMU.518. In silico  
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Table-11: Genes involved in regulation of mutacin IV (NlmAB) production  
Class Gene ID Function/Definition in oralgen database 
Class I (No mutacin production) 
1 SMU.1915 (3) Competence stimulating peptide (CSP) precursor 
2 SMU.1916 (2) Histidine kinase (ComD) 
3 SMU.1917 (2) Response regulator (ComE) 
4 SMU.286   (2) Competence factor transporting ATP-binding/ protein (NlmT) 
5 SMU.287   (1) ABC transport protein ComB, accessory factor for ComA (NlmE) 
6 SMU.518   (2) Conserved hypothetical protein 
Class II (6-mm or less mutacin production) 
7 SMU.1128 (1) Two-component sensor histidine kinase (CiaH) 
8 SMU.832   (1) Hypothetical protein 
9 SMU.2137 (1) Conserved hypothetical protein 
10 SMU.611   (1) ATP-dependent RNA helicase/DEAD family* 
11 SMU.1634 (1) Conserved hypothetical protein, MutT/nudix family* 
12 SMU.421   (1) Translation initiation factor IF-2 
13. SMU.1086 (1) Thymidine kinase 
14 SMU.26     (1) Fatty acid/phospholipids synthesis protein; fatty acid metabolism (PlsX)* 
15 SMU.29     (1) Phosphoribosylaminoimidazole-succinocarboxamide synthase; Purine 
metabolism (PurC)* 
Class III (8-mm to 10-mm mutacin production) 
16 SMU.241   (1) Transport and binding proteins; amino acid ABC transporter, ATP-binding 
protein 
17 SMU.1235 (1) Thiophene and furan oxidation protein; tRNA modification GTPase; Protein 
synthesis; tRNA and rRNA base modification(ThdF) 
18 SMU.502   (1) Conserved hypothetical protein* 
19 SMU.1174 (1) ATP-dependent DNA helicase* (PcrA) 
20 SMU.475   (1) Conserved hypothetical protein 
21 SMU.1914 (1) Bacteriocin (NlmC) 
Class IV (various level of mutacin production) 
22 SMU.121   (7) MATE efflux family, damage inducible protein, cation efflux pump (DinF) 
  
*indicate the double insertions in the genome of a single mutant 
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analysis of the intergenic region present upstream of SMU.516 by BPROM software (Softberry, 
http:// Linux1.softberry.com) indicates that this region contains a strong promoter sequence (-10 
box [AGTTATAAT] at position 90 and -35 box [TTGTTA] at position 72). This suggests that 
SMU.518 is co-transcribed with the SMU.516 and kdtB. Analysis of the downstream IGS region 
of SMU.518 by TransTermHP (http:// transterm. cbcb.umd.edu) program (146) suggests a rho-
independent terminator sequence (GTTCTAGAATTTCTAGGAC) just after the stop codon of 
SMU.518.  
SMU.518 is involved in mutacin production: To verify that the observed phenotype of 
SMU.518 ISS1insertion mutation was not due to additional spontaneous mutations elsewhere in 
the genome, we constructed a marker-less clean deletion of SMU.518 gene in strain UA159 
using a Cre-loxP based system as described in materials and methods. SMU.518 deletion mutant, 
IBS-D29, did not show any significant growth difference (data not shown) in compared to wild 
type UA159. We then tested its ability for mutacin production by deferred antagonism 
bacteriocin assay as described in methods and materials. As shown in Fig. 21A, deletion of 
SMU.518 abolished the mutacin activity of both mutacin IV and V. To further confirm that this 
effect was due to deletion of SMU.518 only, we performed complementation analysis. We 
cloned DNA fragment containing SMU.518 with ribosome binding site into the E. 
coli/streptococci shuttle vector pIB184Km (127) to generate pIB-D52 and introduced it into IBS-
D29. As shown in Fig. 21B, plasmid mediated SMU.518 completely rescued the mutant 
phenotypes for both NlmAB and NlmC. Taken together, our results suggest that SMU.518 is 
involved in mutacins production in S. mutans UA159. 
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Fig. 20. (A) Genetic organization of SMU.518. Gene map along with the putative promoter (bent 
arrow) and terminator (purple bar with a circle on top) is shown. Open reading frames and 
orientation of the transcriptions are indicated with block arrows. Red vertical arrows indicate the 
position of ISS1 insertion. SP indicates the signal peptide. Shaded box represents the respective 
domain in SMU.518 as mentioned. (B) Multiple sequence alignment of SMU.518 and its 
orthologous genes from different bacteria by PRALINE multiple sequence alignments tool. 
Orthologous genes were SPY.1536 (S. pyogenes), BC.3926 (Bacillus cereus), BSU.15050 
(Bacillus subtilis) and MSMEG.1958 (Mycobacterium smegmatis). Red color indicates fully 
conserved residue (score 10) and blue color indicates least conserved residue (score 0).  
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Fig. 21. Mutacin IV and V production by SMU.518 mutant. (A) Ability to produce mutacin IV 
and V by SMU.518 deletion strain. (B) Complementation analysis of the ΔSMU.518 strain (IBS-
D29) with plasmid-derived expression of SMU.518. S. mutans cultures were stabbed into THY 
agar and incubated overnight at 37°C under microaerophilic conditions. The plates were overlaid 
with soft agar containing S. gordonii DL-1 (NlmAB) or Lactococcus lactis MG1363 (NlmC) as 
indicator strain. The zones of inhibition of the indicator strains were evaluated after overnight 
incubation. UA159, deletion strain and indicator bacteria also contain the plasmid, pIB184-Km. 
A representative antagonism assay from at least three independent experiments is shown.  
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SMU.518 regulates several putative bacteriocin genes at transcriptional level: To 
understand the exact molecular basis of defective mutacin phenotype in ΔSMU.518, we tested 
the expression of two well-known mutacins, mutacin IV (encoded by nlmA and nlmB genes) and 
V (nlmC) by sqRT-PCR. As shown in Fig. 22A, deletion of SMU.518 caused the reduction of 
nlmA expression below the detection level and the nlmC expression was reduced around 15-fold 
in compare to wild type UA159. To get better understanding of the regulation of mutacin 
production by SMU.518, we also tested two other mutacins encoding genes (SMU.423 and 
SMU.1906) expression. Surprisingly, we found that both of them were remarkably down 
regulated in mutant strain (Fig. 22A). However, plasmid mediated complementation of SMU.518 
could fully restore the expression pattern as like wild type strain. Taken together, our semi-
quantitative RT-PCR results suggest that SMU.518 works at the transcriptional level and the 
presence of SMU.518 can activate the transcription of mutacin-encoding genes in S. mutans 
UA159.  
Transcription of comC was unaffected in SMU.518 mutant: It is interesting to note 
that all of these four mutacins encoding genes carry the highly conserved consensus binding 
sequences for AlgR/AgrA/LytR family transcriptional regulator in their promoter region (Fig. 
22C)(196, 299). This conserved region contains 9-bp direct repeats separated by a 12-bp spacer 
(153, 299). Several previous studies have demonstrated that all of these four genes were CSP-
inducible and controlled by the ComDE two-component signal transduction system (158, 168, 
237, 299, 320). The ComCDE system is an intraspecies quorum sensing system which is also 
involved in competence development. Moreover, comCDE mutation displayed defective mutacin 
production in both genotypic and phenotypic level (156, 299). In addition, our initial insertion 
mutagenesis studies also revealed that SMU.518 mutant produces the same phenotype as like 
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comCDE mutants. All of these facts impelled us to hypothesize that the observed phenotypes 
were due to defect in CSP expression. To test whether the CSP expression was affected by the 
mutation of SMU.518, we did semi-quantitative RT PCR of comC gene and its putative 
transporter, nlmT. As shown in Fig. 22B, there was no significant change in comC transcription 
as compared to UA159. In contrast, we observed modest reduction (2-fold) in nlmT transcription. 
We also tested the expression of comDE and didn’t find any significant difference between wild 
type and mutant strains (data not shown). Altogether, above findings suggest that the expression 
of CSP, its cognate two-component pathway and CSP-secretion apparatus were not perturbed in 
the mutant. Therefore, the observed phenotype might be due to a potential post-export role of 
SMU.518 on CSP. This notion was further supported by the finding that addition of synthetic 
CSP was not able to restore the Gus activity in reporter strain, IBS-D37 (ΔSMU.518::PnlmA-
gus) as compared to wild type (IBS-D5), which strikingly stimulated Gus activity upon addition 
of external CSP (Fig. 23A). 
Synthetic CSP cannot stimulate the competence development in SMU.518 mutant: 
Development of competence in S. mutans is known for some strains, although the frequency was 
less than other streptococci (172, 178). In S. mutans, alternative sigma factor, SigX, is absolutely 
required for the development of competence for natural transformation (191). Nonetheless, 
presence of ComCDE quorum sensing system is required for optimum transformation phenotype 
(172, 191, 284). External addition of synthetic CSP has been shown to remarkably augment the 
transformation efficiency of S. mutans (6, 9, 156, 172, 191, 221, 237, 239, 284). Synthetic CSP 
can up regulate the sigX (shp61) expression up to 15-fold which might be the reason for 
enhanced transformation phenotype (168). To prove the potential post-export role of SMU.518 
on CSP, we carried out the transformation assay in presence or absence of synthetic CSP. To our  
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Fig. 22. Semi-quantitative RT PCR analysis of mutacins and related genes. (A) sqRT-PCR of 
nlmA, nlmC, SMU.423 and SMU.1906. (B) sqRT-PCR of comC and nlmT. Total RNA was 
harvested from the indicated strains and subjected to cDNA synthesis. Five nanograms of cDNA 
from each strain were used for semi-quantitative RT PCR. The gyrA gene was included to ensure 
that equal amounts of RNA were used for all reactions. The data are representative of RT-PCR 
analyses resulting from at least two different RNA isolations. (C) Sequence conservation of 
upstream regions from four bacteriocins encoding genes. General consensus binding sites for 
AlgR/AgrA/LytR family are shown as capital letters and highlighted with underlines (299). 
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nlmA ACCGTTTAAgacaaaatagctACCATTTAG
nlmC ACCGTTTAGgacaaaatagctACCATTTAG
SMU.423          ACCGTTTAGgacaaaatagctACCGTTTAG
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surprise, we found significantly reduced level of transformation phenotypes in repeated 
experiments in mutant background as compared to UA159 and complemented strain (Fig. 23B). 
Nevertheless, mutant bacteria were transformable without external CSP, although the efficiency 
was lower than the wild type. As shown in Fig. 23B, exposure to exogenous CSP was inept to up 
regulate the transformability in ΔSMU.518. This basal level of transformation phenotype is the 
hall mark of ComCDE mutation (6, 172, 191, 221, 237). As expected, we observed ~100-fold 
increased transformability in wild type and SMU.518 complemented strain upon addition of 
synthetic CSP. This study further substantiated the idea that post-export association of CSP and 
SMU.518 occurs outside the cell and SMU.518 works on ComCDE pathway. 
Synthetic CSP undergoes proteolytic maturation by SMU.518: Because of the lack of 
CSP-responsive nlmAB induction and development of competence, due to its predicted Lon 
protease domain with extracellular localization (membrane-associated), it is reasonable to 
hypothesize that SMU.518 is involved in post-export maturation of CSP and synthetic CSP (21-
residue) cannot function in absence of SMU.518. This idea is further supported by the fact that 
CSP is present as 18-residue form in culture supernatant and 18-residue was shown to be more 
potential than 21-residue form (239). Moreover, its orthologous gene in group A streptococcus 
(GAS) is involved in binding to human extracellular matrix and antibody to it was protective in 
mice (91), which further confirm its predicted surface localization. To investigate whether 
SMU.518 can process synthetic CSP outside the cell and make it more potential, we first 
separated the cells from culture supernatants and incubated 21-residue CSP with the cell pellet of 
UA159, ΔSMU.518 and SMU.518 complemented strain as mentioned in materials and methods 
and tested the PnlmA-gus gene expression in the reporter strain, IBS-D37(ΔSMU.518:: PnlmA-
gus). Surprisingly, we found that CSP processed with UA159 and complemented strain could 
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Fig. 23. Effect of synthetic CSP on expression of PnlmA-gus and transformation efficiency. (A) 
PnlmA-gus expression from the reporter strains, IBS-D5 (PnlmA-gus insertion in SMU.1405 
locus) and IBS-D37 (ΔSMU.518:: PnlmA-gus). Strains were grown in THY broth at 37
0
C and 
harvested at 0.9 OD of 595 nm. When needed, CSPs (200 nM) was added to the actively growing 
culture (0.2 OD at 595 nm). The values were normalized with Gus activity obtained from IBS-
D44 (gusA gene without any promoter inserted in SMU.1405). Experiments were repeated at 
least three times and the mean values are shown. (B) Linear DNA (SMU.198::Em
r
) was 
transformed into indicated strains after grown up to 0.15 OD at 595 nm and in THY medium 
with 10% horse serum. CSP was added 10-minutes prior to addition of DNA when needed. 2-hr 
after incubation at 37
0 
C, bacterial strains were plated onto THY agar plates with respective 
antibiotics. Antibiotic resistant colonies were counted after 3-days of incubation. Total counts 
were measured by plating onto THY agar plate without antibiotic. Transformation efficiency was 
measured as log transformants/10
9
 cfu/µg of DNA. The data shown are means ± standard 
deviations (error bars) of at least three independent experiments. 
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turn on Gus phenotype prominently on THY-X-gluc plate at much lower concentration than the 
CSP treated with ΔSMU.518 cells, where Gus phenotype was turned on to a limited extent only 
with undiluted CSP (Fig. 24A). On the other hand, control CSP (incubation with PBS) could 
produce very little phenotype on THY-X-gluc plate. In addition, we performed quantitative Gus 
assay with the CSPs treated with different strains. In consistent with our qualitative Gus assay, 
we also found that CSP processed with UA159 or SMU.518 complemented strain could turn on 
gus gene expression efficiently at lower concentration (50 nM) in compared to CSP treated with 
the mutant or PBS (Fig. 24C).  This study confirmed that Lon protease of SMU.518 is 
responsible for processing of synthetic CSP and the processed CSP is more potential in gus gene 
expression in compare to intact CSP. The increased activity of ΔSMU.518-treated CSP in 
compared to untreated CSP or the very little activity of untreated CSP can be attributed to the 
non-specific proteolytic activities of other proteases present on the surface of S. mutans cells as 
like processing of CSF (competence and sporulating factors) in Bacillus subtilis where different 
surface proteases impart in generation of pentapeptide competence and sporulating factor, CSF 
(163). Indeed, another surface localized serine protease (HtrA) of S. mutans UA159 has been 
reported to be involved in regulation of competence development (5). 
SMU.518 is localized outside the membrane and contains a Lon-like serine protease: 
Lon is a member of AAA+ (ATPases associated with a variety of cellular activities) super family 
enzymes which is involved in protein quality control system in all domains of life (bacteria, 
archaea and eukaryotes), thereby maintaining cellular homeostasis (77, 92, 264). They can 
degrade specific short lived regulatory proteins and defective or abnormal proteins inside the 
cells (33). All Lon proteases contain a serine-lysine dyad in their active site (33, 264, 300). Lon 
proteases from E. coli and Bacillus subtilis have been characterized (47, 255, 283). Whereas 
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most of the Lon proteases function in the cytosol, Lon protease of Bacillus subtilis found to be 
expressed in the forespore compartment (274). Archaeal Lon protease shown to be membrane 
bound and has ATP-independent activity toward unfolded proteins and ATP-dependent activity 
toward folded proteins (92). Predicted structure of SMU.518 suggests that it has signal peptide at 
the N-terminal region along with a transmembrane region and a C-terminal Lon protease domain 
without any canonical ATP binding motif. As the Lon proteases contain a serine residue in its 
active site and because of its predicted surface localization, treatment with serine protease 
inhibitor or proteinase K should inhibit the SMU.518 mediated CSP cleavage and we should not 
detect the Gus phenotypes on X-gluc plate with the reporter strain, IBS-D37. To test this 
hypothesis, we first treated the cells (UA159) with serine protease inhibitor, AEBSF[4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride] (230) or proteinase K and separated the 
culture pellet from the supernatant and washed twice to remove residual AEBSF and proteinase 
K, followed by incubation with synthetic CSP without any external ATP. In consistent with our 
hypothesis, we found that AEBSF or proteinase K treatment were able to completely abolish the 
SMU.518-mediated CSP cleavage (Fig. 24B) and as a result, we did not see any Gus phenotype 
on X-gluc plate with reporter strain, IBS-D37.  In contrast, control CSP (treated with only 
UA159 cell pellet) exhibited expected Gus phenotype on X-gluc plate with reporter strain, IBS-
D37. Interestingly, very little Gus activity associated with only CSP as shown in earlier 
experiment (Fig. 24A) was also absent with the treatment of AEBSF or proteinase K, which 
indicates that residual Gus activity associated with ΔSMU.518 was indeed the result of very 
limited CSP processing by a non-specific serine protease other than SMU.518. This study also 
confirmed the surface localization of SMU.518 as none of the AEBSF or proteinase K is 
permissible to cell membrane. Altogether, these studies suggest that SMU.518 is an ATP- 
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Fig. 24. Expression of PnlmAB-gusA from the reporter strain, IBS-D37 (ΔSMU.518::PnlmA-gus) 
with processed CSPs. (A) Indicated bacteria were grown overnight and pelleted. After washing 
with PBS, CSP was added at a concentration of 120 µM and incubated at 37
0
C for an hour. Cells 
were separated from the supernatant containing the CSP and the processing of CSP was checked 
by spotting at different concentration onto X-gluc plate seeded with the reporter strain IBS-D37. 
(B) Effect of AEBSF on CSP processing. (C) Gus assay was carried out as described in Fig. 23A, 
except the addition of processed CSPs at a concentration of 50 nM. The data shown are means ± 
standard deviations (error bars) of at least three independent experiments. AEBSF is a specific 
serine protease inhibitor. PK, proteinase K. 
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independent Lon protease which contains a serine residue in the active site and localized on the 
surface of S. mutans. 
SMU.518-mediated cleavage removes three C-terminal residues of 21-residue CSP: 
It was previously proposed that three C-terminal residue must be cleaved to generate the 
functional CSP and induce the competence development in S. mutans (239). Our reporter assay 
also suggested that CSP is processed by SMU.518. To further confirm that SMU.518 cleaves the 
CSP and produces functional or more potential CSP, we did mass spectrometry to identify the 
functional form of CSP. Three samples were prepared to verify the post-export cleavage of CSP 
by SMU.518, such as (1) 21-residue CSP plus PBS as control; (2) 21-residue CSP plus UA159 
cells; (3) 21-residue CSP plus ΔSMU.518 cells. After incubation for 1-hr and separating the cell 
pellets by repeating centrifugation, the samples were subjected to MALDI-TOF ESI mass 
spectrometry as described in methods and materials. 
As shown in Fig. 25, only 21-residue CSP was identified with a single major peak at 
2364-Da in control CSP treatment. Sample treated with UA159 generated a single major peak at 
2066-Da which corresponds to 18-residue CSP without the three C-terminal residues along with 
several truncated versions and one major peak of 21-residue CSP. Interestingly, sample treated 
with ΔSMU.518 also produced all of the truncated versions of CSP except 18-residue CSP. Thus 
18-residue CSP is the unique cleavage product of SMU.518. Taken together, our mass 
spectrometry data suggested that 18-amino acids version of CSP is the functional form to 
activate ComDE pathway and SMU.518 is essential for maturation of CSP. Other small 
fragments might be due to non-specific cleavage of CSP by other surface proteases. In fact, S. 
mutans contains five other membrane associated or extracellular protease such as, mutP (serine 
protease), SMU.648, SMU.1438, SMU.1929 (htpX) and SMU.2163 (htrA, serine protease). We  
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Fig. 25. Mass spectrometry of processed CSP. Three samples were prepared to verify the post-
export cleavage of CSP by SMU.518, such as (A) 21-residue CSP plus PBS as control; (B) 21-
residue CSP plus UA159 cells; (C) 21-residue CSP plus ΔSMU.518 cells. After incubation for 1-
hr and separating the cell pellets by repeating centrifugation, the samples were subjected to 
MALDI-TOF ESI mass spectrometry as described in methods and materials. 
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presume that at least one of these two serine proteases can non-specifically cleaves the CSP to 
various fragments and speculate that anyone of the fragments can activate the ComDE pathway 
for PnlmAB gene expression slightly when reaches a certain concentration as we observed in our 
previous experiments. HtrA has been shown to be associated with competence development and 
involved in processing of extracellular proteins in S. mutans (5, 66).  
18-amino acids but not the 21-amino acids is the functional form of CSP: If 18-
residue CSP is the functional form of CSP, then plasmid mediated expression of the N-terminal 
18-residue without the three C-terminal residues should restore the mutacin phenotype in 
ΔSMU.518 Δ comC double mutations background. To demonstrate that 18-residue CSP is the 
functional form, we cloned 18- residue CSP (excluding the nucleotide sequences for last three 
amino acids) and 21-residue CSP into shuttle vector pIB184Km and introduced it into the double 
mutant, IBS-D45 (ΔSMU.518 Δ comC), which was constructed by Cre-loxP based clean 
mutation system. As expected, plasmid carrying the nucleotide sequences for first 18-amino 
acids could restore the mutacin phenotype in double mutation background (Fig. 26A). However, 
the mutant carrying the full length comC gene could not alter the mutacin phenotype of double 
mutant, IBS-D45. 
To further confirm that 18-amino acids is the functional form of CSP, we added the 
culture supernatants (40% saturation with ammonium sulfate) of IBS-D45 carrying either 18- or 
21- amino acids version of comC to the actively growing culture of reporter strain, IBS-D46 
(ΔSMU.518 ΔcomC::PnlmA-gus) and measured the Gus activity. As shown in Fig. 26B, culture 
supernatants of wild type UA159, IBS-D45 with 18-residue form of CSP and ΔSMU.518:: 
SMU.518 showed the similar Gus phenotype. However, IBS-D45 with 21-residue form of CSP 
could not restore the mutant Gus phenotype. We used three different controls such as culture  
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Fig. 26. Mutacin production by 18-amino acids CSP. (A) NlmAB activity of 18-amino acids 
comC was tested as like Fig. 21. 18-CSP and 21-CSP versions of comC were cloned into the 
vector, pIB184Km and transformed into the double mutation background (IBS-D45). Each 
experiment was performed at least three times and a representative plate is shown. (B) Gus assay 
was performed as mentioned in Fig. 23A, except the addition of CSP, culture supernatants (40% 
ammonium sulfate precipitation) was added to the actively growing culture of IBS-D46 
(ΔSMU.518 ΔcomC::PnlmA-gus). The data shown are means ± standard deviations (error bars) 
of at least three independent experiments. 
 
 
 
 
 
 
 
155 
 
 
 
 
                       
IBS-D45
(pIB184Km)
UA159
(pIB184Km)
IBS-D45:: 
pcomC (18-aa) 
IBS-D45:: 
pcomC (21-aa) 
A
 
 
 
 
 
 
 
156 
 
 
 
 
R
el
at
iv
e 
G
u
s 
ac
ti
v
it
y
 (
M
il
le
r 
U
n
it
)
0
50
100
150
200
250
B
Culture supernatants (40% saturation)
 
 
 
 
 
157 
 
supernatants from ΔnlmTE, ΔcomC and ΔSMU.518 along with the mock (PBS) control for better 
representation of the reporter assay. Taken together, our data suggest that 21-amino acids CSP is 
non-functional and cleavage of three C-terminal residues is required to generate functional CSP. 
S-235 and K-280 form the catalytic dyad of S. mutans Lon protease: SMU.518 and its 
orthologous genes are widely present among bacteria. Multiple sequence alignment suggests that 
they are highly conserved among the species from streptococci to mycobacterium (Fig. 20). A 
typical Lon protease contains an N-terminal substrate recognition domain, an ATPase domain for 
substrate unfolding and translocation to the protease chamber and a protease domain at the C-
termini (77, 264). Lon proteases function as an oligomeric complex as like other AAA+ 
proteases in the cytosol of the cell (77). Archaeal Lon proteases contain a transmembrane 
domain present in between walker A- and walker B- motifs of ATPase domain which attaches 
the protein to the cytoplasmic side of the membrane (263). A non-canonical Lon protease has 
been characterized from Birnavirus which does not have any ATPase domain (26). Lon proteases 
contain Ser-Lys dyad in their catalytic center, which are separated by 40-45 amino acids and 
does not show any similarity with the classical catalytic Ser-His-Asp triad of serine proteases 
(33, 264). Lon protease of SMU.518 is unique as it does not have any ATPase domain and it is 
localized outside the membrane with an N-terminal transmembrane sequence. Moreover, its size 
(345-residue) is comparatively smaller than LonA (581-1133 residue) and LonB (621-1127 
residue) (264). Nevertheless, it contains a PDZ domain which has the ability to bind the peptides 
and lipids (72, 290) .  
To characterize the Lon catalytic sites, we performed multiple sequence alignment of Lon 
signature sequences from E. coli to SMU.518 and its orthologous genes from various gram-
positive bacteria (Fig. 27A & B). We found that Lon signature is well conserved across the 
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species. Sequence comparison revealed that S-235 and K-280 are the homologue of S-679 and 
K-722 of E.coli Lon protease. Three dimensional structure prediction by multiple threading 
alignment algorithm [I-TASSER (265)] suggests that these two residues are closely localized and 
have the potential to form hydrogen bond (Fig. 27C). To verify the function of these two residues 
as possible catalytic dyad in SMU.518, we did site-directed mutagenesis by substituting S235A 
and K280A and investigated the effect of these mutations in CSP processing and mutacin 
production. Substitution of these residues did not change the stability of protein as shown in Fig. 
27D.To elucidate the effect of these mutations, we introduced them into ΔSMU.518 mutant and 
investigated for mutacin production and CSP processing. As shown in Fig. 28A, both of the 
mutations caused the abrogation of mutacin production as compared to wild type strain. To 
understand further, we tested the processability of CSP with these mutants SMU.518. In 
accordance with our mutacin assay, we observed that S235A or K280A mutations were unable to 
process the synthetic CSP into functional form (Fig. 28B). This result underscores that S-235 and 
K-280 have key role in Lon protease domain of SMU.518. Taken all of these facts under 
consideration, we infer that S-235 and K-280 form the catalytic dyad in SMU.518. 
CSP is essential for mutacin production: Results presented above suggested that 
competence stimulating peptide (CSP) is the sole regulator for mutacins production in S. mutans 
UA159. Our initial insertional mutagenesis screening also revealed that ComCDE system is 
essential for bacteriocin production (Table-11).This finding is in agreement with a previous 
report (299), which showed that mutation of any of the components of ComCDE abolished 
bacteriocin production. To assess the involvement of comC in mutacin production, we 
constructed a marker less clean comC deletion mutant and tested it against the indicator bacteria  
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Fig. 27. Characterization of the Lon active residues in SMU.518. (A) Alignment of Lon 
signature sequences from Escherichia coli (264) and SMU.518. (B) Multiple sequence alignment 
of Lon domains of SMU.518 and its orthologous genes from different bacteria by PRALINE 
multiple sequence alignments tool. Orthologous genes were SPY.1536 (S. pyogenes), BC.3926 
(Bacillus cereus), and BSU.15050 (Bacillus subtilis) and MSMEG.1958 (Mycobacterium 
smegmatis). Red color indicates fully conserved residue (score 10) and blue color indicates least 
conserved residue (score 0). Red star indicates the possible catalytic serine and lysine required 
for Lon protease activity. (C) Predicted three-dimensional structure of SMU.518 as determined 
by I-TASSER. (D) Western blotting of whole cell lysates to detect the stability of SMU.518 
mutants (S235A and K280A). Protein lysates were separated by 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting was carried out using anti-
HA monoclonal antibody as the primary antibody and horseradish peroxidase-conjugated anti-
mouse secondary antibody. For each sample, loading volume was equal to 150 µg of whole cell 
lysate for HA-tagged SMU.518 detection and 30 µg of whole cell lysate for enolase detection. 
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Fig. 28. Mutacins production by S235A and K280A mutants. (A) NlmAB and NlmC activity of 
the indicated mutants. Deferred antagonism bacteriocins assay was done as like Fig. 21. Each 
experiment was performed at least three times and a representative plate is shown. (B) Gus assay 
was performed as mentioned in Fig. 23A. CSP, treated with different mutants, was added to the 
actively growing culture of IBS-D37. The data shown are means ± standard deviations (error 
bars) of at least three independent experiments. 
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for mutacin IV and V. In consistent with the previous findings, we did not see any mutacins 
activity in mutant background (Fig. 29A). In addition, plasmid mediated expression of comC 
could restore the mutacins phenotype for both mutacin IV and V (Fig. 29B). Furthermore, 
external addition of synthetic CSP could restore the Gus phenotype of the reporter strain 
ΔcomC:: PnlmA-gus (Fig. 29C). Together with the previous reports, our present results suggest 
that CSP is essential for induction of mutacin genes expression in S. mutans UA159. 
NlmTE (ComAB) is the transporter of CSP: Based on the sequence homology and 
transformation phenotype, it was previously proposed that CslAB (encoded by SMU.1897 to 
SMU.1900) functions as competence related secretion (241) and transporter of CSP in S. mutans 
(103). However, ‘com’ system of S. mutans is strikingly similar to ‘blp’ system of S. pneumoniae 
(187). Co-ordinated expression of mutacin production and competence development has been 
demonstrated in S. mutans UA159 (156) and comC mutation had little or no influence on 
transformation phenotype (5, 172, 221), but diminished the mutacin production (299).Thus, 
regulation of bacteriocin was proposed to be the primary function of CSP (187).  
Since CSP (encoded by comC) is essential for mutacins production in S. mutans UA159, 
then mutation of any of the related genes such as, transporter of CSP and the cognate two-
component system (ComDE) should also abrogate mutacin production in this organism. To 
clarify this, we constructed nlmTE and cslAB deletion mutants and carried out mutacin assay 
against the indicator bacteria. In accordance with our hypothesis, we found that deletion of 
nlmTE caused the complete abrogation of NlmAB production; however, there was no discernible 
change in mutacin production in case of cslAB mutation (Fig. 30A). Our result is in agreement 
with two previous results where deletion of nlmTE blocked mutacin production in S. mutans 
UA159 (103, 237, 299), but cslAB mutation did not produce any mutacin phenotype (103). 
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Fig. 29. Mutacin production by comC mutant. (A) NlmAB activity of comC deletion strain. 
Experiment was done as like Fig. 21. (B) NlmAB activity of the complemented strain. Each 
experiment was performed at least three times and a representative plate is shown. (C) Gus assay 
was performed as mentioned in Fig. 23A, except the reporter strain, IBS-D40 (ΔSMU.1915:: 
PnlmA-gus). The data shown are means ± standard deviations (error bars) of at least three 
independent experiments. 
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Since addition of external CSP can stimulate the mutacin genes expression  (Fig. 23A)  
(156, 168, 237, 299); because a mutation in CSP-transporter should not permit the endogenous 
CSP to secrete into the culture supernatant, then addition of culture supernatant from CSP-
transporter mutation should not induce the gus gene expression in the reporter strains, IBS-
D37(ΔSMU.518::PnlmA-gus), and ΔcomC:: PnlmA-gus (IBS-D40). To further confirm that 
NlmTE, not the CslAB, is the transporter of CSP in S. mutans UA159, we precipitated the 
culture supernatants of both nlmTE and cslAB mutants by 40% ammonium sulfate fractionation 
and added them into the actively growing culture of reporter strains, IBS-D37, and IBS-D40. 
After incubation for several hours, we have harvested the cells and performed Gus assay. We 
also included culture supernatants of UA159 as positive control and ΔcomC, ΔSMU.518 strains 
as negative control in this reporter assay. As shown in Fig. 30B, addition of culture supernatant 
of ΔnlmTE mutant could not stimulate the Gus gene expression in reporter strain, whereas 
culture supernatant from cslAB mutation could completely restore the Gus phenotype as like 
UA159. To further validate this result that NlmTE is the transporter of CSP, we constructed 
another reporter strain named, IBS-D41 where PnlmA-gus gene was transformed into ΔnlmTE 
mutant background which lacks the Gus phenotype. In consistent with above reporter assays, 
Gus phenotype was restored upon addition of culture supernatant of cslAB mutant but not from 
nlmTE mutant (Fig. 30B). This reality is further corroborated by our initial insertional 
mutagenesis where we found that insertion at either nlmT or nlmE locus produced white colonies 
on the THY-X-gluc plate and was mutacin defective. Taken together, our studies highlight that 
CSP uses the same transporter, NlmTE, as like mutacins in S. mutans UA159.  
CSP can up regulate the competency development at early logarithmic phase:  
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Fig. 30. Mutacin production by different mutants. (A) NlmAB (mutacin IV) activity of comC, 
nlmTE and cslAB deletion strains. Experiment was done as like Fig. 21 and a representative plate 
from at least three independent experiments is shown. (B) Gus assay was performed as 
mentioned in Fig. 23A, except the addition of CSP, culture supernatants from the indicated 
strains (40% ammonium sulfate precipitation) was added to the actively growing culture of three 
reporter strains, IBS-D37 (SMU.518::PnlmA-gus), IBS-D40 (ΔcomC::PnlmA-gus ) and IBS-
D41(ΔnlmTE::PnlmA-gus). The data shown are means ± standard deviations (error bars) of at 
least three independent experiments. 
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Competence development is a transient physiological state which triggers the natural genetic 
transformation by activation of a set of regulatory genes which allow the competent cells to 
uptake DNA from the environment (49, 136). Natural transformation was first identified in S. 
pneumoniae (14) and later found in S. mutans (236). Development of competence in streptococci 
occurs at particular growth stage (normally at the early to mid-logarithmic phase of growth) for a 
limited period of time, although there are marked differences prevailed among the species and 
strains (6). In S. mutans, alternative sigma factor, SigX, is absolutely required for the 
development of competence for natural transformation (191). Nonetheless, presence of ComCDE 
quorum sensing system is required for optimum transformation phenotype (172, 191, 284). 
However, external addition of CSP could not influence the transformation phenotype of 
comR/comS mutants (191). Moreover, only a subpopulation of bacterial cells develop 
competence temporarily (shuts down the competence machinery after ~3 to 4 hr of induction) in 
a given population of S. mutans cells in response to external CSP, whereas all of the bacterial 
cells activate the expression of bacteriocin-related genes (168).  
To further elucidate the role of CSP in competency development, we studied the 
transformation efficiency at different growth stages of S. mutans UA159 with or without any 
external CSP addition (Fig. 31). We found that competence development is limited to early 
logarithmic phase (OD595 from 0.1 to 0.6), which reached maximum level when we added DNA 
at OD595 of 0.2 to 0.25. S. mutans UA159 lost the competence below detection level at late 
logarithmic phase (after OD595 of 0.7) even though we add CSP or not. In sum, our results 
suggest that competence development is a transient phenomenon in early logarithmic phase of S. 
mutans and CSP can stimulate the transformation efficiency at the early logarithmic phase. 
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CSP is not essential for transformation but can augment its activity: Competence 
stimulating peptide (CSP) has been shown to remarkably enhance the transformation efficiency 
of S. mutans when added externally (6, 9, 156, 172, 191, 221, 237, 239, 284). However, comC 
mutation had little or no influence on transformation phenotype (5, 172, 221). Since our studies 
suggested that NlmTE is the transporter of CSP, then deletion of nlmTE should provide similar 
transformation phenotype as like comC mutation. To prove this hypothesis, we did 
transformation assay with comC and nlmTE mutants. In addition, we used a comR deletion strain 
as negative control. In accordance with our expectation, we found that comC and nlmTE mutants 
exhibited similar transformation efficiency and the level of transformation was ~2-fold less than 
the wild type strain in absence of exogenous CSP (Fig. 32). However, addition of external CSP 
rescued the transformation phenotype in both of the mutants as to the extent of wild type 
bacteria. Interestingly, transformation efficiency was further less in mutant strain of SMU.518, 
which exhibited ~6-fold reduced transformation phenotype in our assay conditions. This 
unexpected finding can be ascribed to the reduced level of NlmC in SMU.518 mutant 
background, since optimum transformability is also dependent on the availability of NlmC (76). 
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Fig. 31. Effect of CSP on transformation efficiency. Transformation efficiency was measured at 
different growth stages as mentioned in Fig. 23B. A representative of three independent 
experiments is shown. Linear DNA (SMU.198:: Em
r
) was added at different growth stages. CSP 
was added (200 nM) 10 minutes prior to addition of DNA.  Black solid and dotted lines indicate 
the competence development in the presence or absence of CSP respectively.  
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Fig. 32. Transformation efficiencies of various mutants. Transformation efficiency was 
measured as described in methods and materials. Linear DNA (SMU.198::Em
r
) was added at 
OD595 of 0.15. CSP was added (200 nM) 10 minutes prior to addition of DNA. The results 
presented here are the average of three independent transformation assays. 
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REGULATION OF MUTACINS PRODUCTION  
PART-B 
(Regulation of mutacins production by SMU.832 and SMU.2137) 
Introduction 
Cellular responses to environmental cues depend on diverse dynamic posttranslational 
modifications of their integral proteins which play vital roles in signal transduction pathway 
(311). Glycosylation of proteins, a posttranslational modification by carbohydrate moieties, has 
important function in modulating protein structure and function (123). Glycoproteins are widely 
present on cell surface and extracellular matrices of eukaryotes and are involved in cell-cell 
communication and cell-matrix recognition which are essential for numerous biological 
processes; from immune recognition to cancer development (285). However, glycoproteins are 
not limited to eukaryotes; there have been increasing evidences on protein glycosylation in 
prokaryotes, specifically among the mucosal-associated pathogens (123, 285). Two major types 
of proteins glycosylation are present among all domains of life: N-glycosylation, where the 
oligosaccharide is added to the asparagines residue of Asn-X-Ser/Thr consensus sequence 
(where X represents any amino acid except proline) and O-glycosylation, where oligosaccharide 
is attached to a serine, threonine or tyrosine residue (123). For several proteins, O-linked β-N-
acetylglucosamine (O-GlcNAc) and O-phosphate can alternatively occupy the same or adjacent 
sites which suggests the potential regulatory function of O-GlcNAc in signal transduction 
cascades (4, 311). Reciprocity between O-GlcNAc and O-phosphorylation has been documented 
by several groups (3, 51, 105) and a single serine/threonine residue can exist as three forms: 
unmodified, phosphorylated and glycosylated which indicates the possibility of controlling 
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signal transduction system other than classical phosphorylation-mediated on/off system (311). 
This dynamic process has been reported on various nuclear and cytoplasmic proteins, including 
transcription factors, translations initiation factors, cytoskeleton proteins, oncogene products and 
tumor suppressors (51, 94, 109, 311, 324).  
Presence of lipopolysaccharides (LPS) and lipooligosaccharides are hallmark of several 
bacteria. Both N-and O-linked glycosylations are present in bacteria (285, 288, 306). 
Polysaccharides are the major determinant of serological classification and identification of 
streptococci which are present in the cell wall (272). S. mutans contains rhamnose-glucose 
polysaccharides (RGP) which have backbone structure of α 1,2 and α 1,3-linked rhamnan along 
with glucose side chains and linked to alternate rhamnoses of the cell wall (323). This structural 
backbone is also present in the group-specific antigens of Lancefield group A, C and E 
streptococci (272)  Studies on surface-layers also revealed the protein glycosylation in 
prokaryotes (285) and glycosylation of surface appendages such as, flagellum and pilli have been 
reported (23, 244, 267). Several studies have demonstrated that protein glycosylation in bacteria 
have diverse roles such as, adhesion (159, 174), antigenic variation (71), protein assembly (281), 
solubility (185), protection from proteolytic cleavage (120) and protective immunity (262). 
However, regulation of gene expression by glycosylation is yet to be identified in prokaryotes. In 
this chapter, we show that SMU.832, encoding a glucosyl transferase gene, is involved in 
mutacin genes expression in S. mutans UA159. 
Gene expression in bacteria is also influenced by various small molecules beside the well 
known quorum sensing peptide, such as small non coding RNA and proteins (76). These small 
proteins or peptide mediated regulation of gene expression is relatively novel mechanism in 
bacteria and assumed to be involved in diverse physiological functions, such as cell killing, 
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modification of the DNA-binding capacity of a transcription factor, protein degradation/ 
stabilization, activation of sensor kinase and alteration of the specificity of a membrane 
transporter (76). A small protein named MgrB (47-residue) in E. coli interacts directly with the 
sensor kinase PhoQ of the PhoQ/PhoP two-component system which in turn represses multiple 
genes in the PhoQ/PhoP regulon (175). In B. subtilis, the competence-specific transcription 
factor ComK forms a ternary complex with ClpC and MecA which remains sequestered until the 
small protein ComS interacts with ClpC and free it to activate the transcription of genes essential 
for genetic competence (292). Recently, the role of a small peptide, XIP, has been reported in S. 
mutans (191) which forms a complex with ComR and activates the transcription of alternative 
sigma factor, ComX. Dufour et al. (76) also demonstrated the role of a small peptide, CipB, in 
global gene expression and competence development in S. mutans. In this chapter, we show that 
another small peptide, encoded by SMU.2137, regulates diverse physiological functions in S. 
mutans UA159. A mutation in this gene severely impaired the normal growth phenotype, 
mutacin production and competence development in this organism. 
Results 
SMU.832 is involved in mutacins production: Our initial insertional mutagenesis 
demonstrated that an insertion in SMU.832 drastically reduced the mutacin production in S. 
mutans UA159. SMU.832 (also called rgpH) encodes a protein which is involved in glucose side 
chain formation on RGP backbone (231). This gene is organized in rgp locus that regulates the 
biosynthesis of rhamnose-glucose polysaccharide (RGP) backbone in S. mutans (231, 323). To 
confirm that the observed phenotype was due to SMU.832, we made clean mutation in SMU. 
832 locus by advanced Cre-loxP based method (20).We then carried out mutacin assay against 
two different indicator strains and found that mutacin production was notably reduced as 
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compared to wild type strain (Fig. 33A). To further illuminate that SMU.832 is involved in 
reduced mutacin phenotype, we constructed a complemented plasmid which contains SMU.832 
and introduced this plasmid into ΔSMU.832. As expected, complementation could rescue the 
mutacins phenotype in deferred antagonism bacteriocin assay (Fig. 33A). Collectively, our 
results suggest that SMU.832 is required for optimum mutacin production in S. mutans UA159. 
SMU.832 controls mutacin production via transcriptional regulation of comC: 
According to oralgen database, SMU.832 is an integral membrane protein which contains a 
signal sequence followed by 12-transmembrane regions. To better understand how SMU.832 
imparts in regulation of mutacin production, we investigated the expression of nlmA, nlmC and 
comC genes by sqRT-PCR. As shown in Fig. 34 (A, B), we observed significant reduction (~2-
fold) of nlmA and nlmC genes expression in mutant background; whereas we noticed marked 
reduction in comC (~4-fold) gene expression. Plasmid mediated complementation of SMU.832 
restored the mutant phenotypes in all three genes expression. We predict that impaired comC 
expression is responsible for deficient mutacins phenotypes and comC expression is down 
regulated due to perturbation of autogenic regulation of this peptide pheromone. We hypothesize 
that SMU.832 is required for maintaining proper orientation of NlmTE, a transporter of CSP and 
mutacins. Therefore, a mutation in SMU.832 caused reduced level of CSP secretion which in 
turn down regulated mutacin genes expression by less activation of ComDE pathway. This idea 
is supported by the finding that addition of external CSP could fully restore the Gus phenotype in 
the reporter strain, IBS-D54 (ΔSMU.832:: PnlmA-gus) (data not shown). In sum, our data 
suggest that SMU.832 regulates the transcription of mutacin encoding genes by down regulating 
the expression of bacteriocin inducing peptide, CSP.  
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Fig. 33. Mutacin IV and V production by SMU.832 mutant. Mutacin assay was done as 
described in Fig. 21. A representative of at least three independent experiments is shown. 
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Fig. 34. Semi-quantitative RT PCR analysis of nlmA, nlmC and comC. (A) sqRT-PCR 
experiments were done as like Fig. 22. The data are representative of two different RT-PCR 
analyses resulting from a single RNA isolation. (B) Quantification of cDNA abundance of 
various genes. The PCR products were separated on 2.0 % agarose gel electrophoresis and 
quantified by Doc-It-LS (UVP) software. The data shown are means ± standard deviations (error 
bars) of two experiments from a single RNA isolation. 
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SMU.832 influences the competence development: As our sqRT-PCR data 
demonstrated that comC and nlmC genes were down regulated in ΔSMU.832, since comC and 
nlmC expression is required for optimum transformation phenotype (76, 191, 221), we 
anticipated that a mutation in SMU.832 should exhibit impaired transformation phenotype. In 
accordance with our proposition, we found that competence development has been impaired 
greatly in SMU.832 mutant (Fig. 35); however, addition of synthetic CSP was able to restore the 
mutant phenotype to a certain extent as compared to wild type or complemented strain. This 
impaired phenotype can be attributed to the reduced level of nlmC expression which is 
mandatory for maximum transformability in S. mutans (76). This finding further verified the role 
of SMU.832 in expression of comC and nlmC. Taken together, our results suggest that SMU.832 
is involved in regulation of comC and nlmC mediated phenotypes in S. mutans UA159. 
Characterization of SMU.2137 locus: SMU.2137 encodes a short hypothetical protein 
(90-residue long) that is located just after the dnaC and followed by SMU.2136. A short 
intergenic sequence (IGS) is present before and after the start and stop codon of SMU.2137. A 
schematic diagram of the SMU.2137 locus and the neighboring genes are shown in Fig. 36,   
Sequence analysis, confirmed using BPROM online software (prediction of bacterial promoters, 
Softberry, http://linux1.softberry.com), indicates the presence of putative -35 (TTCCAA) and -10 
(TAGTAT) box motifs 234- and 254-bp, respectively, upstream of the putative start codon with a 
putative ribosomal binding site (AGGAGA) 10-bp upstream of the start codon. A putative rho-
independent terminator sequence (GGCTTTGTAAAGCC) was also identified at position 109-bp 
downstream of SMU.2137 by TransTermHP (http://transterm.cbcb.umd.edu) program (146).  
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Fig. 35. Transformation efficiency of SMU.832 mutant. Transformation efficiency was measured 
as described in methods and materials. Linear DNA (SMU.198:: Em
r
) was added at OD595 of 
0.15. CSP was added (200nM) 10 minutes prior to addition of DNA. The results presented here 
are the average of three independent transformation assays. 
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Fig. 36. A schematic diagram of SMU.2137 locus. Putative promoter (bent arrow) and 
terminator (purple bar with a circle on top) are shown. Open reading frames and orientation of 
the transcriptions are indicated with block arrows. Red vertical arrows indicate the position of 
ISS1 insertion.  
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Thus, it appears that the SMU.2137 is a single gene individual operon. This protein is highly 
conserved among streptococci (Fig. 37) and show high level of similarity with other gram-
positive bacteria also. 
SMU.2137 is involved in mutacin production: Our initial insertional mutagenesis 
manifested that an insertion in SMU.2137 caused noticeable reduction in mutacins production 
and Gus phenotypes on X-gluc plate in compared to wild type bacteria. To illustrate that the 
observed phenotype is indeed due to SMU.2137, we deleted the SMU.2137 locus by putting a 
loxP-km
r
 cassette and examined the mutacins production against two indicator bacteria. As 
shown in Fig. 38, a mutation in SMU.2137 drastically reduced the mutacins production as 
compared to wild type bacteria. To further substantiate the role of SMU.2137 in reduced mutacin 
phenotype, we constructed a strain with a plasmid-borne copy of SMU.2137. Plasmid mediated 
expression of SMU.2137 in mutant background restored the mutacin phenotype, showing the 
loss of mutacin production in the deletion mutant was entirely due to the loss of SMU.2137 
function. Taken together, our results implied that SMU.2137 is involved in regulation of 
mutacins production in S. mutans UA159. 
SMU.2137 regulates the expression of nlmA, nlmC and comC: To investigate the 
mechanism by which SMU.2137 regulates mutacins production, we investigated the expression 
of two mutacins encoding genes, nlmA and nlmC, and the inducer peptide, comC by sqRT-PCR. 
As shown in Fig. 39, we found that the expressions of all three genes were considerably down 
regulated in mutant background. Expression of comC and nlmA were affected prominently (~5- 
and 6-fold respectively) in compared to nlmC which was reduced ~2-fold in mutant strain. 
However, plasmid mediated expression of SMU.2137 restored the expression pattern of all three  
195 
 
 
 
 
 
 
Fig. 37. Multiple sequence alignment of SMU.2137 and its orthologous genes from different 
streptococci by PRALINE multiple sequence alignments tool. Orthologous genes were selected 
from S. agalactiae (SAG.2138), S. pyogenes (SPY.2181) and S. pneumoniae (SP.2202). Red 
color indicates fully conserved residue (score 10) and blue color indicates least conserved 
residue (score 0). 
 
 
 
 
 
 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
 
 
 
 
 
 
Fig. 38. Mutacin IV and V production by SMU.2137 mutant. Mutacin assay was done as 
described in Fig. 21. A representative of at least three independent experiments is shown. 
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genes. Together with the preceding results, this study confirmed that SMU.2137 is required for 
optimum level of transcriptional activation of mutacins and mutacins-related genes in S. mutans. 
SMU.2137 mutant is defective in competence development: As we previously 
mentioned that comC and nlmC expression is related to competence development in this 
organism, since our expression studies revealed that SMU.2137 mutant is defective in expression 
of these genes, it is rationale to assume that ΔSMU.2137 strain is defective in competence 
development also. To prove this hypothesis, we investigated the mutant strain for 
transformability with linear DNA (ΔSMU.198:: Em
r
). In accordance with our hypothesis, we 
found severe impairment of competence development in mutant strain (Fig. 40). Further studies 
with plasmid DNA, pMM223 also confirmed that SMU.2137 mutant is crippled in competence 
development (data not shown). Surprisingly, reduction of transformation was remarkably less as 
compared to comC or nlmC mutant as shown in Fig. 40, indicating a unique role of SMU.2137 to 
develop competence in S. mutans UA159. 
  Deletion of SMU.2137 caused severe growth defect in S. mutans UA159:  While 
working with SMU.2137 mutated strain, we noticed a severe growth defect on agar plate as well 
as in THY-broth. To further clarify this observation, we examined the growth kinetics of UA159 
and ΔSMU.2137 in THY broth at 37
0
C. As shown in Fig. 41, the growth of ΔSMU.2137 was 
much slower than UA159. However, the defective phenotype was restored upon 
complementation with a plasmid-borne SMU.2137. Apparent defect in growth kinetics suggests 
that SMU.2137 is involved in expression of key regulatory components needed for normal 
growth phenotypes also.  
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Fig. 39. Semi-quantitative RT PCR analysis of nlmA, nlmC and comC. (A) sqRT-PCR 
experiments were done as like Fig. 22. The data are representative of two different RT-PCR 
analyses resulting from a single RNA isolation. (B) Quantification of cDNA abundance of 
various genes. The PCR products were separated on 2.0 % agarose gel electrophoresis and 
quantified by Doc-It-LS (UVP) software. The data shown are means ± standard deviations (error 
bars) of two experiments from a single RNA isolation. 
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Fig. 40. Transformation efficiency of SMU.2137 mutant. Transformation efficiency was 
measured as described in methods and material. Linear DNA (SMU.198::Em
r
) was added at 
OD595 of 0.15. CSP was added (200 nM) 10 minutes prior to addition of DNA. The results 
presented here are the average of three independent transformation assays. 
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Fig. 41. Growth kinetics of S. mutans UA159 and SMU.2137 mutant. Overnight cultures were 
diluted 1:20 into THY broth and incubated at 37
0
C. Bacterial growth was monitored with a Klett-
Summerson colorimeter (MP Biomedical) at different time intervals. The data shown are from a 
single experiment representative of three independent growth studies. 
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Discussion 
S. mutans is the primary causative agent of dental caries and leads a biofilm life-style in 
the oral cavity. Human oral cavity is regarded as the most dynamic microbial habitat in our body 
due to repeated fluxes of food and water intake, rapid change of temperature, pH, osmotic and 
oxygen tension. Successful colonization and demineralization of tooth depends on the abilities to 
adhere and form biofilm on tooth surface, production of acids from carbohydrate metabolism, to 
withstand the low pH and different environmental stresses in this fluctuating environment. Along 
with these virulence properties, S. mutans can produce antimicrobial peptides (mutacins) to 
inhibit the growth of other competing species; thereby helping in establishment of flourishing 
biofilm in the oral cavity (169). Mutacins mediated cell killing is also considered as a source of 
nutrients during nutrient limited conditions (210). S. mutans UA159, genome sequence reference 
strain, encodes two well known bacteriocins, mutacin IV and V. As almost all of the previous 
studies on regulation of mutacin IV production were focused on two-component regulatory 
system (ComCDE), our understanding on global regulatory pathways remains restricted. To get a 
comprehensive view on regulation of mutacin IV (encoded by nlmAB) production in S. mutans 
UA159, we screened a library of random insertion mutations to select clones with no/less 
mutacin phenotype on THY-X-gluc plate. In this study, we screened ~12,000 colonies in three 
independent screening and identified 22 unique loci involved in mutacin IV production. 
However, this approach also suffered some drawbacks as like other insertional mutagenesis. An 
insertion in essential genes might not have been identified due to growth retardation or weak 
phenotypes could have been overlooked. Since we only looked for white/pale blue colonies on 
X-gluc plate, since we were not able to distinguish more blue clones in compared to our wild 
type reporter strain (IBS-D5); we were not able to identify any repressors associated with 
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mutacin IV production. In addition, mutacin IV defective phenotypes might have been generated 
from polar effect on downstream genes. Among the 22 loci we identified in our preliminary 
analysis, six of them (comC, comD, comE, nlmT, nlmE and ciaH) were previously shown to be 
important for mutacin IV production in S. mutans UA159, which further validated the viability of 
our experimental approach. However, we did not identify liaS or clpP which were previously 
reported to influence mutacin production (41, 46). Our inability to identify them might be due to 
their moderate effect on nlmA gene expression and went unnoticed during primary blue/white 
selection. Based on the level of mutacin production, we have classified all of the mutant clones 
into four different groups; class I (no mutacin production), class II (<6 mm), class III 
(intermediate level; 6-10 mm) and class IV (exhibited variable properties). These loci encode 
proteins for diverse activities, such as two-component signal transduction system, ABC 
transporter, energy metabolism and central cellular processes. Five of them do not have any 
known functions and assigned as hypothetical protein in various database (Table-11). To further 
understand the role of some of these unidentified factors, we made clean deletion in SMU.518 
(class I), SMU.611, SMU.832, SMU.2137 of class II and SMU.121 of class IV. We found that a 
clean mutation in three of them (SMU.518, SMU.832 and SMU.2137) produced prominent 
phenotypes in deferred antagonism bacteriocin assay and all of them encode the hypothetical 
proteins of unknown functions. However, a mutation in SMU.121 and SMU.611 did not show 
any phenotype suggesting the presence of polar effect in initial insertional mutants. In this study, 
we have further characterized these three loci for better understanding the mechanism of mutacin 
IV production in S. mutans UA159.  
Predicted structure of SMU.518 suggests that it contains a Lon-like proteolytic domain at 
C-terminal end along with a PDZ domain in the middle and an uncleavable signal sequence at 
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the N-termini (Fig. 20). This protein is highly conserved across the gram-positive bacteria from 
streptococci to mycobacterium. Its orthologous gene, Spy.1536, in group A streptococci (GAS) 
was shown to be localized outside the cell and antibody to it was protective in mouse model (91). 
ATP dependent Lon proteases are primarily responsible for selective intracellular proteolysis, 
which regulates protein quality control and cellular homeostasis (264). Lon protease was first 
identified in E. coli and later found in every organisms investigated so far (264, 283). These 
cytosolic proteases are homooligomeric in nature and each of the subunit (784 amino acids long) 
contains an N-terminal substrate binding domain, a central ATPase domain and C-terminal 
proteolytic domain with serine-lysine dyad active center (264). In addition to removal of up to 
50% aberrant proteins in E. coli (47), this protein is also involved in cell division (by degrading 
cell division inhibitor, SulA), capsule production, plasmid stability and phage replication (47, 77, 
78). Gram-positive model bacterium, B. subtilis, encodes two lon homolog, lonA and lonB (255, 
274). It has been reported that LonA prevents σ
G
 dependent transcription during vegetative 
growth (268) and LonB found to be expressed in the forespore compartment under the control of 
σ
F 
(271, 274). Archaea contains membrane-bound LonB type protease and compensates the 
absence of ATP-dependent membrane-bound protease, FtsH (309). Whereas all of the Lon 
proteases characterized so far contain ATP binding motifs and resides in the cytosol, SMU.518 
does not possess any ATP binding motif and suggested to be surface localized in GAS. Thus, this 
protease is a unique class of Lon protease present in gram-positive bacteria.  
In this study, we show evidence that SMU.518 is localized on the surface of S. mutans 
and involved in maturation of peptide pheromone, CSP (competence stimulating peptide). It was 
previously reported that CSP undergoes post-export cleavage (loss three C-terminal residues) by 
an unknown factor and activates the two-component signal transduction system in S. mutans 
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(239). Processed CSP (18-amino acids) shown to be functionally more potent than the 21-amino 
acids peptide. Our study revealed that proteolytic domain of SMU.518 is required for specific 
ATP-independent cleavage at the C-termini to release the last three amino acids. We 
demonstrated that this cleavage is essential for generation of functional CSP. In other words, 21-
residue CSP is inactive and it must be cleaved at the C-termini to produce functional form of 
CSP (18-amino acids). We also demonstrated that a serine-lysine dyad (S235 and K280) is 
responsible for catalytic activity by this protease as like other Lon proteases. Our results 
suggested that functional form of CSP (18-residue) works at much lower concentration as like 
other peptide pheromones and consequently, answered the long standing question of the 
requirement of high concentration of CSP in S. mutans (0.5 to 1µM in S. mutans as compared to 
20 nM in S. pneumoniae) (239). Functional form of CSP (18-amino acids) is already present in 
some of the natural strains along with the C-terminally elongated form (9, 172, 239) and 
appeared to be not involved in variation in transformation phenotypes among them. One could 
simply ask about the necessity of having additional residues in the C-termini, while they are not 
required for functional activity. We are not sure why last three amino acids need to be cleaved 
off to produce functional form. Although Syvitsky et al. (284) showed that last three amino acids 
are required for optimum transformation phenotype, our study along with several other studies 
firmly negate the authenticity of their findings (9, 172, 239). We presume that these three amino 
acids provide protection against the proteolytic degradation in the dense multispecies biofilm. In 
support of this assumption, Wang et al. (308) recently showed that the CSP of S. mutans is 
degraded by the proteolytic activity of S. gordonii, thereby giving selective advantage to it in the 
natural habitat. It is also possible that these three amino acids confer protection to its own surface 
proteases to some extent, such as to HtrA. To support this hypothesis, we found several truncated 
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versions of CSP in mass spectrometry of ΔSMU.518-treated sample (Fig. 25) and this proteolytic 
activity was disappeared upon prior treatment with protease inhibitor, AEBSF. It can also be 
presumed that these three amino acids in full length CSP prevents activation domain of CSP to 
interact with ComD; therefore, it is required to make an active form of CSP to activate the 
ComDE system. We can further imagine that intact CSP (21-residue) is an essential defense 
strategy in natural biofilm condition where S. mutans can direct it against other organisms to 
induce their autolytic activity or inhibit their normal physiological process or 21-residue CSP can 
be used as bacteriocin to kill other bacteria. Recently it has been demonstrated that CSP can 
inhibit the formation of hypha in Candida albicans (134). Further study is necessary to unravel 
the exact molecular function of these three amino acids.  
Why is it required to have an extracellular protease to activate an intracellular function? 
While all other Lon proteases are localized inside the cells, why this type of Lon proteases is 
localized outside the cells? Does it require any association with other proteins? Is CSP the only 
substrate of SMU.518? It is likely that this protease is also involved in maturation of other 
peptide pheromones. Indeed, Mashburn-Warren (191) found that competence regulatory peptide 
(XIP) undergoes proteolytic maturation after secretion. We speculate that this protein is required 
for degradation of bacteriocins inducing peptide or bacteriocins directed to S. mutans by other 
competitive bacteria in the oral biofilm.  It is possible that these proteases have other functions in 
vivo. In support of this assumption, Fritzer et al. (91) recently showed that this protein is 
essential for surface proteins expression in both transcriptional and post-transcriptional level as 
well as involved in binding with extracellular matrix proteins in case of GAS. HtrA, a surface 
associated protein, has been shown to be involved in surface protein expression in S. mutans 
(31). It is likely that SMU.518 also imparts in same process. As Lon proteases degrade most of 
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the substrate non-specifically, one can also contemplate that this protease is involved in 
degradation of extracellular proteins or proteinaceous nutrients to small peptides for energy 
efficient uptake as nutrients. Further study will tell us about the range of functions executed by 
SMU.518 among different bacteria. 
Two-component signal transduction system controls diverse physiological functions upon 
induction with peptide pheromone, such as competence development, bacteriocin production, 
biofilm formation, acid tolerance and virulence expression (282). The results presented in this 
study suggest that ComCDE, a two-component system, primarily induces the expression of 
mutacins encoding genes in S. mutans UA159. A mutation in comC, comD or comE locus 
completely abolished the bacteriocin production in consistent with several previous results (299, 
308, 325). Unlike bacteriocin production, our results along with several other previous studies 
suggest that a mutation in comCDE loci still allow competence development but at a lower 
efficiency than the wild type bacteria (172, 191, 221). Recently, Mashburn-Warren et al. (191) 
demonstrated that genetic transformation in S. mutans is absolutely governed by a peptide 
pheromone called, XIP, which activates the expression of alternative sigma factor, SigX. Some 
upstream regulators such as, ComCDE, HtrA, CipB, CiaRH, HdrRM can significantly fluctuate 
the efficiency of transformation phenotypes under different growth conditions, but none of them 
are essential for sigX induction or competence development (5, 6, 221, 237, 250). Thus, the 
prevailing idea on CSP-mediated coordination of competence development and bacteriocins 
production in S. mutans is questionable. Our study revealed that nlmAB genes expression started 
at lower level during early logarithmic phase which reached maximum at late exponential phase 
and then expressed persistently up to stationary phase. In contrast, competence development was 
a transient phenomenon and limited to early logarithmic phase and diminished its activity below 
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detection level after mid-logarithmic phase. Our result is in agreement with several previous 
reports regarding these two phenotypes (156, 207, 236, 299). As our result demonstrated that 
comC expression is growth associated (started at early logarithmic phase and disappeared at 
stationary phase), one can easily speculate that CSP concentration outside the cell reaches 
maximum at late logarithmic phase and prevails during stationary phase which in turn can 
activate the ComDE pathway up to stationary phase. In consistent, we found the maximum level 
of nlmAB expression during stationary phase in sqRT-PCR and the culture supernatant of 
overnight culture was able to trigger the Gus phenotype during our reporter assay. If CSP is the 
stimulator of competence development, then we should also detect the transformation 
phenotypes during late exponential phase or stationary phase. So, it is plausible to conclude that 
CSP is exclusively required for mutacins production and its effect on competence is indirect. We 
assume that the decreased level of transformation phenotype in comCDE mutations, might be 
due to the scarcity of intracellular level of NlmC (also called CipB) which has recently been 
shown to be required for optimum level of competence development (76). We hypothesize that 
NlmC can interact with ComR for up regulation of comS and comX transcription. In low level of 
NlmC (in comCDE or SMU.518 mutations), ComR can only transcribe minimum level of XIP 
and ComX for basal level of competence development. It is also likely that intracellular NlmC 
can stabilize the ComR-XIP complex, which in turn produces increased transformation 
phenotypes by stimulating the expression of comX and its autogenic circuit. This hypothesis is in 
agreement with the microarray data of Dufour et al. (76), where they found that a mutation in 
nlmC caused several fold reduction of comR and comX transcription. In addition, CSP-stimulated 
ComE can directly bind with the promoter of shp61 (encodes XIP) and activates its transcription. 
Therefore, bacteriocin production and competence development is two distinct phenomena in S. 
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mutans as like S. pneumoniae, where ComABCDE governs the competence development and 
BlpABCRH system controls the bacteriocin production (187). Further supports came from the 
fact that competence induction is also transiently developed in S. pneumoniae during early 
logarithmic phase as like S. mutans (243). Moreover, bioinformatics data indicated that Com-
system of S. mutans is more similar to Blp-system of S. pneumoniae (187).  
Our results clearly show that S. mutans cannot be transformed to a detectable level 
beyond OD595 of 0.7 even though comC expression continued until late exponential phase and 
CSP concentrations outside the cells remained active up to stationary phase. It has also been 
reported that the expression of competence master regulator, ComX, continued up to stationary 
phase (168, 191). These facts might instigate someone to speculate that ComX undergoes some 
sorts of posttranscriptional or posttranslational modification which hinder S. mutans to continue 
competence during late exponential or stationary phase. Interestingly, CSP concentration outside 
the cell will be the highest at this stage of growth and one can speculate that increased CSP 
might have some negative feedback role on competence development by blocking ComX. We 
predict that high level of CSP will also generate high level of truncated versions and one of them 
might be imported inside to bind with ComX; thereby preventing it from functioning. In the early 
logarithmic phase, when the CSP concentration is low, low amount of truncated product is not 
sufficient enough to block ComX completely. Small peptide mediated regulation of competence 
development has already been reported in B. subtilis (292) and S. mutans (191). In B. subtilis, 
liberation of ComK (required for transcription of competence related genes) from the ternary 
complex of ComK-ClpC-MecA depends on the presence of ComS (292). In addition, a 
pentapeptide named, CSF (competence and sporulating factor), is internalized in B. subtilis and 
interacts with intracellular receptors (RapB and RapC) to inhibit their function (52, 234); which 
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in turn stimulates the activity of transcription factor ComA (required for genetic competence) 
and Spo0F (a component of phosphorelay that activates sporulation) (52, 276, 294). In S. mutans, 
XIP (product of ComS) interacts with ComR and activates the expression of competence master 
regulator, ComX.  Further study with purified peptides will elucidate the impaired competence 
development during late exponential or stationary phase of S. mutans (191). 
Loss of mutacins production by nlmTE mutant and essentiality of the CSP for mutacins 
expression suggest that the processing and exports of both bacteriocins and CSP are executed by 
the same transporter, NlmTE. In addition, the culture supernatant of ΔnlmTE was not able to 
trigger the Gus phenotype in reporter strain and external addition of CSP could restore the Gus 
phenotype in nlmTE mutation. Our results firmly nullify the earlier notion that CslAB is the 
transporter of CSP. A mutation in cslAB locus did not produce any phenotype in deferred 
antagonism bacteriocin assay and culture supernatant from cslAB mutant strain was able to 
trigger Gus gene expression in our reporter assay, which further suggests that NlmTE is the 
transporter of both mutacins and CSP. This is not surprising because N-terminal leader peptide 
of both CSP and bacteriocins contain same GG-motif and similar in size. Our results conform the 
findings of van der Ploeg (299) who previously suggested that NlmTE (also called ComAB) is 
the transporter of CSP and bacteriocins. 
Gene expression is regulated by diverse mechanisms in both prokaryotes and eukaryotes. 
Role of glycosylation in regulation of gene expression is well established in eukaryotes; 
however, glycosylation-mediated gene expression is not described in prokaryotes so far. In this 
study, we found that a gene responsible for glucose side chain formation on RGP backbone 
regulates the expression of comC, which in turn controls the expression of mutacins encoding 
genes. We speculate that a transcription factor required for comC transcription undergoes 
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glycosylation for efficient transcription of comC. It is likely that ComE undergoes reversible 
glycosylation and regulates the expression of comC and mutacins encoding genes. By 
glycosylation predicting software, we found four unique sites for glycosylation in ComE 
(NetNGlyc 1.0 Server) and we predict that anyone of these sites needs glycosylation for efficient 
transcriptional activation of its responsive genes.  It is also possible that SMU.832 down 
regulates the comC gene expression by blocking the autogenic regulation of comC gene 
expression via ComDE pathway. We also speculate that SMU.832 interacts with the NlmTE and 
helps to maintain functional conformation to secrete the CSP and mutacins. CSP dependent 
autogenic activation of comC has been recently described by Perry et al.(237). Further study will 
uncover the exact molecular mechanism by which SMU.832 regulates comC gene expression in 
S. mutans. 
Our study also demonstrated that a small peptide (encoded by SMU.2137) regulates 
mutacins expression along with diverse physiological functions. This is not completely 
unexpected, since small proteins or peptides mediated regulation of gene expression has already 
been reported to be involved in diverse physiological functions, such as cell killing, modification 
of the DNA-binding capacity of a transcription factor, protein degradation or stabilization, 
activation of sensor kinase, and alteration of the specificity of a membrane transporter (76). It is 
likely that this protein forms a functional multiprotein complex with other regulatory proteins 
and functions in transcriptional or translational level. Intracellular regulation of gene expression 
is not a discrete entity; rather complex interconnected network is required to exert various 
cellular activities. Presence or absence of a particular peptide or protein can greatly influence the 
activity of that protein complex.  
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Based on our current results and existing evidences on mutacins production, we present a 
new model for regulation of mutacins production by peptide pheromone in S. mutans (Fig. 42). 
In this model, we propose renaming of ‘com’ system as ‘bip’ where bip indicates bacteriocin 
inducing pathway. We have changed the name of ComC as BipC (bacteriocin inducing peptide 
C), ComD as BipD and ComE as BipE. According to this model, BipC is translated as pre-pro-
peptide and while passing through the dedicated ABC transporter (BipTE/NlmTE), leader 
sequence is cleaved off after GG-motif by the proteolytic activity of BipTE. Exported peptide 
again undergoes proteolytic cleavage at the C-termini by a Lon-like protease, BipP. This matured 
peptide, BipC, is now sensed by the sensor kinase, BipD, which upon phosphorylation activates 
the response regulator, BipE. BipE induces the transcription of bacteriocins encoding genes 
expression by binding the direct repeats present in the promoter region of responsive genes. Pre-
bacteriocins secrete through the same ABC transporter, BipTE/ NlmTE, and become matured 
upon cleavage after GG-motif and inhibit the sensitive bacteria. However, producer strain has 
specific immunity protein for self-protection. BipC can enhance the transformation phenotype 
indirectly by NlmC, which may interact with ComR, to up regulate the expression of comR, 
comS (xip) and comX, thereby increasing the transformation phenotype.  
In summary, our results revealed that mutacins production in S. mutans is under 
multifaceted regulatory mechanisms involving multiple genes of diverse functions, which 
indicate an intimate link between mutacins production and the normal cellular homeostasis. In 
addition, regulation of gene expression by reversible glycosylation and multiprotein complex 
might play an important role in diverse physiological functions in prokaryotic organisms.  
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Fig. 42. Model of the regulation of mutacins production in S. mutans UA159. Bacteriocin 
inducing peptide, BipC, is translated as pre-pro-Bip and secreted through the ABC transporter, 
BipTE/NlmTE as pro-Bip. A cell surface Lon-like protease, BipP (SMU.518), cleaves the C-
terminal three amino acids of pro-Bip and produces functional peptide pheromone, BipC (18-
amino acids). When it reaches a certain threshold concentration, BipC activates the two-
component signal transduction pathway, BipDE. Activated response regulator, BipE, stimulates 
the expression of mutacins encoding genes (such as nlmAB or nlmC) by binding to the direct 
repeats present in the upstream promoter region. Mutacins are translated as pre-peptide and 
secreted through the same ABC transporter BipTE/NlmTE while a proteolytic cleavage removes 
the leader sequence.  
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CHAPTER SIX 
CONCLUSIONS AND FUTURE DIRECTIONS 
Mutacins play a crucial role in maintaining the favorable ecological niche for S. mutans 
in the oral cavity. Increasing evidences suggest that they provide multiple advantages to the 
producer bacteria in highly heterogeneous oral habitat. Most apparent advantage is that mutacins 
help in vying with other early colonizers for successful colonization. Many of its early 
competitors, such as S. sanguinis can colonize the tooth surface earlier and are less susceptible to 
various stresses (155). Without any countermeasures, it would be very difficult to initiate and 
sustain a biofilm lifestyle in this extremely competitive micro-ecological milieu. In vitro 
competition assay clearly demonstrated that mutacin I and IV are required for maintaining 
dominance over S. sanguinis in dual species biofilm condition (157). 
The experimental works presented in this study provide a comprehensive understanding 
on mutacin IV activity, mechanism of self-immunity and regulation of mutacins expression in S. 
mutans UA159. Critical to our understanding is that both NlmA and NlmB peptides are required 
for maximum mutacin IV activity. By using genetic and biochemical approaches, we resolutely 
clarified that mutacin IV follows the typical definition of class IIb bacteriocins, where both of the 
peptides should be present in equimolar concentration to exhibit maximum inhibitory activity. 
Our studies revealed that the inhibitory spectrum of mutacin IV is much broader than mutacin V, 
and both of these mutacins work synergistically to inhibit various microorganisms. 
 We show evidences that S. mutans UA159 contains a subtle mechanism to protect itself 
from its own bacteriocin. The genome of this bacterium encodes a specific immunity gene, 
SMU.152, which offers immunity to mutacin IV. In addition, in the absence of cognate immunity 
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protein, S. mutans can employ other paralogous proteins to prevent the self-inhibition. We show 
that C-terminal disordered region of the immunity protein is indispensible for conferring 
immunity to the susceptible cells. Our studies further demonstrate that Man-PTS is not the only 
receptor for bacteriocin targeting; other membrane proteins can also function as the target for 
class II bacteriocin mediated cell inhibition. 
 Our key finding is that the expression of mutacins is controlled at multiple levels by 
numerous factors and this process is intricate with cellular homeostasis. Our studies revealed that 
an extracellular ATP-independent Lon-like protease functions specifically on maturation of 
peptide pheromone, CSP. Here, we show that functional form of CSP (18-amino acids) is 
generated by a post-export cleavage with this Lon-like protease. To the best of our knowledge, 
this is the first report on a Lon-like protease locating outside the cell which does not have any 
ATP-binding motifs to exhibit its activity. However, this protease contains the same catalytic 
dyad as other Lon proteases. We demonstrated that the ComCDE two-component system is 
primarily involved in regulation of mutacins production in S. mutans UA159 and proposed the 
renaming of this entire pathway as BIP (bacteriocin inducing pathway). 
Based on the knowledge gained so far on this study, there are several ways to proceed 
further. As many as 15 putative bacteriocins encoding genes are present in the genome of S. 
mutans (Table-6). We have characterized the activities of only mutacin IV and V. Most of them 
still remain unexplored. Interestingly, we found that S. pneumoniae, a predominant bacterial 
pathogen, is susceptible to the mutacins other than NlmAB or NlmC (Table-10). Future studies 
could be directed to unravel the activity spectrum of these uncharacterized mutacins. 
Undoubtedly, the mutacins holds a great promise to use as antimicrobial therapeutics 
against numerous streptococcal species. However, characterization of the activity of a novel 
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bacteriocin is not enough to find more potent bacteriocins for commercial applications. 
Structure-function analysis is an important tool for rationale design of a bacteriocin with 
improved properties, which can be useful for medicinal or biotechnological applications. In 
addition, specific activity of a bacteriocin can be increased by cloning and expressing in 
heterologous hosts. Detail structural analysis by NMR spectroscopy, X-ray crystallography in 
membrane mimicking condition, and site-directed mutagenesis is required to understand how 
these bacteriocins work on target cells. 
 Although we have identified a specific immunity protein which rendered protection to 
mutacin IV, further study is necessary to unravel the mechanism of immunity conferred by this 
protein. So far, Man-PTS is the only recognized receptor for class II bacteriocin and we found 
that this is not the only target for mutacin IV activity. Due to the presence of different inhibitory 
spectrum for each bacteriocin, it is likely that each of them has different specific receptors on 
target cell membrane. Because of the crucial role of receptors in determining specific inhibitory 
spectrum of a given bacteriocin, it will be of great interest to identify the receptor and understand 
the molecular mechanism underlying specific immunity activity of SMU.152.  
 Bacterial cell-cell communication by quorum sensing has been reported to be associated 
with virulence genes expression, including acid tolerance, biofilm formation, competence 
development, sporulation, mating, bioluminescence, and bacteriocin production (62, 119, 171-
173, 266, 299). This holds a great promise to rationally design drugs that can block quorum 
sensing and related pathogenic properties, thereby effectively controlling the pathogens. 
Development of structural analogs can competitively block the receptor binding and inhibit 
quorum-sensing regulated virulence expression. Further study on structure-function of CSP will 
assist in development of new inhibitor that can be used to control the prevalent oral disease, 
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dental caries, by blocking the CSP-related virulence expression in S. mutans. In last decade, 
several studies have described the role of quorum-sensing antagonist to inhibit the respective 
regulatory circuits in different bacteria (119, 180, 316). 
 As our studies revealed that multiple regulatory factors are involved in controlling the 
mutacins production in S. mutans. Here, we have characterized the activity of three hypothetical 
proteins on regulation of mutacins production. It is interesting that our studies show evidence of 
the involvement of a non-canonical Lon-like protease in regulation of mutacins production. 
Further study is necessary to understand how this protease works. Particularly, future 
investigations on mechanism of surface localization, possible interaction with other proteins or 
necessity of homooligomerization like other Lon proteases are expected to get insights into this 
unique protease activity. Regulation of gene expression by glycosylation and multiprotein 
complex is likely prevalent in prokaryotes as like eukaryotic cells also. Further experiments 
would be interesting to decipher the exact regulatory mechanisms underlying the genetic 
regulation by SMU.832 and SMU.2137. At last, but not the least, all other regulators identified in 
our transposon mutagenesis remain for future studies to uncover the complete regulatory 
mechanism of mutacin production in S. mutans UA159. 
 Ever increasing trends of antibiotic-resistance among the pathogenic bacteria and the 
demand of food supply without any chemical additives have accentuated the necessity of novel 
antimicrobial agents in medicine and food industries. Bacteriocins have the potential to be used 
as natural preservatives to control food-spoiling bacteria or food-borne pathogens or can be used 
as species-specific antimicrobial agents to manage the wide-spreading antibiotic resistance 
problems world-wide. Further studies on mutacin biology will provide valuable insights for its 
future applications in food or pharmaceutical industries.  
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